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This dissertation is concerned with determining the prevalence of metabolic syndrome 
(MetS) in Emirati females aged 17–25 years and its relation to overweight and obesity. 
It also aims to determine the glycemic index (GI) and glycemic load (GL) values for 
traditional Emirati foods that have not been tested yet.  
In a cross-sectional study design, anthropometric measurements, blood pressure and 
biochemical measurements were collected from a total of 555 Emirati female college 
students and the prevalence of MetS was concluded. Furthermore, at least fifteen 
healthy subjects participated in the measurement of GI and GL values for each of the 
twenty-three Emirati test foods. 
This study showed a high prevalence of MetS among college female young adults aged 
17–25 years (6.8%). Of the 555 participants enrolled, 23.1% were overweight and 
10.4% were classified as obese. MetS was significantly associated with obesity, waist-
hip ratio, glycated hemoglobin and high sensitivity C-reactive protein. The current 
study also provides a comprehensive food composition table including proximate data, 
minerals, vitamins, lipids, and sugars contents, along with GI and GL values of twenty-
three locally consumed foods in the UAE which could be utilized in offering better 
dietary recommendations for the Emirati population.  
The results advocate the need for MetS identification and immediate intervention 
programs to improve the future health of this youthful group. 
 
Keywords: Metabolic syndrome, Emirati, Young adults, Glycemic index, Glycemic 







Title and Abstract (in Arabic) 
 
 متالزمة األيضمخاطر و السمنة ،لبعض األطعمة التقليدية اإلماراتية سكر الدمنسبة شر مؤ
اإلماراتالشابات في فتيات العند   
 الملخص
 25و17بين  اتي تتراوح أعمارهنواللتهدف هذه األطروحة لتحديد مدى انتشار متالزمة األيض لدى اإلناث 
لبعض األطعمة  عاماً في اإلمارات وعالقتها بزيادة الوزن والسمنة. كما أنها تُعنى بتحديد مؤشر نسبة سكر الدم
 .التقليدية اإلماراتية التي لم يتم اختبارها بعد
 طالبة 555من  البيو كيميائيةضغط الدم والقياسات قياس ية وانتم جمع القياسات الجسم مستعرضة،في دراسة 
 في جامعة اإلمارات العربية المتحدة، واستخدمت البيانات لتحديد مدى انتشار متالزمة األيض لديهن. كما شارك
الثالثة اإلماراتية ن األطعمة لكل م مؤشر نسبة سكر الدم في قياس قيمأصحاء على األقل  اً شخصعشر  ةخمس
 وعشرين التي تم اختيارها.
 25و17 اتي تتراوح أعمارهن بينوالل الشاباتبين  المتالزمة األيضيةأظهرت هذه الدراسة ارتفاع معدل انتشار 
 ً منهن ٪ 10.4ويعانون من زيادة الوزن من الشابات المشاركات في الدراسة ٪ 23.1 كما تبين بأن(. ٪6.8) عاما
 المتالزمة األيضيةكبير بين ارتباط وجود الدراسة عن  كشفتإضافة إلى ذلك، فقد يعانون من السمنة المفرطة. 
. كما والهيموجلوبين السكري وبروتين سي التفاعلي عالي الحساسيةورك، السمنة، ونسبة الخصر لل وكٍل من
طعمة التقليدية اإلماراتية. بما في ذلك وعشرين من األثالث ل ةشامل ةغذائيتوفير جداول إلى الدراسة  خلصت
لهذه  سكر الدم ومؤشر نسبة، لمعادن والفيتامينات والدهون، والسكرياتوا المركبات الغذائية جداول عن نسب
 .سكان اإلماراتلأفضل غذائية تقديم توصيات ل هيمكن استخدامالجداول مرجعاً هاماً  وتعد هذه. األطعمة
ضرورة تطوير برامج والملحة للكشف المبكر عن المتالزمة األيضية  الحاجةن ع هذه الدراسة وعكست نتائج
 .من الشبابالعمرية لهذه الفئة  ةتحسين الصحة المستقبليللتدخل الفوري سعياً ل
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Chapter 1: Introduction 
 
Non-Communicable Diseases (NCDs) are the leading cause of deaths worldwide, 
with diabetes mellitus the fourth major cause of NCD deaths [1]. Diabetes is a chronic 
disease characterized by abnormalities in the metabolism of carbohydrate, fat, and 
protein, along with hyperglycemia. During the past three decades, the prevalence of 
diabetes mellitus in the world has doubled, which has presented a great challenge to 
public health in every country. The International Diabetes Federation (IDF) estimated 
the global prevalence for diabetes mellitus to be 8.3% in 2014, however, it is estimated 
that around 46% of people with diabetes remain undiagnosed [2]. Moreover, the IDF 
expects 205 million new cases of diabetes mellitus by the year 2035.  
The United Arab Emirates (UAE) has been ranked as having the fifth highest 
prevalence in the Middle East and North Africa (MENA) region with 19%, coming 
after other Gulf Cooperation Council (GCC) countries, like Qatar, Saudi Arabia and 
Bahrain [2]. In 2010, a survey conducted in the UAE reported the prevalence of 
undiagnosed diabetes mellitus and pre-diabetes to be 14.6% and 31% respectively [3]. 
This indicates the great number of people living with undiagnosed diabetes mellitus 
and pre-diabetes in the country. The existence of pre-diabetes combined with 
dyslipidemia, elevated blood pressure, and obesity leads to the diagnosis of Metabolic 
Syndrome (MetS) [4]. The MetS has a major public health impact through high 
disease prevalence, significant downstream pathophysiological effects, and enormous 
financial responsibilities. Therefore, the diagnosis of the syndrome and its 






2 diabetes mellitus (T2DM), hypertension, and cardiovascular disease (CVD), and 
may help reduce the risk of morbidity and mortality. 
The prevalence of MetS was reported to be 32.9% among Emirati men, 45.9% 
among Emirati women, and the total prevalence was 40.5%, based on the IDF 
definition for MetS [5]. This alarming prevalence is thought to be emerging from the 
high prevalence of MetS among younger age groups (13% of Emirati adolescents 
suffered from MetS) [6]. The observed increasing incidence of MetS and pre-diabetes 
among children, adolescents, and younger adults caused an equal increase in the need 
for understanding the etiology of the disease, along with developing better screening 
practices, and improved prevention programs in the UAE. Anthropometric measures 
have been reported in several studies to assess in the diagnosis of MetS and its 
components [7-9]. Thus, identification of anthropometric measures of obesity that 
best identify MetS among the Emirati population is essential to improve screening and 
facilitate prevention.  
The causes behind the epidemic of MetS and T2DM are part of a multifactorial 
genetic and social system, controlling behavioral and environmental influences [10]. 
However, there are several key risk factors believed to be contributing to the 
occurrence of the MetS. These include: weight gain and obesity[11]; sedentary 
lifestyle with low physical activity [12, 13]; ethnicity [14]; family history of diabetes 
and poor dietary habits [15]; while other factors could be cigarette smoking and 
alcohol consumption [16]. Accordingly, dietary management could have a great 
impact on the number of people affected by diabetes, or preventing it in those at high 
risk of developing the disease [17]. The American Diabetes Association 






weight loss of seven per cent of body weight and increasing physical activity to at 
least 150 min/week of moderate activity for people living with pre-diabetes [16]. 
Dietary management was found to be dependent on the quality and quantity of nutrient 
intake. Studies suggested that the total amount of carbohydrates or fat in the diet does 
not seem to be associated with T2DM risk, but specific forms of carbohydrates or fat 
were found to be associated with the disease [18, 19]. For example; the ability of 
carbohydrates to increase blood glucose and insulin levels after food ingestion differs, 
and that is known as the glycemic index (GI) of foods [20]. This concept was 
developed in 1981 as a tool for predicting the blood glucose response to various foods. 
Since the amount of carbohydrate in a food varies, researchers have also introduced 
the concept of glycemic load (GL), which is the amount of available carbohydrate in 
a serving size of a food item multiplied by its glycemic index [21]. Prospective studies 
investigating the relations between dietary carbohydrate intake and risk of T2DM 
using glycemic index (GI) and glycemic load (GL) supported the protective role of 
low GI and low GL diets against the development of T2DM [19]. However, a high GI 
food would cause a higher increase in the levels of blood glucose after its ingestion, 
it will in turn increase the demand of insulin. Regular consumption of high GI foods 
would therefore contribute to β cell distraction due to the elevated insulin demand 
and/or continuously raised blood glucose concentration [19]. 
A study in 2010 from the United Arab Emirates aimed to determine factors 
associated with poor glycemic control among patients with T2DM, stated the main 
factor behind poor glycemic control was not following a dietitian recommended eating 
plan and the negative attitude towards diabetes [22]. Another study from the UAE 






ethnic groups in the UAE, reported a higher prevalence among UAE citizens (25%) 
compared to that of expatriates (13–19% depending upon country of origin) [23]. 
These results suggest the need for better counseling programs focusing on the UAE 
citizens, which in turn requires more information about the dietary practices of the 
UAE citizens, food composition tables of locally consumed foods, and the GI values 
of these food to facilitate the role of dietitians in developing better programs targeting 
glycemic control in people living with pre-diabetes. 
This dissertation provides a series of studies aiming to investigate the prevalence 
of the MetS and its components among young Emirati adults; to identify the 
anthropometric measures of obesity that best identify MetS; and to develop a 
comprehensive food composition table with GI and GL values for locally consumed 
foods in the UAE. This was established in an effort to contribute to the understanding 
of these diseases, and to provide objective tools for nutrition therapy planning and 






Chapter 2: Review of Literature 
 
2.1 Introduction to the Metabolic Syndrome 
2.1.1 History of the Metabolic Syndrome 
The metabolic syndrome (MetS) can be described as a clustering of several 
risk factors, including central adiposity, impaired glucose tolerance, dyslipidemia, and 
hypertension.  
The metabolic syndrome concept was first introduced in 1988 by Gerald 
Reaven. He called it the “Syndrome X” and defined it as a cluster of abnormalities 
(dyslipidemia, high blood pressure, and diabetes) arising from the underlying events 
of insulin resistance and hyperinsulinemia [24]. Ten years later, in 1998, the World 
Health Organization (WHO) first recognized the metabolic syndrome and developed 
diagnostic criteria that could officially be used for clinical diagnosis [25]. However, 
during these ten years, many other names were used to describe the co-occurrence of 
these abnormalities all together, such as: the Plurimetabolic Syndrome by Crepaldi 
and Nosadini in 1988 [26]; the Deadly Quartet by Kaplan in 1989 [27]; the Insulin 
Resistance Syndrome by DeFronzo and Ferrannini in 1991 [28]; and Diabesity by 
Shafrir in 1993 [29]. Conversely, Sarafidis and Nilsson proposed that the recognition 
of the metabolic syndrome has evolved over about 90 years [30], starting in World 
War I, when Hitzenberger and Richter-Quittner identified a link between hypertension 
and diabetes [30]. The history of the metabolic syndrome is briefly described in Table 







Table 2.1: Brief History of the Metabolic Syndrome 
Event Year 
Recognition of the co-existing of hyperglycemia and hypertension 
[30]. 
1920s 
Describing fat distribution and emphasis on abdominal obesity [30]. 1950s 
Emphasis on hyperlipidemia/dyslipidemia as part of the cluster [30]. 1960s 
Metabolically-obese, normal weight phenotype defined. 1981 
Gerald Reaven describes “Syndrome X”: clustering around insulin 
resistance [24]. 
1988 
Kaplan describes “deadly quarter”: abdominal obesity, diabetes, 
hypertension, and high triglycerides [27]. 
1989 
Metabolic syndrome first operationalized as clinical diagnosis, based 
on the WHO definition [25]. 
1998 
NCEP ATP III definition: emphasis on abdominal obesity as 
surrogate for insulin resistance [32]. 
2001 
American Academy of Clinical Endocrinologists defines “Insulin 
Resistance Syndrome”. 
2003 
The International Diabetes Federation definition - more emphasis on 
abdominal obesity [33]. 
AHA/NHLBI further refine the NCEP ATP III definition. 
American Diabetes Association denounces the concept of metabolic 
syndrome. 
2005 
ADA/Obesity Society/American Society for Nutrition question 
advantage of abdominal obesity over BMI. 
2007 
IDF/AHA/NHLBI/IAS: “Harmonized Definition” [4]. 2009 
WHO: metabolic syndrome of little utility for clinical practice or 
epidemiologic research. 
2010 






2.1.2 Definition of the Metabolic Syndrome 
Over the past decade, the definition of the metabolic syndrome has been 
greatly argued. The argument lingers to doubt whether there is such a syndrome or 
not [34].  
The first definition for “Syndrome X” proposed by Reaven in 1988 [24], was 
the clustering of dysglycemia, dyslipidemia, hypertension, and insulin resistance. The 
WHO proposed the addition of central obesity to the definition of the metabolic 
syndrome and established the first diagnostic criteria for it in 1998-1999 [25]. The 
WHO diagnostic criteria included the direct or indirect measure of insulin resistance. 
Insulin resistance measurement was also part of the diagnostic criteria proposed by 
the European Group for the Study of Insulin Resistance in 1999 [35]. Aiming to make 
the clinical diagnosis of the metabolic syndrome easier and more user friendly, the 
National Cholesterol Education Program Adult Treatment Panel (NCEP ATP) III 
report established new guidelines in 2001 that do not include the measurement of 
insulin resistance [32]. The American Association of Clinical Endocrinologists then 
proposed an even more flexible definition in 2003 [36]. Other definitions were 
developed and used over the past period included the NCEP ATP definition in 2005 
[37], and the International Diabetes Federation definition in 2006 [33]. The latest and 
most accepted diagnostic criteria for the metabolic syndrome is the harmonized 
definition of the International Diabetes Federation Task Force on Epidemiology and 
Prevention (IDF); the National Heart, Lung, and Blood Institute (NHLBI) ; the 
American Heart Association (AHA); the World Heart Federation (WHF); the 
International Atherosclerosis Society (IAS); and the International Association for the 






2.1.3 Diagnostic Criteria of the Metabolic Syndrome 
 The diagnostic criteria of the metabolic syndrome that was published by the 
WHO 1998, and revised in 1999 [25], considered cardiovascular disease as the main 
outcome of the syndrome, and highlighted the importance of detecting insulin 
resistance along with the presence of at least two of the following criteria: elevated 
triglycerides; elevated blood pressure; central obesity; or reduced HDL [25]. The 
European Group for the study of Insulin Resistance (EGIR) in 1999, also required the 
measurement of insulin resistance [35]. This made the definition not very practical for 
use in epidemiological studies of large populations. 
 The NCEP ATP III diagnostic criteria proposed in 2001 [32] did not require 
the measurement of insulin resistance. However, it required the occurrence of at least 
three of the following five criteria: central obesity; reduced HDL; elevated 
triglycerides; elevated blood pressure; or elevated fasting glucose. The incidence and 
the number of these components was thought to contribute to increase the risk and 
progression of the syndrome [32]. 
 The American Academy of Clinical Endocrinologists (AACE) proposed in 
2003 a criteria for the diagnosis of the “Insulin Resistance Syndrome” [36]. It focused 
the discussion on insulin resistance and hyperinsulinemia as the underlying 
pathophysiology of the syndrome. Therefore, this definition was considered very 
broad as it included cardiovascular and non-cardiovascular consequences of insulin 
resistance, such as hypertension, polycystic ovarian syndrome (PCO), fatty liver 
disease, and acanthosis nigricans[36]. The purpose of this definition was to alert 






cardiovascular risk. A summary of the four discussed criteria for the diagnosis of 
metabolic syndrome is presented in Table 2.2.  
Table 2.2: Summary of the Metabolic Syndrome’s Diagnostic Criteria according to 
the WHO, the EGIR, the NCEP ATPIII, and the AACE 
WHO [25] 










-Type 2 diabetes 
- Impaired fasting 
glucose 












glucose test >140 mg/dl 
+ 2 of the following: + 2 of the following: Fasting glucose: 
- ≥ 110 mg/dl 
Fasting glucose: 
- between 110 and 126 
mg/dl 
Hypertension: 
- BP (≥140/90 
mmHg) 
Hypertension: 










≥ 130/85 mmHg  
 
Dyslipidemia: 
- Triglyceride (≥150 
mg/dl)  
OR 
- HDL (<35 mg/dl in 
men, <39 mg/dl in 
women) 
Dyslipidemia: 
- Triglyceride (≥180 
mg/dl)  
OR 






- (≥150 mg/dl)  
Dyslipidemia: 
- Triglyceride (≥150 
mg/dl)  
AND 
- HDL (<40 mg/dl in 
men, <50 mg/dl in 
women) 
Obesity: 
- BMI > 30 kg/m2 
OR 
- WHR >0.9 in men, 
>0.85 in women. 
Central Obesity: 
- WC (Men ≥ 94 cm, 
women ≥80 cm) 
Central Obesity: 
- WC (Men ≥ 102cm, 
women ≥88 cm) 
Overweight: 
- BMI > 25 kg/m2 
Microalbuminuria: 




- Albumin: Creatinine 
ratio ≥30 mg/g  
Impaired fasting 
glucose: 
- FPG ≥ 110 mg/dl 
Reduced HDL: 
- <40 mg/dl in men, 
<50 mg/dl in 
women)  
OR 
-  HDL medication 
Other related factors: 
- Family history of 
T2DM, HTN, or CVD. 
- PCO. 
- Ethnicity. 
- Sedentary lifestyle. 
- Fatty liver disease. 
- Acanthosis nigricans.  
 
WHO: World Health Organization; EGIR: European Group for the study of Insulin Resistance; NCEP 
ATP: National Cholesterol Education Program Adult Treatment Panel; BP: blood pressure; AACE: 
American Academy of Clinical Endocrinologists; HDL: high-density lipoprotein Cholesterol; BMI: 
body mass index, WHR: waist-to-hip ratio; WC: waist circumference; FPG: Fasting Plasma Glucose; 







 In 2005, the International Diabetes Federation proposed a new diagnostic 
criteria emphasizing abdominal obesity. The IDF removed the WHO requirement for 
insulin resistance measurement, and made abdominal obesity required for the 
diagnosis, combined with four other factors (elevated triglycerides, elevated blood 
pressure, elevated FPG, and reduced HDL cholesterol) [33]. The central obesity was 
defined as waist circumference (according to an ethnic-specific value), which is 
considered a simple and easy screening tool; the rest of the criteria remained identical 
to the 2001 NCEP ATP III criteria.  
The AHA/NHLBI also attempted to further refine and update the NCEP ATP 
III definition in 2005. They proposed changing impaired fasting plasma glucose to 
FPG ≥ 100 mg/dl compared to the old FPG ≥110 mg/dl used by the ATP III [37]. The 
AHA/NHLBI did not mandate central obesity for the diagnosis of the metabolic 
syndrome, and did not use ethnic-specific values for WC when defining central 
obesity. This lack of agreement on the definition of central obesity between the IDF 
and the AHA has resulted in confusion in the definition of metabolic syndrome among 
researchers and scientists.  
 In 2009, the International Diabetes Federation Task Force on Epidemiology 
and Prevention (IDF); the National Heart, Lung, and Blood Institute (NHLBI); the 
American Heart Association (AHA); the World Heart Federation (WHF); the 
International Atherosclerosis Society (IAS); and the International Association for the 
Study of Obesity have all agreed on a joint interim statement for a new harmonized 
definition for the metabolic syndrome [4].The diagnostic criteria of the  IDF (2005), 
the AHA/NHLBI (2005) and the harmonized definition (2009) are summarized in 






obesity is no longer obligatory. Modifications might happen in the future, however, 
using single definition in the previous couple of years have allowed the ability for 
better comparisons among epidemiological studies.   
Table 2.3: Summary of the Metabolic Syndrome’s Diagnostic Criteria according to 











At least 3 of the 
following: 
At least 3 of the 
following: 
+ 2 of the following: Central Obesity: 
- WC (Men ≥ 102cm, 





Impaired fasting glucose: 
- FPG ≥ 100 mg/dl 
OR 




- FPG ≥ 100 mg/dl 
OR 




- FPG ≥ 100 mg/dl 
OR 
- Medication for 
hyperglycemia 
Hypertension: 















- (≥150 mg/dl) 
OR 
- Treatment of lipid 
abnormality  
Elevated triglyceride: 
- (≥150 mg/dl) 
Elevated triglyceride: 
- (≥150 mg/dl) 
OR 
- Treatment of lipid 
abnormality 
 Reduced HDL cholesterol: 
- Men <40 mg/dl 
- Women <50 mg/dl  
OR 
- HDL medication 
Reduced HDL 
cholesterol: 
- Men <40 mg/dl 
- Women <50 mg/dl  
OR 
- HDL medication 
Reduced HDL 
cholesterol: 
- Men <40 mg/dl 
- Women <50 mg/dl  
OR 
- HDL medication 
IDF: International Diabetes Federation; AHA: American Heart Association; HHLBI: 
National Heart, Lung, and Blood Institute; HDL: high-density lipoprotein 







2.2 Risk Factors of the Metabolic Syndrome 
 There are many underlying risk factors discussed in the literature that could be 
related to the pathophysiology of the metabolic syndrome. Some are modifiable 
factors and others are non-modifiable. It has been proposed that all factors, whether 
they are lifestyle factors (excess nutrients and physical inactivity), hormonal factors, 
macronutrient factors or even aging factors, they are interlinked together in a very 
complicated manner. Some are simplified and summarized in Figure 2.1.  
 
Figure 2.1: Schematic Presentatin of the Metabolic Syndrome Risk Factors and 
Consequances 
 
2.2.1 Genetics of the Metabolic Syndrome 
Each component of the MetS could be explained by a complex set of 
interactions between the genes and the environment. Limited data is available about 
the genetic factors behind the prevalence of metabolic syndrome; however, the genetic 
susceptibility to the MetS can be organized in two groups: genes leading to insulin 
resistance, and genes related to obesity phenotypes. Several genes were identified to 
play a role in the development of MetS, yet the mechanisms of acting remained poorly 
understood. There is no doubt that the MetS is a polygenetic disease, along with a 
great number of influences from the environment. Moreover, even if the genetic-based 
risk was successfully assessed, it would be unlikely to play the main role in the MetS 











- Elevated blood glucose
- Elevated blood pressure
- Atherogenic dyslipidemia
- Type 2 diabetes (T2DM)
- Cardiovascular disease
- Fatty liver
- Polycystic ovary syndrome
- Sleep apenea
- Sexual dysfunction






In 2001, the ATP III identified obesity as the main underlying risk factor of 
the MetS. The hypothesis emphasized the role of obesity in the development of MetS, 
explained by individuals having the genetic susceptibility of the syndrome but failing 
to manifest it because they never developed obesity [32]. In 2003 the WHO and the 
AACE identified insulin resistance as the main underlying risk factor of the MetS 
[36]. They agreed that physical inactivity, obesity, and aging all play a role in the 
development of the syndrome, but focused on insulin resistance as the key trigger. 
The most accepted view on the origins of the metabolic syndrome suggests the 
importance of obesity and insulin resistance to engender the metabolic syndrome 
along with other environmental and genetic factors. This considers the independent 
effect of obesity and insulin resistance on the syndrome, and the effect of each of them 
on the other. This hypothesis is adopted from the Atlas of Atherosclerosis and 







Source: Grunday, 2011 [39]. 
 Studies focusing on the MetS genetics have discussed two main genes in an 
attempt to explain the pathophysiology of the syndrome; these are the FTO (fat mass 
and obesity associated) gene and the PPARG (Peroxisome Proliferator-Activated 
Obesity and adipose 
tissue disorders 
Insulin resistance 


















Receptor Gamma) gene [40, 41]. The FTO gene is thought to increase caloric 
consumption by upregulating the starvation signals of the hypothalamus resulting in 
increased BMI and overall adiposity [42, 43]. The PPARG gene transcripts the nuclear 
receptor family of the PPARs isotypes (PPARα, PPARδ, and PPARγ) that are 
involved in the regulation of carbohydrate and lipid metabolism. Of these, the PPARγ 
appears to play a principle role in the assimilation of lipids, insulin signaling, glucose 
metabolism, fatty acids storage, and inflammation in endothelial cells [40]. 
 
2.2.2 Insulin Resistance  
 The insulin resistance mechanism was used by many researchers to justify the 
occurrence of the MetS as a cluster and its individual components. Insulin resistance 
alone was not enough to provide an explanation for the 30% of individuals diagnosed 
with the MetS, yet had normal insulin sensitivity. Insulin resistance was suggested to 
result from ectopic fat deposition and lipotoxicity [44]. It is characterized by high 
concentrations of plasma insulin (hyperinsulinemia) that fail to maintain plasma 
glucose homeostasis resulting in hyperglycemia and other components of the MetS. 
The contributing factors to insulin resistance are very complex. Many hypothesis were 
developed trying to explain it, such as the adiponectin hypothesis [45], and the plasma 
copeptin hypothesis [46]; however, the obesity-induced insulin resistance hypothesis 
is the most accepted [47]. 
 Insulin sensitivity could be measured in different ways at whole-body level. 
Traditional approaches use the hyperinsulinemic euglycemic clamp technique, which 
requires measuring the amount of glucose needed to match the rate of removal of 






fasting insulin value. An easier and faster way is to calculate the fasting insulin 
concentration to fasting plasma glucose (FPG) ratio by a mathematical formula known 
as HOMA-IR (homeostasis model assessment for insulin resistance) [48]. As the 
presence of insulin resistance is linked to the presence of central obesity, it is now 
proposed to use the “hypertriglyceridemic waist” as an easy and simple measure for 
the screening of insulin resistance [49]. 
 
2.2.3 Abdominal Obesity 
 Not all people living with obesity suffer from the MetS; similarly, not all 
normal weight people are healthy and free from all components of the syndrome. 
Modern medicine is still debating over the interaction between obesity, insulin 
resistance and the MetS. Obesity itself is a multifactorial condition, caused by a 
complex group of genetics and behavioral factors. Ectopic fat is the accumulation of 
fat in tissues other than the subcutaneous adipose tissue, such as the liver, epicardium 
of the heart, and the abdominal viscera. This is thought to happen when the 
subcutaneous adipose tissue becomes dysfunctional, insulin resistant, lipodystrophic 
(rare condition characterized by adipose tissue deficiency) or simply saturated with 
fat during excess nutrient intake [50]. This accumulation of fat in the liver leads to 
atherogenic dysglycemia, and the accumulation of fat in the muscles leads to insulin 
resistance [51]. Ectopic fat and visceral fat have shown greater correlations with the 
MetS when compared to the BMI [50]. Moreover, the role of the subcutaneous adipose 
tissue as an endocrine organ cannot be ignored. The adipose tissue can release a range 
of hormones (TNF-alpha, leptin, and resistin) pro-inflammatory, pro-thrombotic 






causing an increase the risk of metabolic disorders, such as diabetes, hypertension and 
CVDs [52]. The release of these cytokines into the blood circulation could also induce 
an inflammatory response in the epithelial arterial wall, leading to a disturbance in the 
atherosclerotic plaques, which triggers plaque rupture, generating acute coronary 
syndromes [53].  
 Simple anthropometric measures are used for the assessment of obesity and 
fat deposition, such as the body mass index (BMI), the waist-to-hip ratio (WHR), and 
the waist circumference (WC) [54]. Moreover, modern accurate computed imaging 
systems became available and allowed direct quantifying of body fat. 
 
2.2.4 Glucose Intolerance 
 Glucose intolerance is caused by the effect of insulin resistance on different 
body tissue. Insulin resistance causes impairment in the uptake of insulin by cells, 
which effects the cascade of reactions induced by insulin, causing dysregulation of 
gluconeogenesis and glycogenolysis in the liver resulting in hyperglycemia. Detecting 
glucose intolerance (or prediabetes) can be done by oral glucose tolerance test 
(OGTT) 2-h PG in the 75-g OGTT 140 mg/dL (7.8 mmol/L) to 199 mg/dL (11.0 
mmol/L) (IGT), or impaired fasting glucose (IFG) FPG 100 mg/dL (5.6mmol/L) to 
125 mg/dL (6.9 mmol/L), or elevated HbA1c 5.7–6.4% [16]. 
 
2.2.5 Elevated Blood Pressure 
 The association between the MetS and the elevation in blood pressure has been 
identified, but the mechanisms have not been fully defined [4]. This elevation might 






to the next category (>140/190 mmHg). Multiple factors were proposed to be 
involved, some of these are: 
- Obesity  Oxidative stress  reduce bioavailability of nitric oxide  
vasodilation  elevate blood pressure [55]. 
- Obesity  increase adipocytes tissue  adipocytes produce angiotensinogen 
 elevate blood pressure [56]. 
- Obesity  increase adipocytes tissue  adipocytes produce inflammatory 
cytokines  pro-inflammatory state  endothelial dysfunction  elevate 
blood pressure [56].  
- Obesity  compresses the kidney with fat tissues  induce renal dysfunction 
 increase renin  elevate blood pressure [57]. 
- Insulin resistance  enhances the sympathetic nervous system  elevate 
blood pressure [58].  
- Insulin resistance  increase sodium reabsorption  sodium retention  
elevate blood pressure [58]. 
 
2.2.6 Atherogenic Dyslipidemia 
 Another underlying risk factor of the metabolic syndrome is atherogenic 
dyslipidemia. This condition is characterized by increased fasting and post-prandial 
triglycerides level, increased Apo-lipoprotein (Apo-B), increased very low-density 
lipoprotein (VLDL) cholesterol, increased small dense low-density lipoprotein (LDL) 
profile, low high-density lipoprotein (HDL) cholesterol and small HDL particles [59]. 
Atherogenic dyslipidemia is the core of the MetS, and it is defined according to the 
harmonized definition of the metabolic syndrome (IDF/ NHLBI/ AHA) [4] and the 
2012 European guidelines on cardiovascular disease prevention [60] as an HDL-C 
level < 40 mg/dL in men and <50 mg/dL in women, with a triglyceride level ≥150 






have been identified in the literature [59]. Due to insulin resistance, and/or fatty liver, 
and/or lipid overloading of the liver, the liver will overproduce Apo-B containing 
VLDL and VLDL triglycerides. VLDL is metabolized in the circulation into 
intermediate density lipoprotein (IDL) and LDL. The origins of the small dense LDL 
is not fully understood; however, many mechanisms were proposed to explain it. It 
could be the activity of cholesterol ester transfer protein (CETP), which catalyzes the 
exchange of cholesterol esters for triglyceride between LDL and VLDL, resulting in 
the depletion of cholesterol ester from the LDL, and the production of small LDL 
particles [59].  
Other investigators believe that the increased production of Apo B-VLDL 
from the liver, would produce VLDLs that are already smaller in size, and when 
hydrolyzed they will produce smaller, denser LDL particles [61].  Lastly, it could be 
the higher activity of hepatic triglyceride lipase (HTGL) (existing in MetS patients), 
that is degrading the normal LDL into smaller denser LDL particles [62]. These 
mechanisms also account for the production of less overall HDL and smaller size HDL 
particles, causing less efficient reverse cholesterol transport in the circulation. 
Whereas, the small, dense LDL is more likely to get oxidized and has a great ability 
to transport cholesterol for the vessel. 
 
2.2.7 Inflammation 
 People with the MetS were found to have a low-grade of systemic 
inflammation [47, 63]. Many biomarkers of inflammation were shown to have an 
association with the MetS, such as: increased high sensitivity C-reactive protein  (Hs-






increased leptin, decreased adiponectin, and increased resistin [64]. Inflammation in 
the MetS is developed by the effect of insulin resistance on the liver and the 
dysregulation of the adipose tissue, along with the effect of insulin resistance on the 
sympathetic nervous system, causing an activation of inflammation and chemotaxis 
pathways. The pro-inflammatory state of the MetS is illustrated in Figure 2.3. Under 
the effect of insulin resistance, the liver produces higher levels of C-reactive protein 
(CRP), fibrinogen, and plasminogen activator inhibitor 1 (PAI-1). On the other hand, 
the adipose tissue produces a number of pro-inflammatory cytokines such as IL-6 and 
TNF-α, and reduce the production of adiponectin, which is considered an important 































Many inflammation markers were used through the years to predict 
cardiovascular events [63, 65], and a great number of investigators reported an 
association between pro-inflammatory state and MetS [65, 66]. Ridker and others 
showed evidence that the MetS represents an inflammatory state that could be seen 
by the progressive increase of Hs-CRP levels with the increased number of the  MetS 
components according to the ATP III criteria (Figure 2.4) [67]. Up to date, the only 
well-standardized marker of inflammation and a predictor of the MetS and future 
cardiovascular events, is the Hs-CRP [68]. However, the measurement of Hs-CRP is 
not yet included in the diagnostic criteria of the MetS, although it has been 
recommended by a large number of investigators [67-71]. Inflammation is usually 
measured through the measurement of serum Hs-CRP, where a level above 3 mg/l is 
considered high according to the recommendations of the CDC and the AHA for 
cardiovascular disease (CVD) risk assessment [63]. Although levels of fibrinogen, IL-
6, and adiponectin are also highly correlating with the prevalence of MetS in clinical 
research studies [38, 64], routine measurement of these inflammation markers is not 
yet recommended. 
Source: Ridker and others, 2003 [67]. 






2.3 Consequences of the Metabolic Syndrome 
The MetS is linked to the increased risk of a range of disease consequences 
including CVD, diabetes, polycystic ovary syndrome, fatty liver, asthma, cholesterol 
gallstones, sleep apnea, and sexual dysfunction, as shown earlier in Figure 2.1. 
Moreover, people living with diabetes, CVD, hypertension, and coronary heart 
disease were reported to have a much higher prevalence of the MetS when compared 
to the general population. 
The Syndrome X was proposed in 1988 by Gerald Reaven [24] to explain the 
grouping of CVD risk factors in individuals with insulin resistance. However, the 
current understanding of the MetS includes increased risk of atrial fibrillation, 
coronary heart disease (CHD), ischemic stroke, myocardial infarction, aortic valve 
disease, and cardiomyopathy [72, 73].  
The first epidemiological study associating the MetS with CVD morbidity and 
mortality was the Botnia study in 2001 [74]. It included 4,483 subjects, aged between 
35 and 70 years in Finland and Sweden. The study used the WHO 1998 definition for 
the MetS and reported a three-fold increase in the risk for CHD and stroke in subjects 
with the MetS (P < 0.001).  
A year later (2002), the Kuopio Ischemic Heart Disease Risk Factor Study was 
published [75]. This prospective cohort study included 1,209 Finnish men, between 
the age of 42 and 60 years, who were studied from 1984 till 1998. The study concluded 
an increase in CVD and all-cause mortality in men with the MetS, even in the absence 






A meta-analysis and a systematic review published in 2010, investigated the 
association between cardiovascular risk and the ATP III definitions of the MetS. It 
reported data from 87 studies including 951,083 patients, and showed that the MetS 
is associated with an increased risk of CVD mortality (RR: 2.40), CVD (RR: 2.35), 
stroke (RR: 2.27), all-cause mortality (RR: 1.58), and myocardial infarction (RR: 
1.99) [76]. Moreover, the prevalence of the MetS among people living with diabetes 
from various ethnic groups and different populations was reported to be between 76% 
- 92% [77-79].  
It is important to highlight that the risk of the MetS occurs even when diabetes 
is absent. In 2003, Alexander and others [80] showed that patients with the MetS but 
without diabetes had a higher prevalence of CHD (13.9%) than patients with diabetes 
but without the MetS (7.5%), as presented in Figure 2.5. 
Figure 2.5: Prevalence of CHD Categorized by Presence of MetS and Diabetes 
Source: Alexander and others, 2003 [80]. 
This does not propose that there is no relation between the MetS and diabetes. 






diabetes. Additionally, the relative risk of diabetes was reported to be three-fold 
higher among patients with the MetS compared to those without it [81].   
The pathophysiology of T2DM is usually explained by a two-step hypothesis. 
First, individuals develop insulin resistance partly caused by obesity as explained 
earlier in Section 2.2.2. Second, pancreatic β-cells get damaged or/and their function 
decline gradually with time, which might happen even before the clinical diagnosis of 
hyperglycemia. Considering the MetS is a state of pre-diabetes and insulin resistance, 
it should not be surprising that it has the ability to predict new cases of T2DM. 
 The San Antonio Heart Study was published in 2003 [82]. It included 1,734 
participants, between the age of 25 and 64 years, who completed eight years of follow-
up. The study concluded that the MetS predicts T2DM independent of impaired 
fasting glucose. It also showed that the MetS was associated with a five-fold higher 
risk of diabetes over the eight years follow-up even with normal fasting plasma 
glucose. This finding would suggest the need for a measure of diabetes that could have 
a greater prediction power for diabetes and the metabolic syndrome than fasting 
plasma glucose.  
The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial [83] 
showed an association between higher HbA1c levels and increased risk of mortality 
over a 3.4 years follow-up. Glycated hemoglobin (HbA1c) is a simple, practical 
measure, and has the ability to reflect glucose levels in the blood from the previous 
three months. As a matter of fact, the new recommendation by the ADA on the 
Standards of Medical Care in Diabetes-2015 [16], have added HbA1c test for the 






and did not require the confirmation of the test with other tests like fasting plasma 
glucose or glucose tolerance test if the HbA1c has been confirmed by replication. 
In 2007, two studies were conducted to study the association of glycated 
hemoglobin (HbA1c) and the MetS. The first is the Chennai Urban Rural 
Epidemiology Study (CURES) [84], which included 1,644 Asian Indian participants 
with normal glucose tolerance (FPG <100 mg/dl and 2-h post-prandial plasma glucose 
<140 mg/dl). It used the ATP III guidelines for the diagnosis of MetS. The study 
showed strong association between HbA1c and the MetS (OR: 2.9 (95% CI 2.08–
4.00); P < 0.001). 
The second study was conducted among 22,465 middle aged non-diabetic 
Korean participants [85]. The study concluded that the prediction of MetS could be 
archived at 5.45% of HbA1c and it recommended the use of HbA1c as a predictive 
measure of impaired fasting glucose and MetS among the Koreans. 
To conclude the consequences of the MetS and show the relative risk factor 
between the MetS and CVD morbidity, CVD mortality, diabetes, and all-cause 
mortality, a summary of all systematic reviews and meta-analyses published to 





Table 2.4: Summary of Systematic Reviews and Meta-analyses on the association of the MetS with CVD morbidity, CVD mortality, Diabetes, 
and All-Cause Mortality 
Source: Wild and others, 2011 [91]
Author and year of 
publication 
Selection criteria Definition of the MetS Outcome and follow-up 




Ford, 2005 [86] Articles published between 
1998 and August 2004 






Galassi et al., 2006 
[87] 
Articles describing 
prospective studies published 
between 1966 and April 2005 
WHO 1999, NCEP 
2001 and modifications 
All-cause mortality 
Cardiovascular disease mortality 
Incident cardiovascular disease 
21 studies 1.35 (1.17–1.56)  
1.74 (1.29–2.35)  
1.53 (1.26–1.87)  
Gami et al., 2007 [88] Articles describing 
prospective studies published 
between 1966 and March 2005 
WHO 1999, NCEP 
2001 and modifications 
Cardiovascular events or death  37 studies, 43 cohorts 
and 172,573 participants 
1.78 (1.58–2.00) 
Ford et al., 2008 [81] Articles published between 









Incident diabetes over 2.3–20 years 42,419 participants (total 
– subgroups for different 
definitions) 
5.17 (3.99–6.69) 4.45 
(2.41–8.22) 3.53 (2.84–
4.39) 5.16 (4.43–6.00) 
5.12 (3.26–8.05) 4.42 
(3.30–5.92) 
Li et al., 2008 [89] Articles published up to July 
2007 
WHO 1999, NCEP 
2001 
Incident stroke 13 studies and 92,732 
participants 
1.6 (1.48–1.75) 
Hui et al., 2010 [90] Articles published between 
2001 and 2009 
WHO 1999, NCEP 
2001 and modifications 
All-cause mortality over mean 11.5-
year follow-up 
21 studies and 372,411 
participants 
1.46 (1.35–1.57)   
Mottillo et al., 2010 
[76] 
Articles published up to June 
2009 
NCEP 2001 and revised 
NCEP 2004 
Cardiovascular disease 




87 studies and 951,083 
participants 
2.35 (2.02–2.73) 2.40 
(1.87–3.08) 1.58 (1.39–







2.4 Management of the Metabolic Syndrome 
The management of the MetS is achieved by treating underlying risk factors of 
the syndrome. Therefore, the first-line therapy usually targets lifestyle modifications 
including weight reduction for people living with obesity and introduction to regular 
workout for inactive individuals [4]. Therapeutic lifestyle changes such as introduction 
of the Mediterranean diet and teaching patients about the low glycemic index diet 
along with recommending a certain intensity and duration of physical activity (for 
example 10,000 steps/day) will help in decreasing insulin resistance, which in turn will 
facilitate the treatment of the syndrome.  
Drugs were also used in certain conditions to treat or even prevent the MetS. 
Some of these are used for the management of diabetes (Metformin), hypertension 
(ACE-inhibitor), CVD (aspirin) [92] and atherogenic dyslipidemia (statin, fibrate, and 
niacin). However, some drugs have adverse side effects that include raising insulin 
resistance; which should be stopped (if possible) and replaced with agents that do not 
increase insulin resistance. Bariatric surgery could also be a treatment option, 
especially for those patients living with morbid obesity. It has shown to resolve all 
components of the MetS by a single procedure, eliminating the necessity for daily 
drugs consumption.  
Many guidelines are available from different organizations to help in the 
management and prevention of the MetS. However, most lack simplicity, or not 







2.4.1 AHA/NHLBI Guidelines 
 In 2005, the American Heart Association (AHA) and the National Heart, Lung, 
and Blood Institute (NHLBI) published detailed guidelines for the diagnosis and 
treatment of MetS [37]. These guidelines are a great tool for health care professionals 
to use during clinical settings, or for research purposes. 
 According to the AHA/NHLBI guidelines, the primary goal of clinical 
management in patients with MetS is to decrease the risk of atherosclerosis and to 
delay progression of T2DM, hypertension and CVD. A summary of these guidelines 
and recommendations is presented in Table 2.5.  
Table 2.5: AHA/NHLBI Guidelines for Metabolic Syndrome Management 
Metabolic risk factors Goals of Therapy 
Atherogenic dyslipidemia Primary target: reduce LDL-C  
Secondary target: reduce non-HDL-C 
Tertiary target: increase HDL-C 
Elevated BP Reduce BP to <140/90 mm Hg 
And to <130/80 mm Hg if diabetes present. 
Elevated glucose IFG  delay progression to T2DM 
Diabetes  HbA1c < 7.0% 
Pro-thrombotic state Reduce thrombotic and fibrinolytic risk factors 
Pro-inflammatory state Lifestyle therapies 
Lifestyle risk factors 
Abdominal obesity Reduce body weight by 7% to 10% during the first 
year of therapy.  
Continue weight loss till achieving desirable weight 
(BMI <25 kg/m2) 
Physical inactivity Regular moderate-intensity physical activity (30 
min/day 5 days/week (and preferably ≥60 min, 
every day). 
Atherogenic diet Reduced intake of saturated fat (<7% of total 
calories), trans fat, cholesterol (<200 mg/dL), and 
total fat (25% to 35% of total calories). 






2.4.2 The ABCDE Approach 
Five requirements were suggested for effective MetS management guidelines, 
these include being simple, comprehensive, easy to remember, easy to update and 
does not focus much on the details [31]. In 2008, Blaha and others [93] developed 
the first practical and comprehensive approach tailored especially for patients with 
MetS, that is known as the “ABCDE” approach. This approach was established at 
Johns Hopkins Hospital and peer-reviewed in the literature. It was then updated in 
2010 to take into consideration new, and novel, research in the field of prevention 
and management of the MetS [94]. The ABCDE approach was derived, in large, 
from the existing 2005 AHA/NHLBI guidelines. Using this approach allows health 
care professionals to provide the same attention and care to all their patients in an 
equal manner. The “ABCDE” letters are easy to memorize as they are the first five 
letters of the alphabet, and each of them represents an aspect in the management of 
the syndrome. This is presented in Figure. 2.6.
 
Figure 2.6: Summary of the ABCDE Approach with Recommendations 
Source: Blaha and others, 2012 [31]. 
A Assessment/ Aspirin
Increase intermediate risk 
group (5-20%)
B Blood Pressure Target 125-135/80 mmHg
C Cholesterol Aim to reduce Non-HDL-C
D Diabetes prevention/ Diet Intensive lifestyle therapy







Assessment is the most important step of any management program. If 
assessment was accurately performed, then diagnosis would be easily determined, 
intervention will be more effective, and evaluating the intervention can be effortless 
and more beneficial. The Framingham Risk Score (FRS) [95] in the United States and 
the Systematic Coronary Risk Evaluation (SCORE) project [96] in Europe are widely 
used for the assessment and prediction of CVD risk. These scores could predict the 
risk of developing CVD within a ten-year period through the Ten-Year Risk model. 
The model is divided into three risk groups, low (0-10%), intermediate (10-20%) and 
high risk group (>20%). However, evidence from the DECODE study [97], showed 
that patients classified in the low-risk group and had the MetS, presented around three-
fold more fatal CVD events compared to those from the same low-risk group but 
without the syndrome. These findings lead to a novel risk detection strategy by Blaha, 
suggesting the expansion of the intermediate-risk group to 5-20% in the presence of 
the MetS. That would allow health care providers to initiate earlier intervention 
strategies. 
In addition to assessment, aspirin therapy has been added to the management 
approach because evidence form the JPAD trail showed that a low dose of aspirin (81-
100 mg) can lessen thrombotic complications linked to CVD [92]. 
 
2.4.2.2 Blood Pressure 
Elevated blood pressure is a key underlying risk factor of the syndrome. 
According to the 2011 guidelines of the  National Institute of Health and Clinical 






hypertension [98]. The target of the MetS management is to achieve < 125-135/80 
mmHg based on the recommendations of the ACCORD trail [99], as the results of this 
study found no difference between SBP of 134 mmHg and SBP of 119 mmHg in 
decreasing CVD events after a 4.7 years follow-up. The targeted blood pressure level 
could be achieved by several approaches from lifestyle therapies including diet and 
physical activity to pharmacologic agents (if needed) such as ACE-inhibitor, beta-
blockers, thiazide diuretics, and calcium channel blockers. 
 
2.4.2.3 Cholesterol 
The “C” letter refers to “Cholesterol” and could also stand for “Cigarettes”. 
However, smoking cessation is not often highlighted in the management of the 
syndrome, because smoking is a risk factor for atherosclerotic cardiovascular disease, 
but not for the MetS.  
Cholesterol is a key measure of atherogenic dyslipidemia, one of the main 
underlying risk factors of the MetS (see section 2.2.6). Under cholesterol, the focus 
should be on measuring non-HDL-C. Non-HDL-Cholesterol includes the 
concentrations of Apo-B lipoproteins, LDL, VLDL, IDL, and chylomicron remnants. 
It can predict CVD better than LDL-C, especially when the levels of triglycerides are 
high [59]. It can be calculated by measuring total cholesterol and HDL-C during 
routine lipid profile testing.  
Lifestyle therapies are the first approach in the management of atherogenic 
dyslipidemia. A meta-analysis published in 2008 [100] included 37 prospective cohort 






diets with high fiber content and low glycemic index were preferable because of their 
favorable effects on serum glucose, serum triglycerides, and insulin levels. 
Regular exercise is also recommended for the management of atherogenic 
dyslipidemia. The HERITAGE Family Study showed that people with elevated 
triglycerides levels and reduced HDL levels, acquired the greatest advantage from a 
regular aerobic exercise training program [101].  
If dyslipidemia was still existing even after therapeutic lifestyle changes were 
implemented, then certain drugs could be used to assist patients in achieving their 
target lipid profile. The use of statins, fibrates and niacin has been recommended by 
the AHA [37], which is presented in Table 2.5 based on the risk group of the patient. 







Low 160 190 Therapeutic lifestyle 
changes 
Intermediate 130 160 Therapeutic lifestyle 
changes 
Intermediate high (130-100) (160-130) Use statin to achieve goals. 
High (100-70) (130-100) To achieve LDL goal  
use statin. 
To achieve non-HDL goal 
 intensify statin, and if 
the goal was not met, add 
fibrate or niacin. 
Source: Grundy and others, 2005 [37]. 
 
2.4.2.4 Diet/Diabetes Prevention 
“D” refers to diet and diabetes prevention. However, many therapies are now 
available for diabetes prevention, thus it is treated as a separate aspect in the 
management approach. Diet is supposed to feature weight reduction goals and 






Weight reduction is the primary goal of treatment for patients with central 
obesity. It was proven that a reduction of 7%-10% from the initial weight will improve 
all MetS components through reducing underlying risk factors like insulin resistance, 
inflammation and ectopic fat storage [102].  
Many diets were suggested and used over the years to induce weight loss. Very-
low-caloric diet (800 Kcal/day) was able to reduce 6.5% of weight during four weeks, 
resulting in a significant reduction of blood pressure, serum triglyceride, serum 
glucose, and serum cholesterol [103]. However, these kinds of diet are usually 
deficient in many essential nutrient and have poor compliance on the long run. Over 
the period of one year a hypocaloric high-carbohydrate, low-fat diet (HCLF) was 
compared with a hypocaloric low-carbohydrate, high-fat (LCHF), or high-protein diet, 
also known as the Atkins diet. The study found significant weight reduction, 
improvement in insulin sensitivity, and reduction in blood pressure were associated 
with both diets, and no significant difference was found between the two [104].  
A randomized control trail studied the effectiveness of four different diets for 
reducing weight and MetS risk factors. One hundred and sixty obese/overweight adult 
participants (22-72 years old) with hypertension, impaired fasting glucose, or 
dyslipidemia were equally divided into the four following groups, Atkins diet (low-
carbohydrate), Zone diet (macronutrient balance), Ornish diet (low-fat), and Weight 
Watchers diet (calorie restriction) [105]. After a year of dietary intervention, all four 
diets triggered a modest reduction in body weight and a significant reduction in the 
LDL/HDL ratio. Greater dietary adherence rates were associated with greater weight 
reduction and improved cardiac risk factors for all groups; however, all groups had 






 The Mediterranean diet characteristics matches that of the diet recommended 
by the AHA in 2005 [37]. It is rich in omega-3 fatty acids, natural antioxidants and 
fiber from fruits, vegetables, nuts and whole grains. A recent meta-analysis of 50 
studies including 534,906 participants, investigated the association between the 
Mediterranean diet and the MetS. Adherence to the diet revealed a protective role 
against MetS components like waist circumference (-0.42 cm; 95%CI -0.82 to -0.02), 
triglycerides (-6.14mg/dl; 95%CI -10.35 to -1.93), systolic BP (-2.35 mmHg; 95% CI 
-3.51 to -1.18), and plasma glucose (-3.89mg/dl; 95%CI -5.84 to -1.95) [106]. These 
findings are very important from a public health perspective, since this diet is easy to 
follow and it is highly efficient for prevention of the MetS and its components. 
 The low glycemic index diet is another great dietary approach for the 
management of the MetS and prevention of T2DM and CVD [107, 108]. It is easy to 
adopt by various populations and cultures because cultural or traditional diets can be 
tailored to follow it. It is simply about choosing low glycemic index foods and 
avoiding those with high glycemic index, regardless of the cuisine. The aim of the diet 
is to cause a slow increase in plasma glucose after food ingestion. This diet is 
recommended by the ADA for the prevention and management of diabetes [16]. A 
randomized control trial included 73 obese young adults compared the metabolic 
benefits of a low glycemic index diet and a low-fat diet for a total of 18 months (six 
months dietary intervention and 12 months follow-up). After the six months of 
intervention, the low glycemic index group had a greater reduction in triglyceride 
(P=0.02) and greater increase in HDL-C (P =0.002). At 18 months, the low glycemic 
index diet group had significantly more reduction in weight (–5.8 vs –1.2 kg; P = .004) 
than the low-fat diet [107]. These findings demonstrate how beneficial a low glycemic 






 All discussed diets had the ability to reduce weight; however, weight reduction 
is not enough. Maintenance of weight reduction is the key to prevention of metabolic 
risk factors. Before recommending a certain diet for a patient, the dietitian should think 
about the possibility of adopting that diet for life. Short-term (maximum of two years) 
dietary intervention studies are only available, and they all show partial weight regain 
and poor compliance on the long run [105, 107, 109]. Therefore, long-term studies are 
required to confirm the ability of patients to lose weight using dietary interventions 
without regaining it. 
Patients should also be advised about improving their sleeping patterns. Recent 
meta-analyses and systematic reviews provided evidence that quality and quantity 
(very-long or short) of sleep are highly associated with weight gain and increase 
incidence of diabetes, they could also predict cardiovascular and metabolic outcomes 
[110-112]. 
 Diabetes prevention programs usually use lifestyle therapies to reduce the 
incidence of diabetes by reducing weight and increasing physical activity levels [113]. 
Moreover, other approaches like pharmacologic therapies including metformin [114], 
α-glucosidase inhibitors [115], and thiazolidinedione [116] were investigated for 
prevention and management of diabetes. Even bariatric surgery is considered one of 
the treatment options, especially for people living with morbid obesity and other 
comorbidities. 
 A randomized control trail entitled “The Diabetes Prevention Program” 
included 3,234 non-diabetic adults, with elevated fasting plasma glucose and/or 
elevated two-hour post prandial plasma glucose concentrations. The study included 






twice/day) group, and one control group receiving placebo. The mean follow-up period 
of the study was 2.8 years. The metformin group reduced the risk of diabetes 
development by 31%, whereas the intensive lifestyle intervention group decrease it by 
58%, in comparison with the placebo group [114]. 
 The ADA’s recommendations in 2015 included the use of intensive lifestyle 
modifications as a first line therapy for diabetes prevention and management that 
embraces reducing the weight by 7% to 10% and increasing physical activity to 150 
minutes per week (moderate-intensity). The use of metformin could be considered for 
patients with higher risk of developing diabetes (HbA1c > 6%, metabolic syndrome, 
or family history of diabetes). The use of other oral drugs has currently no specific 
recommendations, and could be used as a tertiary line of therapy [16]. 
 
2.4.2.5 Exercise  
 Physical activity was shown to promote weight reduction, improve insulin 
sensitivity, reduce ectopic adipose tissue, and decrease inflammatory markers. A 
systematic review and meta-analysis compared the effectiveness of dietary 
interventions versus dietary plus exercise interventions on the long-term (two years), 
confirmed the significant effect of diet plus exercise interventions in reducing weight, 
compared to the diet only interventions [117].  
 Many studies from around the world confirmed the beneficial effect of exercise 
in preventing and delaying the onset of MetS [118-121]. In the USA, 8,570 adult men 
participated in a cross-sectional fitness study. The study concluded high inverse 







In Mexico, 5,118 adult participants were enrolled in a cohort study 
investigating the association of MetS risk factors and level of physical activity. The 
cohort noted a great reduction in the risk of developing MetS among men (OR 0.72; 
95%CI 0.57-0.95) and women (OR 0.72; 95% 0.57-0.95) who reported exercising for 
more than or equal to 30 minutes per day during their leisure time [123]. 
 Current recommendations of the IDF/AHA/NHLBI advocate working out for 
a minimum of 30 minutes five times per week. However, it is preferred to do moderate-
intensity physical activity for ≥ 60 min/day, every day [4]. Patients should be advised 
to aim for weight reduction and weight maintenance when choosing the type and 
intensity of their work out. Pedometers and other activity tracker could be used for 
motivation [120]. Cardiac rehabilitation is highly recommended for patients with a 
high risk of CVD or who recently experienced coronary heart failure[124]. 
 
2.4.3 Bariatric Surgery 
 Treatment options for patients with obesity could also include bariatric surgery. 
Bariatric surgery could be considered as a treatment option for patients with morbid 
obesity (BMI >40 kg/m2) or those with obesity (BMI >35 kg/m2) plus serious obesity 
related comorbidities [125]. A meta-analysis published in 2013 included 11 studies 
and 796 participants (BMI mean 30-52), and compared non-surgical methods of 
treating obesity with surgical methods. The study found significantly higher reduction 
in weight induced by bariatric surgery [126]. A randomized control trail included 60 
patients (30 and 60 years) with a BMI ≥ 35, a five-year history of diabetes, and an 
HbA1c ≥ 7.0%, randomly divided into three groups. The first group received medical 






gastric bypass or biliopancreatic diversion. After two years of follow-up, the study 
found no reduction in diabetes in patients from the medical therapy group, a 75% 
reduction in the gastric bypass group and a 95% reduction in the biliopancreatic 
diversion group (P<0.001, Figure 2.7) [127]. The same results were obtained with 
similar trails investigating other surgical techniques like Roux-en-Y gastric bypass and 
Sleeve gastrectomy [128, 129]. 
Source: Mingrone and others, 2012 [127]. 
  
Figure 2.7: Change in the percentage of HbA1c during two years intervention of 






2.5 Prevalence of the Metabolic Syndrome 
 Prevalence of the MetS differs between nations, genders, age groups, ethnic 
groups, and also according to the definition used for diagnosing. Moreover, the 
prevalence of the syndrome is increasing among many populations around the world, 
this is mainly due to the decrease in physical activity, increase in rates of obesity and 
overweight, along with other environmental factors [130]. The total prevalence of the 
MetS among Emirati adults according to the IDF and ATPIII definitions was 40.5% 
and 39.6%, respectively in 2008[5]. This is higher than all other Gulf Cooperation 
Council (GCC) countries (Table 2.7, Figure 2.8), and amongst the highest worldwide 
(Table 2.8). 
 
Table 2.7: Prevalence of the MetS among adults in GCC Countries 
WHO: World Health Organization; ATP: National Cholesterol Education Program 
Adult Treatment Panel; IDF: International Diabetes Federation; UAE: United Arab 





































































It was noted that the MetS is more prevalent among adult women. The 
difference between men and women ranged from 0.1% in Kuwait to 13% in the UAE. 
This could be explained by the lower physical activity levels reported among Emirati 
females due to cultural and weather restrictions [135]. 
The prevalence of the syndrome was reported to be significantly associated 
with older age, in the same population. For example, in Saudi Arabia the prevalence 
was 12.8% in the 18-29 years old group, increased to 32% in those aged 30-39, 53.1% 
among adults aged 40-49 and 67.1% among older people (50-55 years) [134]. A 
greater association was also observed between obesity level and the prevalence of the 
syndrome in both genders. In China, for example, the prevalence of MetS increased 
from 9.8% in normal weight adult men to 26.9% in overweight adult men, and from 
17.8% in normal weight adult females to 31.1% in overweight adult females [136]. 
The MetS prevalence is generally increasing significantly over time. For instance, the 
Korean population witnessed a great increase from 24.9% in 1998 to 31.3% in 2007 
[137]. The prevalence of the MetS in different countries around the world is presented 
in Table 2.8. 







































































































































































































Gentles et al., 
2007 [155]. 
MENA: Middle East and North Africa; USA: United States of America; ATP: National 
Cholesterol Education Program Adult Treatment Panel; IDF: International Diabetes 
Federation; CDS: Chinese Diabetes Society; WHO: World Health Organization; EGIR: 






 This high prevalence of the syndrome was not only observed among adults, 
many studies reported high numbers in adolescents as well. In the US, the prevalence 
of the MetS among adolescents (12-19 years) was 4.2% [156]. Six point five percent 
of Mexican children and adolescents (10-18 years) met the ATPIII definition of the 
syndrome [157]. In Saudi Arabia, the prevalence among 10-18 years old boys and girls 
was 9.4% [158]. In Kuwaiti female adolescents (10-19 year), 14.8% met the IDF 
defining criteria of the MetS [159]. Moreover, 13% of Emirati adolescents were 
reported to have the MetS [6]. These numbers are extremely high and action is urgently 
needed at the national and global level to reduce the prevalence of MetS, and its 
components, especially obesity. The obesity epidemic is usually blamed on physical 
inactivity and poor dietary habits [160]. 
 Studies from the UAE reported very low physical activity levels between adults 
and adolescents, especially females [135, 161, 162]. In 2009, Belal reported that the 
prevalence of physical inactivity is almost 37.9% among men and 56.7% among 
women. Moreover, 38.4% of adolescent males and 42.6% of adolescent females spend 
≥ 3 hours/day sitting [163]. In a qualitative study among Emirati female adults, the 
first barrier to being physically active was stated to be the lack of social support from 
friends and families [164]. Another study claimed that low physical activity levels 
between Emirati female adolescents is mainly due to cultural and climate restrictions 
[135]. As a matter of fact, there is a lack of national-level studies investigating the 
level of physical activity in the country, barriers to being active, and transition of 
physical activity trends overtime. This type of information is highly important as it is 
the basis for developing future interventions, policy making decisions, and assessing 






 Dietary habits in the UAE are better documented in the literature. In 1998, 
Musaiger and others reported very low consumption of vegetables, fruits and dairy 
products (yogurt, cheese and milk) among Emirati adults [165]. In 2009, Bin Zaal and 
others, indicated high consumption of fast food and high caloric snacks among Emirati 
adolescents, and found a significant association between the consumption of 
chocolates, sweets, fast foods, soft drinks, and rates of obesity in Emirati adolescent 
girls [166]. In the same year, Bilal stated that 77.5% of men and 75.7% of women eat 
less than five servings of fruits and vegetables per day [163].  
Recently, a study was published about nutrition transition in the UAE. The 
study presented data about the high prevalence of obesity and factors behind it. 
Positive energy balance was seen among all age groups, with around 40% of boys and 
girls (6-10 years) consuming more calories than their requirements. More than 20% of 
calories consumed were coming from calorie-dense snacks and 14% from empty-
calorie drinks [167]. Other than the low consumption of fruits and vegetables, many 
studies blamed high rates of obesity on the replacement of traditional Emirati foods by 
westernized high caloric fast foods, and the replacement of water with empty-calorie 
soft drinks [165-168]. A very recent study investigated the nutritional knowledge about 
Emirati traditional foods among Emirati adults. About 50% of females and 70% of 
males stated that they consider traditional foods healthy; however, only 18.2% of 
males and 14% of females reported daily consumption of traditional foods [169]. 
Conversely, other studies from the Gulf region reported considering traditional food 
as an unhealthy option, and it might be the reason behind the epidemic of obesity and 
T2DM. These studies build their conclusions on food composition data available in 







Unfortunately, very little information is available about the food composition 
and glycemic index of Emirati traditional foods. Food composition databases offer 
comprehensive information on the concentrations of nutrients in foods; this 
information is considered the base of any quantitative study of nutrition. It is also 
useful in clinical practice, food manufacturing, designing health promotions, 
regulation of nutrition and health claims, epidemiological studies, and policy decision 
making [174]. 
Recently, ten traditional dishes commonly consumed in the UAE were 
chemically analyzed for proximate composition and mineral content [175]. However, 
some information is still needed to make better nutritional recommendations. For 
instant, lipid profile, such as monounsaturated fatty acids, polyunsaturated fatty acids, 
saturated fatty acids and trans-fatty acids content is considered crucial for planning a 
diet like the Mediterranean diet. Glycemic index and glycemic load are also very 
necessary for meal planning, especially in a population with high prevalence of MetS, 
diabetes and CVD. Planning low glycemic diets using traditional foods could be the 
key for better glycemic management and might prevent the progression of the MetS 







2.6 Glycemic Index: History 
 The dietary fiber hypothesis developed in the 1970s by Trowell was the first 
step into the establishment of the glycemic index concept [176]. Trowell observed that 
the fiber part of carbohydrates was not absorbed in the gut, which influenced certain 
actions within the lumen of the gastrointestinal tract. He linked this observation to the 
risk of some diseases like diabetes and ischemic heart disease [177, 178].  
 In 1981, David Jenkins and his colleagues invented the term “glycemic index” 
[20]. The concept was developed from observing the dramatic variation in blood 
glucose response after the ingestion of carbohydrate rich foods. Ever since, many 
studies started investigating the possible health benefits of low glycemic index diets. 
The GI concept was first used for the prevention and management of diabetes [21]. 
Afterwards, studies also investigated other important implications of the GI for the 
prevention and treatment of obesity and coronary heart disease [179, 180]. Recent 
evidence indicates the role of low glycemic index diets in the treatment and prevention 
of diabetes [181], hyperlipidemia and CVD [182]. Moreover, low GI diets were 
associated with improved insulin sensitivity [183] and regulating appetite [184]. 
In 1995 the first International Tables of Glycemic Index were published. The 
aim of these tables was to gather all published data on the GI from different studies 
and produce a convenient tool to be used in research and clinical practice [185]. About 
600 separate entries were included in the first edition of the GI tables. Furthermore, in 
2002 [186] and in 2008 [187] an updated version of the GI tables was published and 
included GL values as well. The 2008 International Table of Glycemic Index and 






The use of GI for the classification of carbohydrate-containing foods has been 
validated by the Food and Agriculture Organization of the United Nations and the 
World Health Organization in 1998 [188]. They recommended the use of GI of foods 
along with food composition tables as a guide for food choices. The American 
Diabetes Association also recommends the use of low GI diets for diabetes 
management and prevention [16]. Since many studies reported a reduction in HbA1c 




2.6.1 Definition of the Glycemic Index and Glycemic Load 
 The glycemic index is a measure of how fast a certain food could increase 
blood glucose after ingestion compared to that of pure glucose. It is defined as “the 
incremental area under the blood glucose response curve of a 50g carbohydrate portion 
of a tested food expressed as a percent of the response to the same amount of 
carbohydrate from a standard food taken by the same subject (either white bread or 
glucose), on a different day” [188]. The area under the curve (AUC) of the blood 
glucose response after consumption of pure glucose is given the value of 100. The 
AUC of blood glucose curve after ingestion of a carbohydrate-containing food is 
compared to that of pure glucose and classified as low (induces a slow raise of plasma 
glucose), intermediate, or high (causes a quick and sharp increase of plasma glucose) 
[20]. The categories of the GI values are presented in Table 2.9. Foods like legumes 
and non-starchy vegetables tend to have low glycemic index, while foods like rice, 
white bread, and honey cause larger post prandial elevation in plasma glucose 






In 1997, the concept of “glycemic load” was introduced [21, 191]. Glycemic 
load is a way to measure the glycemic index of foods depending on a standard portion 
size. It is typically calculated as the glycemic index of the food multiplied by the 
amount of available carbohydrate in standard serving, divided by 100 [21]. It is 
regularly essential to consider the GL in conjunction with GI values, particularly when 
the carbohydrate content of the test food is relatively small. For instance, broad beans 
have a high GI but because of their low carbohydrates content, they are classified as a 
low GL food [186] . The categories of the GL values are presented in Table 2.9. 
Table 2.9: Categories of Glycemic Index and Glycemic Load Values 
Category Glycemic Index Value Glycemic Load Value 
Low  ≤ 55 ≤ 10 
Medium 56-69 11-19 
High ≥ 70 ≥ 20 
Source: Brand-Miller and others, 2005 [192], Salmeron and others, 1997 [191]. 
 
2.6.2 Methodology of the Glycemic Index 
 The first protocol of measuring GI with clinical utility and without 
methodological controversy was described by Wolever and others in 1991 [193]. This 
protocol was later adopted by the FAO/WHO in 1998 with minor modifications [188]. 
The sample size for testing glycemic index with sufficient statistical power 
should be at least 10 test subjects [188]. Fifty grams of available carbohydrates is used 
to calculate the portion size of test foods, which is equivalent to 50 g of standard food 
(glucose). However, for low carbohydrate foods, 25 g could be used [194]. Tests 
should be randomized in blocks and the duration of testing should not exceed four 






with one day gap between tests [188]. The evening before a test, volunteers should 
restrict caffeine-containing drinks, avoid vigorous physical activity and fast overnight 
[195]. During the test, subjects should consume foods with 250 ml of water within 10-
15 min. Capillary finger-prick blood samples are collected while fasting and at 15, 30, 
45, 60, 90, and 120 min after ingesting the test meal. The area under the glucose-
response curve is calculated based on incremental AUC, by ignoring the area under 
the baseline. Incremental area under the curve (IAUC) for each food is calculated as a 
percent of the mean response to the IAUC of standard food taken by the same subject. 
The values of all subjects are then averaged to obtain the GI value for the food [193]. 
According to the FAO/WHO expert report on the GI methodology, The GI is 
calculated using the following equation: 
𝐺𝐼 =  
𝐼𝐴𝑈𝐶 𝑓𝑜𝑟 𝑡ℎ𝑒 𝑡𝑒𝑠𝑡 𝑓𝑜𝑜𝑑 𝑐𝑜𝑛𝑡𝑎𝑖𝑛𝑖𝑛𝑔 (𝑋)𝑔 𝑜𝑓 𝑎𝑣𝑎𝑖𝑙𝑎𝑏𝑙𝑒 𝐶𝐻𝑂
𝐼𝐴𝑈𝐶 𝑜𝑓 𝑎 𝑟𝑒𝑓𝑒𝑟𝑛𝑐𝑒 𝑓𝑜𝑜𝑑 𝑤𝑖𝑡ℎ 𝑎𝑛 𝑒𝑞𝑢𝑎𝑙 𝐶𝐻𝑂 𝑝𝑜𝑟𝑡𝑖𝑜𝑛
× 100 
 The IAUC under each blood glucose response curve (for standard food or test 
food) is calculated as illustrated in Figure 2.9, by adding areas A+B+C+C+D+E+F all 
together and ignoring the negative areas [188]. The individual IAUC values for each 
test food in each subject are presented as a percentage of the mean IAUC value for the 
repeated standard food tests taken by the same subject. The GI of each test food is 








Source: FAO/WHO, 1998 [188] 
 
2.6.3 Factors influencing the Glycemic Index 
The GI of foods varies significantly due to many factors such as cellular 
structure (e.g. degree of ripening), gross structure (e.g. grinding and particle size), 
granular starch structure (e.g. heat treatment), amount of carbohydrates, type of sugar 
(i.e. glucose, sucrose, lactose, or fructose), co-existence of nutrients (i.e. dietary fiber, 
fat, or protein), starch nature (amylose and amylopectin), cooking method, and food 
processing [194]. Other factors could include the addition of organic acids, gelling 
fibers, amylase inhibitor or sugars to the food [196]. Therefore, there is usually a 
considerable variation in the GI of the same food produced by different manufacturers 




































Figure 2.9: The Incremental Area Under the Curve (IAUC) equals the sum of the 






Table 2.10: Main Factors Affecting the GI of Foods and Meals 
Food Factor Example Effect on GI 
Starch type Amylopectin (branched) Higher GI 
 Amylose (unbranched) Lower GI 
Starch granular 
structure 
Heating Higher GI when 
gelatinized 
Degree of ripeness Higher ripeness Higher GI 
Processing Grinding, milling, or rolling Higher GI 
Acids Added Reduce GI 
Gelling fibers Added Reduce GI 
Amylase inhibitor Added Reduce GI 
Added sugars Fructose Reduce GI 
Protein Added  Reduce GI 
Fat Added Reduce GI 
Source: Arvidsson-Lenner and others, 2004 [196]. 
2.6.4 Glycemic Index in Health and Disease 
 Recently, the glycemic index became not only popular as a useful tool in 
planning meals for patients with diabetes, but also as an important intervention for the 
prevention and management of dyslipidemia, cardiovascular disease, obesity, and 
other chronic diseases in the general population [189]. The hypothesis suggests that a 
higher increase in the postprandial glycaemia, is the triggering mechanism for disease 
progression [19]. 
 
2.6.4.1 Glycemic Index and Obesity 
 Epidemiological studies show a great increase in the epidemic of obesity 
worldwide. In the United States, the prevalence of overweight adults (≥ 20 years) was 
33.9% in 2012 [197]. In the same report, 35.1% of the US population was found obese, 
and 6.4% met the criteria of extreme obesity (BMI greater than or equal to 40) [197]. 






from 36% in 2000 to reach 48% in 2010 [167]. This included an increase in extreme 
obesity among Emirati women from 7% in 2000 to 17% in 2010 [167]. The reason 
behind this epidemic is blamed on positive energy balance, characterized by low 
energy expenditure due to physical inactivity, and high energy intake due to over 
consumption of calorie dense foods [198]. Yet the reality is that it is more complicated 
because many genetic and environmental factors are involved. In an attempt to solve 
the issue, many diets were developed over the years to promote weight loss and 
maintenance, such as the low fat diet, high protein diet, low calorie diet and very low 
calorie diet [104, 199]. These diets have shown poor compliance in the long run, and 
were all associated with weight regain after a period of time [105]. This is probably 
due to the effect of these diets on reducing basal metabolic rate, therefore, 
compensating for caloric reduction [200]. 
 The low glycemic index diet does not restrict caloric intake nor limit the intake 
from any of the food groups that are essential for a balanced diet. It simply advises 
increasing the consumption of foods from the low glycemic index category and avoid 
those from the high glycemic index category. Moreover, recent evidence suggest that 
low glycemic index diets may help prevent weight regain and promote weight 
reduction maintenance after weight loss, by reducing the usual decrease in energy 
expenditure and basal metabolic rate associated with weight reduction [201]. 
 There are two suggested mechanisms by which a low GI diet is suggested to 
promote weight loss. First, by reducing appetite and food intake owed to differences 
in plasma glucose and insulin concentrations. The second hypothesis is that low GI 







Many studies investigated the effect of a low glycemic index diet on body 
weight. In 2014, a randomized control trail of 104 obese adolescents (15-18 years), 
evaluated the effect of a low GI diet versus a conventional Chinese diet on BMI over 
six months. This intervention trial reported an association between low GI diet and 
decreased calorie intake, healthier dietary composition (increased fiber intake and 
reduced fat intake), and reduced BMI in obese adolescents [202]. Another randomized 
control trail published in 2014 included 122 individuals with overweight and obesity. 
Participants were randomly assigned to a high-GI diet, a low-GI diet, or a low-fat diet. 
After six months of intervention, the trail reported a significant reduction in the BMI 
(Figure 2.10) and improvement in insulin sensitivity in the low GI diet group compared 
to the low-fat [203]. 
Source: Juanola-Falgarona and others, 2014 [203]. 
 In contrary, another randomized clinical trial entitled “DIOGENES” 
investigated the effect of a high dietary protein diet and GI diet on weight loss 
maintenance in people living with overweight and obesity in two centers across 
Europe. The one-year results of this intervention reported no significant difference 






between the two diets in reducing weight; however, the high protein diet was 
associated with less weight regain after the year of intervention [204]. 
 It is important to keep in mind that a high GI diet is not the only factor 
contributing to the epidemic of obesity. In fact, many genetic and environmental 
factors are involved in a very complex manner, not only at the individual level, but 
also at the family, community, country and even global level [179]. Low GI diet has 
been shown to reduce weight and help in maintaining lost weight, however, 
controversy is still present because there are no long-term and big-scale studies 
available on GI and body weight [100]. 
 
2.6.4.2 Glycemic Index and Diabetes 
 Diabetes is a chronic disease characterized by abnormalities in the metabolism 
of carbohydrate, fat, and protein along with hyperglycemia. Complications of the 
disease include macrovascular and microvascular damage in the eyes (retinopathy), 
kidneys (nephropathy) and nerves (neuropathy). If left untreated, these complications 
could progress into blindness, kidney failure, amputation and even death [205]. 
During the past three decades, the prevalence of diabetes mellitus in the world 
has doubled, which presented a great challenge to the public health of all nations. 
According to the recent regional fact sheets of the International Diabetes Federation 
[2] there are 382 million people living with diabetes in the world with a prevalence of 
8.3%. The IDF expected an increase by 205 million by 2035. The prevalence of 
diabetes in the Middle East and North Africa (MENA) region is even higher than the 
world average with 9.7%. Based on the same fact sheets, United Arab Emirates was 






other GCC countries, Saudi Arabia, Kuwait, Bahrain and Qatar having the prevalence 
of 23.9%, 23.1%, 21.9% and 19.8% respectively [2]. 
 Diet and lifestyle modifications are considered the basis for preventing and 
managing diabetes. The main aim of therapeutic lifestyle changes for people living 
with diabetes are weight reduction, improving glycemic control and reducing the risk 
of cardiovascular comorbidities [16]. Postprandial glycaemia could be controlled by 
controlling the amount of carbohydrates in a diet (carbohydrate counting and exchange 
list) or the nature of carbohydrates in food (glycemic index). The use of glycemic index 
for managing diabetes is still controversial. The American Diabetes Association 
(ADA) reviewed the evidence on the use of GI as an intervention for diabetes 
prevention and management in the “2015-Standards of Medical Care in Diabetes” 
publication [16]. They stated that the use of glycemic index and glycemic load in 
individuals with diabetes is recommended as studies have demonstrated a reduction in 
HbA1c by -0.2% to -0.5% when a low GI diet was followed [16]. The European 
Association for the Study of Diabetes (EASD) also recommended people with diabetes 
to choose low GI foods for better postprandial glycemic management [206]. However, 
some researchers have criticized the use of the GI system for people with diabetes, 
claiming that it is very complex and it might limit food choices if adopted as a lifestyle 
[182]. 
 
2.6.4.3 Glycemic Index and Cardiovascular disease 
 According to the World Health Organization, cardiovascular diseases are the 
leading cause of death globally. In 2012, about 17.5 million people died from 
cardiovascular diseases, representing 31% of total global deaths [1]. Among these 






stroke [1]. Cardiovascular diseases (CVDs) are a cluster of disorders occurring in the 
heart and blood vessels, such as coronary heart disease, ischemic heart disease, stroke, 
cerebrovascular disease, peripheral arterial disease, rheumatic heart disease, 
congenital heart disease and others. Most of the CVDs are preventable through 
improving dietary habits, cigarettes cessation, physical activity and reduction in 
alcohol consumption. Diets targeting prevention of CVDs mainly focus on the type 
and amount of fats present in a diet, such as the Mediterranean diet [207]. However, 
epidemiological studies have reported an association between high glycemic index and 
glycemic load diets and increased risk of CVDs [100, 108]. 
 The 2011 DIOGENES trail, a controlled dietary intervention study from across 
Europe that included 932 overweight adults who were randomized to one of the five 
ad libitum diets for 6.5 months. The diets were either high protein, low protein, high 
GI, low GI, or a control. The study resulted in a greater reduction in high-sensitivity 
C-reactive protein blood levels (−0.46 mg/L; 95% CI −0.79 to −0.13) among the 
groups assigned to GI diet, compared to the high GI diet group (P<0.001). This 
reduction in low-grade inflammation suggests a positive effect of GI diet with 
cardiovascular risk [208]. A randomized control trail among 73 people living with 
obesity (18-35 years) studied the difference between low GI diet and low-fat diet for 
six-months intervention and a one-year follow-up. The study indicated a beneficial 
effects of the low GI on high-density lipoprotein cholesterol (HDL-C) and triglyceride 
concentrations even after the intervention was over [107]. 
 Available evidence supports the role of glycemic index and glycemic load in 






investigating risk of CVD in relation to GI and GL are needed to provide the required 
power for future meta-analyses on this topic [209]. 
 
2.7 Summary 
 The epidemic of metabolic syndrome was thoroughly discussed in this 
literature review. The importance of addressing this cluster of diseases in the UAE 
population was highlighted, and recommendations for prevention and management 






Chapter 3: Materials and Methods 
3.1 Introduction 
This chapter outlines and discusses the research design, methodology and 
analyses followed in each of the two experiments presented in this dissertation; 
therefore, it is divided into two sections: 
- Section I: prevalence of the metabolic syndrome and its component factors 
among female students at United Arab Emirates University and their 
association with anthropometric measurements; 
- Section II: Glycemic Index (GI) values of commonly consumed foods in 
the UAE. 
For both sections, the participants’ recruitment, research design schemes, data 
collection and data analysis are discussed. 
 
3.2 Prevalence of the Metabolic Syndrome and its Component Factors among 
Female Students at United Arab Emirates University and their Association 
with Anthropometric Measurements 
 
3.2.1 Study Population 
This study is a cross-sectional population-based epidemiological study. It was 
conducted during the academic year 2013/ 2014 at United Arab Emirates University 
(UAEU) in Al-Ain, United Arab Emirates. The study population included students 
from all eight colleges of the university except the College of Medicine and Health 
Sciences, as they are located in a different campus The sampling method was stratified 
random sampling [210]. All female students were divided into strata by college, then 
a random subsample consisting of 10% of the students from each college were 
proportionally selected. Those were then contacted through e-mail to voluntarily 






The total number of females registered in the university during that academic 
year was 8846 students. 885 students received an invitation to participate. 654 students 
showed interest in the study with a response rate of 74%, and out of these 99 students 
were excluded from the study for the following reasons: 56 students did not show up 
for the data collection appointment, 25 students refused to give blood, 7 students were 
pregnant, 5 students were breastfeeding, 4 students were on long-term medication and 
2 students did not have good blood flow. Therefore, the final number of participants 


















Participants were asked to read the study information sheet carefully and were 
given the chance to ask questions related to the study before taking part (Appendix 1). 
Figure 3.1: Study Participant’s Enrolment Process 
n=885 Students received invitation to participate 
n=654 Students responded (Response Rate=74%) 
n=555 Students completed the study 
 
 
n=99 Excluded for the following reasons: 
n=56 Did not show for appointment 
n=25 Refused blood collection 
n=7 Pregnant 
n=5 Breastfeeding 
n=4 On long-term Medication 






Participants were excluded if they did not meet the following inclusion criteria: had a 
disease or was on medication; was pregnant or breastfeeding; older than 25 years old 
or younger than 17 years old; and if she refused to provide blood sample. A written 
informed consent to participate in the study has been obtained from all participants 
before taking part (Appendix 2). An identification number was assigned to each 
participant to maintain anonymity, which confirmed confidentiality and helped link 
the participant to their clinical measurements and blood samples. Only cumulative data 
was reported to protect the privacy of all participants. 
 
3.2.2 Ethical Approval 
 Ethical approval for the study was obtained from the United Arab Emirates 
University Scientific Research Ethics Committee (UAEU, Reference Number 
DVCRGS/370/2014) and from Al Ain Medical District Human Research Ethics 
Committee (Number 14/48) (Appendix 3). All participants who agreed to join the 
study provided a written informed consent before taking part, as attached in Appendix 
2. 
 
3.2.3 Anthropometric Measurements 
The use of anthropometric measures for the assessments of the nutritional 
status of individuals and societies was first introduced by Brožek in 1956 [211]. It has 
been found that anthropometric measures have a great advantage as they can be related 
to past exposures, present practices or health related events in the future. 
Anthropometric measurements are normally divided into two groups, the first group 






head circumference. The second group determines body composition, which includes 
body fat and body fat-free mass [10, 212]. Both groups are highly important and their 
use has been recently increased in clinical settings, assessing interventions’ outcomes 
and conducting surveillance at the population level [213].  
Body size and composition measures including: height, weight, body fat 
composition, waist circumference (WC), hip circumference (HC]), waist-to-hip ratio 
(WHR), neck circumference (NC), mid-upper arm circumference (MUAC) and skin-
fold thickness at four sites (biceps, triceps, subscapular and suprailiac) were all carried 
out by the researcher (Mohamad, M.) in the nutrition clinic of the Nutrition and Health 
Department at UAEU. All measurements were completed during a single fifty-minute 
session with the participants reporting to the clinic at fasting state and have restricted 
fluid (excluding water intake) for 12-14 hours prior to testing. 
Results were recorded immediately after the measurements on a data sheet 
(Appendix 4) and were then checked by another skilled researcher. Each measurement 
was taken three times and averaged. As the participants of this study were all females, 
they were asked not to visit the clinic during their menstrual cycle. Measures were 
taken while the participants wore minimal clothing (as local culture permits) and no 
shoes. Participants were asked to rest for 15 minutes to allow climate adjustments and 
relaxation before any measurements were taken. During rest time, they were asked to 
complete a brief health questionnaire (Appendix 5). It included questions about 
demographic data, supplements and medications use, tobacco use, diet, physical 
activity, sleeping patterns, perceptions about obesity, personal history of NCDs, and 
family history (first-degree relatives) of NCDs. Participants completed the 






needed on any aspects of the questionnaire or the study as a whole. All devices used 
for measurements were calibrated on a daily basis though out the study. 
 
3.2.3.1 Height 
Height was measured using a portable stadiometer (Seca Stadiometer, Seca 
Ltd, Birmingham, UK), and was measured to the nearest millimeter. Participants were 
asked to take a deep breath and stand upright, looking straight ahead horizontal with 
the Frankfurt plane, with shoulders relaxed, legs straight, and knees placed together. 
They were also asked to keep their feet flat with heels close together, and their shoulder 
blades, buttocks, and heels touching the measurement board [10]. 
 
3.2.3.2 Body Weight and Body Composition 
Body weight and body composition were measured using the Tanita Segmental 
Body Composition Analyzer (Tanita BC-418 Ltd, Tanita UK, Figure 3.2). The 
analyzer was placed on a hard, flat surface, and body weight was recorded to the 
nearest 0.1 kg. 
The Tanita segmental body composition analyzer uses the BIA (bio-electrical 
impedance analysis) method for analysis. It measures impedance by introducing a safe 
known amount of constant current source with a high frequency (50 kHz, 500μA) into 
the body. It then calculates body fat percentage, fat mass, fat-free mass, and predicted 
muscle mass through a regression formula using height, weight, age, and impedance 







Participants were asked to step bare foot on the weighing platform unassisted, 
looking straight ahead, making sure that heels were placed on the posterior electrodes, 
and the front part of the feet were in contact with the anterior electrodes. Participants 
were asked to stand still for few seconds to allow weight measurement to appear on 
the screen, then were asked to grasp the grips with both hand and wait for a few more 
seconds to allow measurement of the impedance.  
 
3.2.3.3 Body Mass Index 
The most commonly used measure for the classification of adult population 
according to their weight status is the ratio of weight to height which is known as Body 
Mass Index (BMI) or (Quetelet’s Index). BMI is calculated by dividing the weight in 
kilograms by the height squared in meters (kg/m2) [215]. The latest publication of the 
World Health Organization (Table 3.1) was used as a guideline for the classification 
of adults according to BMI [198]. 
  






Table 3.1: WHO Classification of Overweight in Adults According to Body Mass 
Index 
Classification BMI (kg/m2) Risk of comorbidities 
Underweight < 18.50 Low 
Normal range 18.50 – 24.99 Average 
Overweight ≥ 25.00  
Pre-obese 25.00 – 29.99 Increased 
Obese class I 30.00 – 34.99 Moderate 
Obese class II 35.00 – 39.99 Severe 
Obese class III ≥ 40.00 Very severe 
Source: WHO, 2000 [198]. 
 
3.2.3.4 Waist Circumference  
 Waist circumference (WC) showed high correlation with abdominal fat 
content, measured by computer tomography or by dual X-ray absorptiometry (DXA), 
in several studies [54, 216]. Measurement was performed using a plastic tape touching 
the skin, with a width of 0.7cm, held in a horizontal plane, midway between the inferior 
margin of the ribs and the superior border of the iliac crest or at umbilicus level for 
obese participants [217]. The participants were asked to stand erect, relaxing the 
abdomen, with arms placed on the side, and weight equally divided over both legs. 
WC was recorded to the nearest millimeter. The IDF and the American Heart 
Association/the National Heart, Lung, and Blood Institute (AHA/NHLBI) cut-offs [4] 
(Table 3.2) were used according to ethnicity and gender  to identify the increased risks 







Table 3.2: Cut-off Values of Waist Circumference Based on Ethnicity and Gender 
Country/ ethnic group Gender Waist circumference 
Europids Male ≥ 94 cm 
Female ≥ 80 cm 
South Asians Male ≥ 90 cm 
Female ≥ 80 cm 
Chinese Male ≥ 90 cm 
Female ≥ 80 cm 
Japanese Male ≥ 85 cm 
Female ≥ 90 cm 
Ethnic South and Central 
Americans 
Use South Asian recommendations until more 
specific data are available 
Sub-Saharan Africans Use European data until more specific data are 
available 
Eastern Mediterranean and 
Middle East 
Use European data until more specific data are 
available (Arab) populations 
Source: Alberti, 2009 [4]. 
 
3.2.3.5 Hip Circumference 
 Hip circumference (HC) is usually not used for assessing body composition 
and the distribution of body fat as a single measure. It is rather used along with the 
WC to calculate the waist-hip circumference ratio (WHR). HC was measured using a 
plastic tape, with a width of 0.7cm, held in a horizontal plane by touching the skin 
without pressing the soft tissue, at the level of maximum posterior extension of the 
buttocks [218]. Participants were standing erect, relaxing the abdomen, feet together 







3.2.3.6 Waist-Hip Circumference Ratio  
 Waist-Hip circumference ratio (WHR) is a simple and easy method which 
allows distinguishing between fatness in hips and buttocks areas and fatness in the 
abdomen and waist areas. It is calculated by dividing waist circumference by hip 
circumference. Several studies reported strong association between elevated WHR and 
increased risk of developing type 2 diabetes (T2D), ischemic stroke and coronary heart 
disease [220, 221]. The cutoffs values used for waist–hip ratio were (0.90) and (0.80) 
for men and women, respectively, as suggested for Middle Eastern populations in 2011 
by the World Health Organization [222]. 
 
3.2.3.7 Neck Circumference 
Neck circumference (NC) is used as an indicator for upper-body subcutaneous 
adipose tissue distribution. Several population-based studies have shown an elevation 
of cardiovascular and metabolic syndrome (MetS) with the increase of neck 
circumference values [9, 223]. NC was measured at mid-neck height, between 
midcervical spine and midanterior neck and recorded to the nearest 1 millimeter, using 
plastic tape, calibrated weekly, with the tape not being too tight or too loose, and just 
lying flat on the skin. Participants were asked to keep the head up, relax the shoulders 
and look straight ahead [224]. The cutoffs for neck circumference are not well 
established yet; however, in the Chinese population the values of ≥38 cm and ≥35 cm 
for men and women respectively, were reported to be the best cutoffs to identify 
overweight participants. However, the same study suggested that the values of ≥39 cm 
and ≥35 cm for men and women respectively, were the best cutoffs to determine 







3.2.3.8 Mid-Upper-Arm Circumference 
Mid-upper-arm circumference (MUAC) is usually used for the determination 
of nutritional status in population-based studies, as it is useful for the diagnosis of 
protein-energy malnutrition and participants’ starvation, especially in children and 
adolescents [225] . Participants were asked to remove their sleeves and stand erect, 
and bend their right arm at the elbow in a perpendicular angle. The edge of the shoulder 
(acromion process on shoulder blade) and elbow (olecranon process of the ulna) were 
located and marked. Plastic non-stretchable tape was used to measure the distance 
between the two marks and the middle point was located and marked. The MUAC was 
then measured using the same measuring tape, wrapped around the mark, while the 
arm is hanging down the side of the body and relaxed. MUAC was recorded to the 
nearest millimeter [226]. MUAC values of 23.0 cm and 22.0 cm for men and women 
respectively, were suggested to be useful cut-off points for simple screening of 
nutritional state in adults of the third world [227]. 
 
3.2.3.9 Skinfold Thickness 
 Skinfold thickness measurements are usually used for the estimation of total 
body fat; a single skinfold measure or multiple skinfolds could be used. Many studies 
have suggested the use of skinfolds for assessing subcutaneous fat considering the low 
cost, simplicity (when performed by trained examiner) and effectiveness in 
comparison with ultrasound [228, 229]. 
A Lange Caliper (Cambridge Scientific Industries, Cambridge, MD, Figure 
3.3) was used for the measurement of skinfold thickness at four sites: triceps, biceps, 






During all skinfold measures, participants were asked to stand erect, with 
shoulders relaxed and arms hanging freely at their sides. The right side of the body has 
been used for taking all measures, as it is the current practice by the National Health 
and Nutrition Examination Survey (NHANES). The middle point in the upper right 
arm was already marked for the measurement of the MUAC. This point was used for 
the measurement of triceps (from the back side of the arm) and biceps (from the inner 
side of the arm). The skin and underlying fat were grasped at a vertical angle, about 2 
cm above the mark, using the thumb and the forefinger of the left hand of the examiner. 
The caliper was then placed on the mark and the value was recorded to the nearest 0.5 
millimeter. Measures were repeated three times and averaged [231]. The subscapular 
skinfold was measured by grasping the skin and underlying fat at the inner border of 
the scapula at an angle of 45° from horizontal. The suprailiac was taken from the 
midaxilary line directly above the iliac crest by picking up the skin and underlying fat 
at an angle of 45° following the natural folding of the skin [10]. 
The logarithmic transformation of the sum of means from all four sites of 
skinfold thickness was used for the calculation of equivalent fat content as a percentage 
of total body weight. Fat content was calculated using specific linear regression 
equation for females between 17-29 years old, as described by Durnin and Womersley 
in 1974 [232]. 






3.2.4 Biochemical Measurements 
 Biochemical measurements are usually used to confirm a clinical diagnosis or 
to detect abnormalities in the levels of lipid profile. Unlike clinical, dietary and 
anthropometric measures, biochemical measures provide an objective method for the 
assessment of nutritional status [10]. Static biochemical measures were used in this 
study, with the biological fluid being blood, and the parameters of interest being: 
fasting plasma glucose (FPG); total cholesterol (TC); high density lipoprotein (HDL); 
low density lipoprotein (LDL); triglycerides (TG); high sensitivity C-reactive protein 
(Hs-CRP); hemoglobin (Hb); and glycated hemoglobin (HbA1c). Wet blood chemistry 
method using venous blood samples was used for the analysis of all previously 
mentioned tests. Hemoglobin and glycated hemoglobin tests were completed using 
whole blood, while serum was used for other tests. 
 
3.2.4.1 Blood Collection 
Blood collection was performed by a registered phlebotomist nurse. All 
equipment needed for blood collection was prepared and organized at the blood 
collection station ahead of time, including: gel separator in Sekurplast test tubes with 
clot activator (5 ml) (VACUTEST KIMA, Arzergrande, Italy); vacutainer system with 
butterfly needle attachment (Greiner Bio-One, Gmbh, Austria); alcohol swabs; cotton 
swabs; tourniquet; plastic gloves; sharp container and safe-box containing dry ice to 
transport blood samples into the laboratory for analysis, which was adjacent to the 
nutrition clinic in our case. Labels with the identification number of each participant 






The World Health Organization guidelines published in 2010 for drawing 
blood were followed [234].The nurse identified a good size vein in the antecubital 
fossa or forearm and used a vacutainer with a butterfly needle to collect blood into the 
test tube. Two drops (8µL) of whole blood from the vacuum tube were utilized for the 
analysis of hemoglobin and glycated hemoglobin. All used butterfly needles were 
disposed in the sharp container and all other contaminated supplies were properly 
disposed according to proper biohazards waste disposal. Test tubes were inverted 
gently six to seven times and allowed to clot for two hours in ice. Tubes were then 
centrifuged at 1500 RPM for 15 minutes. Serum was transferred (1 ml * 2 aliquots) 
into 2 ml Eppendorf safe-lock tubes, properly labeled and immediately stored using 
labeled Eppendorf containers at - 80°C until the time of analysis. The date of 
withdrawal, centrifugation and storage were recorded. At the time of analysis, samples 
were thawed on ice for 30 minutes with proper handling during thawing and storage 
[235]. 
 
3.2.4.2 Analytical System 
 An in vitro diagnostic test for the quantitative determination of total 
cholesterol, triglyceride, LDL-cholesterol, HDL-cholesterol, high sensitivity C-
Reactive protein and fasting plasma glucose concentrations in human serum was 
performed using an automated biochemical analyzer (Cobas® C111, Roche 
Diagnostics, Indianapolis, IN, Figure 3.4), which has been evaluated and 
recommended for such use [236]. All tests were run in triplicate and averaged. 
 The researcher (Mohamad. M) attended the training held by the Roche 
Company on the proper operation methods of the Cobas® c111 analyzer and was 






used according to the manufacturers’ recommendations. The reagents needed to 
perform lipid, glucose and hs-CRP tests were loaded into the reagent disk and 
calibrated using appropriate calibrators provided by the company. Calibrator f.a.s® 
was used for the calibration of glucose, triglyceride and total cholesterol. Calibrator 
f.a.s Lipids® was used for the calibration of LDL and HDL cholesterol, and Calibrator 
f.a.s.Proteins® was used for the calibration of high sensitivity C-reactive protein. The 
daily operation included routine tasks that are needed to prepare and monitor the 
system and to analyze samples. When the system is switched on it performs several 
checks to make sure that all preconditions are met, and the screen displays the current 
status of the system. The system asks for daily maintenance orders that include: 
checking external fluid containers; loading the reagent disk; checking the cuvettes; 
performing calibration and performing quality control using PreciControl ClinChem 
Multi 1® and PreciControl ClinChem Multi 2®, as required. Once preparation was 
done, the samples were identified, required tests were selected and samples were 
placed. 
 






3.2.4.3 Lipid Assessment 
 Cobas® C111 uses the homogeneous enzymatic colorimetric principle for 
testing a lipid profile. A lipid profile is a group of blood tests used as a screening tool 
to identify abnormalities in cholesterol, HDL, LDL and triglyceride blood levels. This 
could help in the diagnosis of a certain disease, such as a genetic disorder, a 
cardiovascular disease or any other diseases. It is also important for monitoring the 
efficiency of certain drugs. 
Dyslipidemia is one of the risk factors for many diseases like diabetes, 
ischemic heart disease and hypertension [237-239]. The clinical interpretation of lipid 
values in this study was according to the Integrated Guidelines for Cardiovascular 
Health and Risk Reduction in Children and Adolescents (Table: 3.3) set in 2011 by the 
National Heart, Lung, and Blood Institute (NIH)[240]. 
Table 3.3: Recommended Cut Points for Lipid and Lipoprotein Level in Young 














Total Cholesterol - - <190 190-224 ≥225 
LDL-Cholesterol - - <120 120-159 ≥160 
Non-HDL 
Cholesterol 
- - <150 150-189 ≥190 
Triglycerides - - <115 115-149 ≥150 
HDL Cholesterol <40 40-44 >45 - - 








 The determination of triglycerides is useful for the diagnosis and treatment of 
many diseases like diabetes mellitus and nephrotic syndrome [241, 242]. 
Determination of triglycerides using Cobas® C111 follows the principle of enzymatic 
colorimetric test, as described by Siedel and others in 1993 [243]. The triglyceride 
reagent was handled as described by the manufacturer. Excessive foaming was 
removed from the surface of the reagent prior to loading into the analyzer. Human 
serum was collected and prepared according to Tietz, 1995 [244] as described in 
section 3.2.4.1. 2µL of serum and 120µL of the reagent were required for each run of 
the test. The measuring range of the test was 8.85-885 mg/dL. The expected value for 
the normal range is <115 mg/dL and the cut-off value used for defining metabolic 
syndrome was ≥150 mg/dL [4]. 
 
3.2.4.5 Total Cholesterol 
 Cholesterol analyses are used for screening against atherosclerotic risk and in 
the diagnosis and treatment of disorders involving elevated cholesterol values, such as 
heart diseases [245]. Cobas® C111 follows the enzymatic colorimetric method for the 
analysis of cholesterol as described by Allain and others (1974) [246]. The Roche 
cholesterol assay meets the National Institute of Health 1992 goals of less than or equal 
to 3% for both precision and bias [247]. The Cholesterol reagent was handled as 
recommended by the manufacturer. 2µL of serum and 47µL of the reagent were 
required for each run of the test. The measuring range of the test was 9.7-800 mg/dL. 







3.2.4.6 Low Density Lipoprotein 
 Low Density Lipoproteins (LDL cholesterol) play an important role in causing 
and influencing the progression of atherosclerosis especially coronary sclerosis [248]. 
Various methods are available for the determination of LDL cholesterol such as: 
ultracentrifugation as the reference method; precipitation methods; and lipoprotein 
electrophoresis. Cobas® C111 follows the homogeneous enzymatic colorimetric 
method for the analysis of LDL cholesterol as described by Bachorik and Ross, 1995 
[249]. This direct LDL cholesterol assay meets the National Cholesterol Education 
Program 1995 [249] goals of < 4% total Coefficient of Variation, bias < 4% versus 
reference method, and 12% total analytical error [250].The LDL cholesterol reagent 
was handled as recommended by the manufacturer. Human serum was collected, 
stored and prepared as described in section 3.2.4.1. 2µL of serum and 200µL of the 
reagent were required for each run of the test. The measuring range of the test was 
3.86-548 mg/dL. The acceptable value for normal range is <120 mg/dL [240]. 
 
3.2.4.7 High Density Lipoprotein  
 Monitoring HDL cholesterol in human serum is of clinical importance, as an 
inverse correlation exists between HDL cholesterol concentrations and the risk of 
atherosclerotic disease. Elevated HDL cholesterol concentrations are protective 
against coronary heart disease, whereas lower concentrations of HDL cholesterol 
coexisting with elevated triglyceride levels, increase the risk for cardiovascular disease 
[251]. A variety of methods are available to determine HDL cholesterol, including: 
ultracentrifugation; electrophoresis; precipitation-based methods; high performance 
liquid chromatography (HPLC); and direct methods. Cobas® C111 follows the 






cholesterol as described by Sugiuchi and others in 1995 [252]. This direct HDL 
cholesterol assay meets the 1998 National Institutes of Health (NIH)/ National 
Cholesterol Education Program (NCEP) goals for acceptable performance [253]. The 
HDL cholesterol reagent was handled as recommended by the manufacturer. Human 
serum was collected, stored and prepared as described in section 3.2.4.1. 2.5µL of 
serum and 200µL of the reagent were required for each run of the test. The measuring 
range of the test was 3-120 mg/dL. The normal reference range of the HDL-
Cholesterol for females is >45 mg/dL [240]. The cut-off value used for defining 
metabolic syndrome for females is HDL cholesterol of <50 mg/dL [4]. 
 
3.2.4.8 Fasting Plasma Glucose  
 The concentration of glucose in blood is controlled within narrow limits by 
many hormones, the most important of which are produced by the pancreas. An 
increase in blood glucose concentration is usually caused by a deficiency in the insulin 
hormone secretion or action, which is referred to as diabetes mellitus [17]. Measuring 
fasting plasma glucose has been recommended by the ADA for the diagnosis of 
diabetes and screening of high risk populations [16]. It is also part of the harmonized 
joint statement (IDF/AHA/NHLBI) diagnostic criteria of MetS [4]. Cobas® C111 
follows the enzymatic reference method with hexokinase UV test for the analysis of 
glucose as described by Tietz, 2006 [254]. The glucose reagent was handled as 
recommended by the manufacturer. Human serum was collected, stored and prepared 
as described in section 3.2.4.1. 2µL of serum and 180 µL of the reagent were required 
for each run of the test. The measuring range of the test was 1.98-720 mg/dL. The cut-






values for fasting plasma glucose are presented in Table 3.4 according to the standards 
of medical care in diabetes set by the American Diabetes Association, 2016 [255]. 
Table 3.4: Blood Test Levels for Diagnosis of Diabetes and Pre-diabetes 
 FPG mg/dL OGTT mg/dL HbA1c % 
Normal ≤99 ≤139 About 5 
Pre-Diabetes 100-125 140-199 5.7–6.4 
Diabetes ≥126 ≥200 ≥6.5 
Source: American Diabetes Association, 2016 [255]. 
 
3.2.4.9 High sensitivity C-Reactive Protein 
 High sensitivity C-reactive protein (Hs-CRP) is an acute phase protein in 
inflammatory reactions. Measurement of CRP is used for the detection of infection, 
inflammatory disorders and associated diseases. Highly sensitive measurement of CRP 
may also be used for the assessment of risk for future coronary heart disease [256]. 
Several studies have suggested the addition of Hs-CRP for metabolic syndrome 
diagnostic criteria and for the assessment of global cardiovascular risk [69, 71]. A 
variety of methods are available to determine Hs-CRP, including nephelometry and 
turbidimetry. The Cobas® C111 Hs-CRP assay is based on the principle of particle-
enhanced immunological agglutination, were human CRP agglutinates with latex 
particles and coated with monoclonal anti-CRP antibodies. The precipitate is then 
determined turbidimetrically as described by Price and others in 1987 [257]. The Hs-
CRP reagent was handled as recommended by the manufacturer. Human serum was 
collected, stored and prepared as described in section 3.2.4.1. 6µL of serum and 110 






test as recommended by the Centers of Disease Control and Prevention (CDC) and the 
American Heart Association (AHA) [63, 258] for cardiovascular disease (CVD) risk 
assessment is shown in Table 3.5. 
Table 3.5: High Sensitivity CRP Cut-off Points for CVD Risk Assessment 




Source: Pearson and others, 2003 [63].  
 
3.2.4.10 Hemoglobin and Glycated Hemoglobin 
 Hemoglobin (Hb) is a protein in the red blood cells responsible for carrying 
oxygen from the lungs to all body tissues and returning carbon dioxide from tissues 
into the lungs. Measurement of hemoglobin concentration in whole blood is the most 
commonly used test for iron deficiency anemia [10]. HemoCue® Hb 201+ portable 
photometer system (HemoCue® Ltd, UK, Figure: 3.5) was used for the assessment of 
hemoglobin concentration using 4µL of venous whole blood according to the blood 
collection method described in section 3.2.4.1. The precision and accuracy of 
hemoglobin values obtained using HemoCue® Hb 201+ are comparable to those 
obtained using the cyanmethmoglobin method [259]. Standardized procedures for 
measuring hemoglobin concentration using HemoCue® Hb 201+ were followed to 
enhance the accuracy and reliability of the test, as described by Burger and Pierre-
Louis, 2003 [260]. The interpretive criteria used for defining anemia as recommended 















Non-pregnant women  
(15 years of age and above) 





Source: WHO, 2011 [261]. 
Glycated Hemoglobin (HbA1c) is a form of hemoglobin that was first 
identified as an unusual hemoglobin found in patients with diabetes. It has been 
correlated to glucose measurements and was clinically used for monitoring diabetic 
patients, as it reflects average blood glucose over the previous eight to twelve weeks 
[262]. HbA1c is recommended to be used as a diagnostic test for diabetes mellitus by 
the World Health Organization [263].  
The HemoCue® HbA1c 501 system (HemoCue® Ltd, UK, Figure: 3.6) has 
been used for assessing glycated hemoglobin percentage using 4µL of venous whole 
blood. Blood collection method is described in section 3.2.4.1. The HemoCue® 
HbA1c 501 system uses a boronate affinity assay to separate the glycated hemoglobin 
fraction from the nonglycated fraction. The setup, operating procedures and storage 
instructions for the analyzer, reagent cartilage and check cartilage were performed as 
described in the operating manual. Quality control of the system was performed on 
daily and monthly bases using the appropriate check cartilage (HemoCue® HbA1c 
501 Daily Check Cartilage and HemoCue® HbA1c 501 Monthly Check Cartilage). 
Good correlation has been found when the HemoCue® HbA1c 501 system was 
compared to the KESLAB laboratory method, Variant II (BioRad), using venous blood 






pre-diabetes are presented in Table 3.4, which follows the 2015 recommendations of 
the American Diabetes Association [16]. 
 
 
3.2.5 Blood Pressure Measurement 
 Blood pressure is the pressure that blood applies on the wall of the arteries in 
the circulatory system. It is measured per unit area on the walls of arteries (mm Hg). 
The cardiac cycle consists of two phases, the contraction phase causing systolic blood 
pressure (SBP) and the relaxation phase causing diastolic blood pressure (DBP). Blood 
pressure is used for the diagnosis and monitoring of hypertension, which is 
characterized by an increase of systolic or diastolic blood pressure. Hypertension is 
found to be associate with increased incidence of renal disease and cardiovascular 
disease (CVD) [265]. Systolic and Diastolic blood pressures were measured using a 
calibrated digital automated blood pressure monitor (Omron HEM-907-E7 Digital 
Figure 3.6: HemoCue® HbA1c 501 System 
 






Blood Pressure Monitor, Omron Healthcare Europe, Mie, Japan, Figure 3.7). Blood 
pressure was measured using the participants’ right upper arm, after removing clothing 
covering the cuff placement. Appropriate cuff size was determined according to the 
MUAC measurements of the participant. They were seated on a comfortable chair, 
asked to uncross their legs with the back of the right arm supported on a table to keep 
it at the level of the right atrium. They were then instructed to relax and avoid talking 
during the measurement procedure. The measurement was taken twice with 5 minutes 
break between measures, and the average measurement was recorded [266]. 
The Omron HEM-907 device has been validated and evaluated in several 
studies, having passed the two phases of the International Protocol, and therefore 
becoming eligible for use in clinical measurement of blood pressure [267, 268]. The 
use of such an automated device for measuring blood pressure requires no expensive 
training, reduces observer errors and minimizes the white coat effect [266]. The cut-
off values used for the interpretation of blood pressure measures are presented in Table 
3.7, as published in the Seventh Report of the Joint National Committee (JNC7) on 
prevention, detection, evaluation and treatment of high blood pressure in 2003 [269]. 
Table 3.7: Classification of Blood Pressure 
Category SBP mm Hg  DBP mm Hg 
Normal <120 and <80 
Prehypertension 120-139 or 80-89 
Hypertension, Stage 1 140-159 or 90-99 
Hypertension, Stage 2 ≥160 or ≥100 







3.2.6 Power Analysis 
 A school-based study conducted by Mehairi and others in 2013 reported the 
prevalence of MetS among adolescents (12-18 years old) according to the IDF criteria 
to be 22% and 4% among boys and girls respectively [6]. Minitab software (version 
16, Minitab Inc., PA) was used to calculate sample size. With a planned proportion 
estimate of 4% at 95% confidence level, a sample size of 555 would achieve a 1.58% 
margin of error for the survey of the female student population. With a planned 
proportion of 50%, generally used when there is no prior information, at 95% 
confidence level the sample size of 555 would achieve a 4.04% margin of error.  
 
3.2.7 Statistical Analysis 
 Data analyses were carried out using Stata version 13 (Stata Corp, College 
Station, TX). Descriptive statistics were computed; continuous variables were 
summarized by means and standard deviations (SD) and proportions for categorical 
variables. The Student’s t-test was used to compare means for continuous variables 
between participants with and without MetS. Univariable and multivariable logistic 
regression analysis was used to study the association between anthropometric and 
chemical measures and the presence or absence of metabolic syndrome as the outcome 






variable. To account for perfect prediction of MetS by BMI categories and the small 
sample size across BMI class, we applied the Firth logistic regression to obtain 
reasonable and robust estimates. All statistical significance was assessed at the 5% 
significance level. 
 
3.3 Glycemic Index (GI) Value of Commonly Consumed Foods in the UAE 
 
3.3.1 Study Population 
 A total of 112 healthy participants from UAEU students and staff were 
recruited voluntarily to participate in this study. This was done through posters 
distributed around the campus buildings, e-mail invitations and word of mouth. 
Participants did not take part if they had any of the exclusion criteria, defined as: age 
being less than18 or more than 55 years old; body mass index (BMI) value more than 
or equal to 25 kg/m2 or less than 18.5 kg/m2; fasting plasma glucose (FPG) value of 
more than 6.1 mmol/l, and having a known history of impaired glucose tolerance or 
diabetes mellitus. Participants were asked to complete a health-screening 
questionnaire before taking part in the study to make sure that they met the inclusion 
criteria (Appendix 6). Participants who met the inclusion criteria were given complete 
details about the study protocol (Information sheet, Appendix 7) and the chance to ask 
questions. They were asked to fast for 12 hours the night before the test, while water 
consumption was allowed in moderation. The day before the GI test, they were 
requested to limit their intake of caffeine-containing drinks and to minimize their 
participation in any intense physical activity, such as: long periods of swimming or 






3.3.2 Ethical Approval 
Ethical approval for the study was obtained from the United Arab Emirates 
University Scientific Research Ethics Committee (UAEU, Reference Number 
(516/09) (Appendix 8)). All participants provided written informed consent before 
taking part. An example of the consent form used in this study is attached in Appendix 
9. 
 
3.3.3 Anthropometric Measurements  
 Anthropometric measurements were carried once for each participant, prior to 
recruitment, to confirm the participant fit the inclusion criteria. All measurements were 
completed in the fasting state from 7-10 a.m., while wearing minimal clothing (as local 
culture permits) and no shoes, after resting for 15 minutes to allow climate adjustments 
and relaxation. All devices used for measurements were calibrated on a daily basis. 
Results were recorded immediately after measurement on a data sheet (Appendix 7) 
and were checked by another skilled researcher. Each measurement was taken three 
times and averaged. 
Height, weight, body composition, waist circumference, and hip circumference 
were measured as described earlier sections 3.2.2.1, 3.2.3.2, 3.2.3.4, and 3.2.3.5. Body 
mass index and waist-hip ratio were calculated using equations described in sections 







3.3.4 Blood Glucose  
 Blood samples were obtained using the OneTouch® UltraSoft™ Adjustable 
Blood Sampler (Johnson and Johnson, Middle East, Inc) which uses the OneTouch® 
UltraSoft™ pen and the OneTouch® FinePoint™ lancets with a thin tip for less painful 
penetration. Capillary blood was obtained from the third finger on the left hand. 
Several reports suggested the use of capillary blood rather than venous blood sampling 
for reliable glycemic index (GI) testing [194, 270]. Before the finger-pricking process, 
all the equipment and supplies that were needed were assembled and hand hygiene 
was performed. Participants were asked to warm their hand to increase blood flow. 
The WHO 2010 guidelines for withdrawing blood were followed [234]. The site of the 
finger-pricking was selected, and 70% isopropyl alcohol was applied and allowed to 
air dry. Then, the skin was punctured and the first drop of blood was wiped away using 
dry tissue. Squeezing the finger was avoided to minimize plasma dilution. A 5 µL 
blood sample was collected in the microcuvette by capillary action. All sharps, and 
waste materials were disposed of appropriately. Blood glucose was measured using 
the HemoCue Glucose 201+ portable system (HemoCue® Ltd, UK, Figure 3.8). This 
machine uses the principle of modified glucose dehydrogenase in which the total 
amount of glucose is measured at the end point photometrically. It is factory calibrated 
and traceable to the ID GC-MS method; therefore, it needs no further calibration. It 
has been previously used in a number of investigations [195, 271]. 






3.3.5 Test Foods 
 Twenty-three different foods commonly consumed in the United Arab 
Emirates were tested, including breads (n=6), entrée dishes (n=2), main dishes (n=7) 
and sweet dishes (n=8) as shown in Table 3.8. The test foods were purchased from 
three popular restaurants in the UAE that specialize in Emirati cuisine and have 
standardized recipes (see Table 3.8 for major ingredients). These restaurants were 
selected based on a questionnaire conducted on 315 participants, to investigate the 
most popular Emirati cuisine restaurants in the area. Three samples from each dish 
were obtained at three different occasions for the chemical analyses, and each food 








Table 3.8: Main ingredients used in the preparation of 23 traditional foods commonly 
consumed in the UAE 
Test Food Description Major ingredients 
Breads  
Arabic bread Baked bread Wheat flour, salt, yeast and water 
Regag bread Thin crispy crepe Wheat flour, salt and water 
Chebab bread Emirati pancake 
Wheat flour, egg, yeast, salt, sugar, milk 
powder, saffron and water 
Muhalla bread Emirati crepe 
Wheat flour, egg, sugar, milk powder, 
saffron, cardamom and water. 
Khameer bread Baked bread 
Wheat flour, egg ,yeast, salt, sugar, milk 
powder, saffron and water 
Gurus Fried bread 
Wheat flour, vegetable oil, egg, sugar, salt 
and water 
Entrée Dishes 
Fendal Boiled sweet potato Sweet potato and water 
Chami Cottage cheese Buttermilk, salt and white cumin seeds 
Main dishes  
Harees, beef 
Crushed wheat with 
meat 
Crushed wheat, meat, water, ghee, salt and 
cardamom 
Thareed, beef 
Bread with meat 
stew 
Wheat flour, meat, potatoes, onions, 
tomatoes, zucchini, tomato paste, vegetable 
oil, spices and water 
Thareed, chicken 
Bread with chicken 
stew 
Wheat flour, chicken, potatoes, onions, 
tomatoes, zucchini, tomato paste, vegetable 
oil, spices and water 
Biryani, chicken Rice with chicken 
Rice, salt, Ghee, spices, chicken, garlic and 
onion 
Machbous, fish Rice with fish 
Rice, tomato, onion, water, salt, spices and 
fish 
Arseyah Rice with chicken 
Rice, salt, chicken, water, cardamom and 
cinnamon 
Marqoqa 
Bread with chicken 
stew 
Wheat flour, chicken, potatoes, onions, 
tomatoes, carrots, tomato paste, vegetable oil, 
garlic, spices and water 
Dessert Dishes 
Khabisa Cardamom pudding 
Wheat flour, Water, Ghee, sugar and 
cardamom 
Leqemat Doughnut cake 
White flour, vegetable oil, salt, sugar, egg and 
yeast 
Batheetha Date paste 
Date fruit, wheat flour, Ghee, sugar, 
cardamom and cinnamon 
Kanfaroosh Doughnut cake 
Wheat flour, yeast, sugar, egg, vegetable oil, 
saffron, cardamom and backing powder 
Sago Sago seed with sugar Sago seeds, sugar, saffron and water 
Asida Flour with sugar Wheat flour, sugar, salt and water 
Habba Hamra Red seed drink 
Evaporated milk, red seed, cardamom, 
saffron, black pepper and sugar 







3.3.5.1 Chemical Analyses 
 Food composition databases offer comprehensive information on the 
concentrations of nutrients in foods, this information is considered the base of any 
quantitative study of nutrition. It is also useful in clinical practice, food manufacturing, 
designing health promotions, regulation of nutrition and health claims, 
epidemiological studies and policy decision making [174]. Awareness about the 
importance of establishing food composition tables in the UAE and other Gulf 
Cooperation Council (GCC) countries has increased during the last twenty to thirty 
years. In Saudi Arabia, twenty Saudi dishes were analyzed for their cholesterol and 
fatty acid contents [272], and six dishes were investigated by Al-Jebrin and others in 
1985 for chemical composition and nutritional quality [170]. In Qatar, seventeen 
traditional Qatari dishes were chemically analyzed in the year 1994 [273]. In a 1998 
study, conducted by Musaiger and others, where they studied the physical, proximate 
and mineral composition of four types of fermented dairy products in Bahrain [171]. 
In Oman, the proximate, mineral, fatty acid and cholesterol compositions of twenty 
dishes were analyzed [172]. In Kuwait, thirty-two Kuwaiti composite dishes were 
analyzed for their proximate composition and phytate content [274]. Recently, ten 
traditional dishes commonly consumed in the United Arab Emirates (UAE) were 
chemically analyzed for proximate composition and mineral content [175]. Although 
nutritional-composition data of traditional dishes in the U.A.E. and other Arab Gulf 
countries exist, it does not cover all test foods selected in this study. Also, available 
carbohydrate content should be known to perform glycemic index testing for any food. 
It was not calculated in other studies, and one could not even calculate it by subtracting 







Proximate composition, mineral content, vitamin content, lipids and sugars 
analyses for test foods were carried out in the Nutrition and Health Department 
laboratory at UAEU. The standard procedures of the Association of Official Analytical 
Chemists (AOAC) 2003 were followed [276]. Mineral content was determined by 
Inductively Coupled Plasma Optical Emission Spectroscopy ICP-OES [277]. Sugar, 
vitamin, caffeine, and cholesterol analysis were conducted using the HPLC technique. 
Total carbohydrate and available carbohydrate content were estimated by difference 
[274]. The energy content was calculated by multiplying the protein, carbohydrate, 
and fat by factors of 4, 4, and 9 respectively [273]. Each test was done in triplicate and 
averaged to minimize possible errors, and to increase reliability and accuracy. 
 
3.3.5.2 Sample Preparation 
 Each test food was purchased and analyzed on three different occasions 
(beginning, middle and end of the month) to ensure consistency of restaurants in 
preparing and standardizing the recipe. Upon purchase, each food was transported into 
the laboratory in a cool‐box. Extraneous matter such as bones from chicken and meat, 
was removed. The main components of each meal were then individually weighed. 
Test foods were thoroughly homogenized using a mechanical high-speed blender and 
then sampled for moisture analysis. The residual homogenized samples were dried in 
the oven at 65°C for 16 hours, ground into fine powder and stored in air-tight 







3.3.5.3 Proximate Analysis 
a) Determination of Moisture 
 
Moisture analysis follows the simple principle of evaporation of water from the 
sample through oven drying. Dry matter is then determined as the residual after drying 
[278]. Aluminum dishes were dried at 105°C for two hours and then allowed to cool 
down to room temperature in the desiccator. Dishes were then weighed using Scaltec® 
SBA 31 analytical electronic balance sensitive to 0.01 mg (Scaltec® Instruments, 
Heiligenstadt, Germany, Figure 3.9). Approximately 1 gram of sample food was 
weighed and spread uniformly across the aluminum dish. Mommert® forced-air 
drying oven (Schutzart DIN 400-50-IP20, Figure: 2.10) was used to dry the samples 
for 16 hours at 105°C ± 3°C. Samples were placed uniformly in the oven to allow air 
circulation, then moved to the desiccator to cool down to room temperature and 
weighed to the nearest 0.01 mg. The percentage of total dry matter and total moisture 
were calculated using the following equations [276]: 
% 𝑇𝑜𝑡𝑎𝑙 𝐷𝑟𝑦 𝑚𝑎𝑡𝑡𝑒𝑟 =  
(𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑑𝑟𝑦 𝑠𝑎𝑚𝑝𝑙𝑒 𝑎𝑛𝑑 𝑑𝑖𝑠ℎ 𝑖𝑛 𝑔𝑟𝑎𝑚𝑠 −  𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑑𝑖𝑠ℎ 𝑖𝑛 𝑔𝑟𝑎𝑚𝑠)
𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒 𝑖𝑛 𝑔𝑟𝑎𝑚𝑠
× 100 
% 𝑇𝑜𝑡𝑎𝑙 𝑀𝑜𝑖𝑠𝑡𝑢𝑟𝑒 = 100 − % 𝑇𝑜𝑡𝑎𝑙 𝐷𝑀 
 






b) Determination of Ash Content 
 
Crucibles were dried in the drying oven for at least two hours at 105 °C, and moved 
into a desiccator using tongs. They were allowed to cool down to room temperature, 
weighed, and recorded to the nearest 0.01 mg. Approximately one gram of the sample 
was weighed and ashed in a muffle furnace oven (Carbolite EML 11/6, Figure 3.11) 
at 500 °C for four hours. Crucibles were then allowed to cool in the furnace to less 
than 200°C, and then weighed with the ash to the nearest 0.01 mg. The percentage of 
ash was calculated using the following equation [279]: 
% 𝐴𝑠ℎ =  
(𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑐𝑟𝑢𝑐𝑖𝑏𝑙𝑒 𝑎𝑛𝑑 𝑎𝑠ℎ 𝑖𝑛 𝑔𝑟𝑎𝑚𝑠 − 𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑐𝑟𝑢𝑐𝑖𝑏𝑙𝑒 𝑖𝑛 𝑔𝑟𝑎𝑚𝑠)  
𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒 𝑖𝑛 𝑔𝑟𝑎𝑚𝑠 
× 100 
  
Figure 3.11: Muffle Furnace Oven and Crucibles 






c) Determination of Protein Content 
 
The Kjeldahl method was used for nitrogen determination in food samples and a 
factor of 6.25 was adopted for protein-content estimation [280].The first step in the 
Kjeldahl method is the digestion of samples. Around 0.5 gram of sample was weighed 
into the digestion tube and was digested by sulfuric acid (96%) and a catalyst (Kjeldahl 
catalyst selenium tablets) using Foss Tecator 2020 digester (Foss Tecator, Höganäs, 
Sweden, Figure 3.12) at 410°C for about 45 minutes. This process resulted in the 
conversion of nitrogen to ammonia. A Foss 2300 Kjeltec Analyzer Unit (Foss 
Technologies Co., Ltd., Höganaös, Sweden, Figures 3.13) was then used to determine 
ammonia and protein content [276]. 
 
Figure 3.13: Foss Tecator 2020 Digester 






d) Determination of Fat Content 
 
The fat content was determined by Soxhlet extraction according to the AOAC and 
Horwitz, 2003 [276]. The extraction cups were dried at 105°C, for 2 hours then 
weighed to the nearest 0.1 mg. 2 grams of sample were placed in a 33 mm × 80 mm 
extraction thimble (supplied by the manufacture), and extracted with 50 ml n-
hexane/acetone (1:1, v/v) in boiling solvent for 60 minutes using the Soxhlet extraction 
in a Sotex system 2050 (Foss, Hillerød, Denmark, Figure: 2.14). Thimbles were then 
raised to the rinse position for another 60 minutes to allow evaporation of as much 
solvent as possible. The extraction cups were removed from the extractor and placed 
in an operating fume hood to finish evaporating the solvent at low temperature, then 
dried at 105°C for 30 minutes, allowed to cool down in the desiccator and weighed to 
the nearest 0.1 mg [281]. The percentage of fat content was then calculated using the 
following equation [276]: 
% 𝐶𝑟𝑢𝑑𝑒 𝐹𝑎𝑡 =  
(𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑐𝑢𝑝 +  𝑓𝑎𝑡 𝑟𝑒𝑠𝑖𝑑𝑢𝑒 𝑖𝑛 𝑔𝑟𝑎𝑚𝑠) − (𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑒𝑚𝑝𝑡𝑦 𝑐𝑢𝑝 𝑖𝑛 𝑔𝑟𝑎𝑚𝑠)










e) Determination of Fiber Content 
 
The Neutral Detergent Fiber (NDF) method was used to determine fiber content in 
food samples, which measures fiber residue (hemicellulose, cellulose, and lignin) 
remaining after digestion in a detergent solution [282]. NDF analyses was performed 
using ANKOM 200 fiber analyzer (ANKOM200, 65 rpm agitation; ANKOM 
Technology, Macedon, New York, USA, Figure: 3.15). The ANKOM Technology 
NDF method was followed [283]. The ANKOM filter bags (F57 and F58, ANKOM 
Technology) were weighed. Subsequently 0.50 grams of sample was placed in each 
bag, weighed, sealed using heat sealer (1915, ANKOM Technology) and marked using 
a solvent and acid-resistant marking pen (F08, ANKOM Technology). A bag was left 
empty and used as a blank. Afterwards, the bags were soaked in acetone for 10 
minutes, and placed on a wire screen to dry. Samples inside the bags were spread 
uniformly within them by shaking and flicking the bags to eliminate clumping. The 
bags were then placed in the ANKOM 200 fiber analyzer (Figure 3.15) with Neutral 
Detergent Solution, alpha-amylase, and sodium sulfate. When the NDF extraction was 
over, the bags were rinsed, soaked in acetone again, and allowed to dry. Then they 
were placed in an oven at 105°C for 3 hours, allowed to cool in the desiccator, and 
then weighed. The percentage of Neutral Detergent Fiber content was then calculated 
according to the following formula [283]: 
% 𝑁𝐷𝐹 =









The Total Dietary Fiber (TDF) was also analyzed in this study. According to 
the FAO/WHO in 1998[188], it is defined as the edible part of plant and animal 
material that is not hydrolyzed by the digestive enzymes in humans. It was determined 
using the AOAC 991.43 method[276]. TDF analyses was performed using the 
ANKOMTDF dietary fiber analyzer (ANKOM Technology, Macedon, New York USA, 
Figure 3.16). The ANKOM filter bags (DF-S, DF-FT, ANKOM Technology) were 
labeled, and weighed using the bag weighing holder (TDF52, ANKOM Technology). 
The chemicals and the enzymes containers were filled before each use of the analyzer 
as recommended by the manufacturer. After completing the automated processes, the 
SDF bags were rinsed with acetone twice. Once the acetone has evaporated, the bags 
were sealed with a heat sealer (1915, ANKOM Technology). They were then placed 
in the oven to dry for 90 minutes at 105°C. Afterwards, their weight was recorded. 
One bag of each sample was then sent for the determination of the protein content and 
the other one is used for the determination of the ash content. The Percentage of Total 
Dietary Fiber Value was then calculated using the dietary fiber data spreadsheets 
available on the ANKOM Technology website [284]. 







3.3.5.4 Exchange List Development 
Exchange list was first used as a method of meal planning for patients with 
diabetes and for those on weight loss regimens [285]. The food exchange list helps 
people to monitor food portion sizes, and energy intake. Basically it translates 
scientific nutrition knowledge into a practical tool. Foods from the same list can be 
used interchangeably without changing estimated amounts of carbohydrates, fat, 
protein, and total energy obtainable in a meal [286]. 
The rounding-off method described by wheeler and colleagues [285] was used 
to fit food items into exchanges as follows:  
For carbohydrate exchange: if a food portion had 1g to 5g of carbohydrates, it 
was not counted as a serving. If it had 6g to 10g of carbohydrates, it was counted as a 
half serving. When food had 11g to 20g of carbohydrates, it was counted as one 
serving. 






For fat exchange: if a food portion had 0g to 2g of fat, it was not counted as a 
serving. Yet, if it had 3 g of fat, it was counted as a half serving. Food portion was 
counted as one serving if it had 4g to 7g of fat. 
For protein exchange: if a food portion had 0g to 3g of protein from the meat 
and meat substitutes list, it was not counted as a serving. However, if it had 4g to 10g 
of protein, it was counted as one serving. 
 
3.3.5.5 Determination of Minerals 
 Major minerals and trace metals (Ca, K, Na, Mg, P, S, Co, Cu, Fe, Mn and Zn) 
were simultaneously determined in foods by Inductively Coupled Plasma Optical 
Emission Spectrometer (ICP-OES) on a Varian ICP-OES model 710-ES (Varian, Palo 
Alto, CA, USA). Simultaneous axially viewed plasma with full computer control of 
instrument settings and compatible accessories was used for the analysis as outlined in 
the manufacturers’ manual. Food samples were prepared for mineral determination by 
CEM Mars 5 microwave digestion system (Mars 5, CEM Corporation, Matthews, 
USA, Figure 3.17). The process of preparing the samples was preformed based upon 
the recommendation in US EPA method 3015A guidelines [287] as described by 
Heckman in 1971 [288]. 
Homogenized food samples were weighed into portions of 0.5 grams and 
placed into the microwave digestion vessels; then 10 ml of concentrated nitric acid and 
2 ml hydrochloric acid were added into the sample. The vessels were capped and 
placed in the microwave digestion system [289]. After cooling, de-ionized water was 
added, and the sample solution was aspirated through a nebulizer. The resulting aerosol 






emission spectra were created by radio-frequency inductively coupled plasma, which 
was dispersed by a grading spectrometer; concentrations of the line spectra were 
observed at specific wavelengths by a charged coupled detector. A fitted background 
correction was used to offset the blank signal and the matrix effect. 
 
3.3.5.6 Determination of Sugars  
 Various types of sugars including monosaccharides (glucose, and fructose), 
disaccharides (sucrose, maltose, and lactose) and trisaccharide (raffinose) were 
determined in foods by the High-Performance Liquid Chromatography (HPLC) 
method. 
Determination of sugars was performed using a Waters HPLC system (Waters, 
Milford, MA, USA, Figure 3.18). The system is composed of a Waters 717 Plus 
Autosampler, a Waters 1525 Binary HPLC pump, and a Waters 2414 Refractive Index 
Detector, operated with the Breeze software. Sugars were simultaneously analyzed 
onto a µBondapak® NH2 10µm 125Å column, 3.9 mm inner diameter by 300 mm 
(Waters Associates, Milford, MA, USA). The temperature was kept at 35 °C. The 






mobile phase consisted of acetonitrile and water (83:17, v/v), and the flow rate was 
1.5 mL/minute. Sample preparation and analysis procedures were adopted with 
modification from Yuan and others (1999) [290] and from Smith and others (1986) 
[291]. 
 
3.3.5.7 Determination of Lipids 
 The fatty acid composition of foods has recently become mandatory to be listed 
on food labels, which helps the consumer make healthier choices. However, the fatty 
acid composition is a complex combination of saturated, monounsaturated, and 
polyunsaturated fatty acids with a diversity of carbon chain lengths.  
The identification of key fatty acids requires several standards and capillary 
columns. The fatty acid composition analysis was performed using a Young Lin 6500 
gas chromatograph (YL-6500 GC, Gyeonggi-do, South Korea, Figure 3.19), fitted 
with a SP-2380 Fused Silica Capillary Column (30 m × 0.25 mm I.D × 0.20 µm film 
(2-4110), Sigma Aldrich, St. Louis, MO).  
The analytical column was heated at 50°C for 2 minutes, afterwards it was 
raised to 250°C at 4°C/min, and then held for 15 min. The carrier gas used for the 
analysis was helium, (20 cm/second) at 150°C. The Supelco 37 Component FAME 






Mix standard was used for the identification of key fatty acids in the tested food 
samples. The Fatty Acid Methyl Esters (FAMEs) were prepared following AOAC 
Method 969.33 [276]. The analysis procedure followed was as described in the 
application notes of the manufacture (Sigma Aldrich) [292]. 
The determination of the cholesterol content in food is also very important. 
However, the possible relationship between dietary cholesterol and atherosclerosis is 
still debatable and lacks homogenous scientific evidence [293]. The determination of 
cholesterol was performed using a Waters HPLC system (Waters, Milford, MA, USA, 
Figure 3.18). The system is composed of a Waters 717 Plus Autosampler, a Waters 
1525 Binary HPLC pump, and a Waters 2487 Dual λ Absorbance Detector, operated 
with the Breeze software. Cholesterol was simultaneously analyzed onto a reversed 
phase XTerra C18 column, 4.6 mm inner diameter by 150 mm, 5 µm (Waters 
Associates, Milford, MA, USA). The oven temperature was kept at 25 °C. The mobile 
phase consisted of methanol and 2-propanol (70:30, v/v), and the flow rate was 1.0 
mL/minute. Cholesterol components were detected by the UV detector that was set at 
the wavelength of 212 nm. Sample preparation and analysis procedures were adopted 
from Indyk (1990) and Essaka (2007) with modification [294, 295]. 






3.3.5.8 Determination of Vitamins 
 Vitamins are a wide-ranging group of organic compounds that are essential for 
the functioning of human bodies. They are classified in two main groups: water-
soluble and fat-soluble vitamins. The determination of vitamins in the food we 
consume is important when it comes to adopting good eating habits in humans, 
understanding possible loss in vitamins through food storage and preparation, and 
developing food labels.  
 Seven water-soluble and all fat-soluble vitamins (Vitamin C, Thiamin, 
Riboflavin, Niacin, Vitamin B-6, Folate, Vitamin B-12, Vitamin A, Vitamin E (alpha-
tocopherol), Vitamin D (D2+D3), and Vitamin K (phylloquinone)) were 
simultaneously determined in foods by the High-Performance Liquid Chromatography 
(HPLC) method. 
 The determination of water-soluble vitamins was performed using a Waters 
HPLC system (Waters, Milford, MA, USA, Figure 3.18) [296]. The system is 
composed of a Waters 717 Plus Autosampler, a Waters 1525 Binary HPLC pump and 
a Waters 2487 Dual λ Absorbance Detector, operated with the Breeze software. Water-
soluble vitamins were simultaneously analyzed onto a reversed-phase XTeera C18 
column (4.6 mm inner diameter by 150 mm, 5 μm) from Waters (Waters Associates, 
Milford, MA, USA). For water-soluble vitamins, the mobile phase consisted of 50 mM 
K2HPO4 (pH7): methanol, gradient: 1% methanol for 5 minutes, 1-30 % methanol 
(liner gradient) over 15 minutes, 30 % methanol for 5 minutes and the flow rate was 
1.0 mL/minute. The column temperature was kept at 35 °C. The injection volume was 






soluble vitamins. Supelco Application Note 148, was used as a reference for sample 
preparation and analysis procedures [297]. 
The determination of fat-soluble vitamins was performed using Waters 
ACQUITY UPLC system (Waters, Milford, MA, USA, Figure 3.20). The system is 
composed of a Waters ACQUITY sample manager, a Waters ACQUITY Binary 
solvent manager, and a Waters ACQUITY PDA eλ Detector, operated on an Empower 
software. Fat-soluble vitamins were simultaneously analyzed onto a reversed-phase 
ACQUITY BEH C18 column (2.1 mm inner diameter by 100 mm, 1.7 μm) from 
Waters (Waters Associates, Milford, MA, USA). For fat-soluble vitamins, the mobile 
phase consisted of Solvent A: Water: Acetonitrile (90:10), and solvent B: methanol 
and Acetonitrile (50:50, v/v), and the flow rate was 0.7 mL/minute. The temperate was 
kept at 35 °C. The injection volume was 5μl. The analytical column effluents were 
monitored at λ=285nm for vitamin E, at λ=265nm for vitamin K1, K2, D2, D3 and at 
λ= 325 for vitamin A acetate. Sample preparation and analysis procedures were 
adopted from Moreno and Salvado (2000) with modification [298].  






3.3.5.9 Determination of Caffeine 
  Caffeine content should be listed on the food label according to food labelling 
legislations. Although none of the foods investigated in this study have caffeine-
containing ingredients; caffeine analysis was still required to examine the possible 
addition of caffeine during preparation. 
 The determination of caffeine was performed using a Waters HPLC system 
(Waters, Milford, MA, USA, Figure 3.18). The system is composed of a Waters 717 
Plus Auto-sampler, a Waters 1525 Binary HPLC pump, and a Waters 2487 Dual λ 
Absorbance Detector, operated with the Breeze software. Caffeine was 
simultaneously analyzed onto a reversed-phase XTeera C18 column (4.6 mm inner 
diameter by 150 mm, 5 μm) from Waters (Waters Associates, Milford, MA, USA). 
The mobile phase consisted of acetonitrile and water (10:90, v/v), and the flow rate 
was 1.0 mL/minute. Caffeine was detected by the UV detector that was set at the 
wavelength of 265 nm. Samples preparation procedures were adopted with 
modification from Srdjenovic and others (2008) [299]. Whereas the analysis 
procedures were adopted from Erickson (2011) with modification [300]. 
 
3.3.6 Glycemic Index (GI) Procedure 
The GI measurement procedure followed was adapted from Wolever et al. 
(1991) [193] and Brouns et al. (2005) [194]. This same protocol is also recommended 
by the FAO/WHO (1998) [188]. Testing was repeated in at least fifteen participants 
for each test food. Prior to the test day, participants were requested to limit their intake 
of caffeinated drinks and avoid involvement in intense exercise, such as: long periods 






were asked to fast for 12 hours (overnight) the night before each test, though drinking 
water was allowed in moderation. 
Using the randomised crossover design, participants tested the reference food 
three times and each test food for one time only. Food testing was carried out on 
separate occasions with at least one-day gap between measurements to minimize any 
carry-over effects. The reference food provided was glucose powder (glucose dextrose 
monohydrate) dissolved in 200ml of water. Test foods were tested in equivalent 
available carbohydrate amounts (25 or 50 g) as per the reference food and were also 
served with 200 ml water. Test foods were purchased one day before the test, then 
heated in the morning of the test. Participants were encouraged to consume the 
reference or test foods within 15 minutes and to minimise physical activity during the 
testing time. Available carbohydrate content was used to determine the experimental 
portion (g) that would provide 50g or 25g of available carbohydrates from each test 
food. The amount of available carbohydrate was calculated by subtracting dietary fiber 
content from total carbohydrate content [227].The majority of test foods were tested 
against 50 grams of available carbohydrate. Nevertheless, if the serving size was found 
too large to ingest comfortably, this test food was tested against 25 grams of available 
carbohydrate [194]. In this study, only Chami (Cottage cheese) was tested against 25 
grams of available carbohydrate due to its very low carbohydrates content 
(5.44g/100g). The experimental portion size of each test food, shown in Table 3.9, 

















Arabic bread 63.47 ± 0.32 50 79 
Regag bread 44.37 ± 0.49 50 113 
Chebab bread 45.88 ± 1.17 50 109 
Muhalla bread 67.66 ± 4.79 50 74 
Khameer bread 54.93 ± 3.47 50 91 
Gurus 54.45 ± 2.60 50 92 
Fendal 31.64 ± 0.24 50 158 
Chami 5.31 ± 0.58 25 471 
Harees (beef) 7.74 ± 1.15 50 323 
Thareed (beef) 10.87 ± 0.24 50 460 
Thareed (chicken) 12.73 ± 2.65 50 393 
Biryani (chicken) 19.69 ± 2.05 50 254 
Machbous (fish) 18.00 ± 0.82 50 278 
Arseyah 9.85 ± 0.37 50 508 
Marqoqa 16.00 ± 0.52 50 313 
Khabisah 56.13 ± 4.65 50 89 
Leqemat 44.19 ± 1.35 50 113 
Batheetha 38.24 ± 0.97 50 131 
Kanfaroosh 39.62 ± 0.92 50 126 
Saqo 23.43 ± 3.54 50 213 
Assidah 21.09 ± 1.14 50 237 
Habba Hamra 15.96 ± 1.20 50 313 
Balalet 27.89 ± 2.19 50 179 
*Data are expressed as Mean ± SD 
 
As recommended by the FAO/WHO in 1998 [270], each participant was tested 
for the reference food twice and once for each test food. Tests were done in random 
order and on separate days, with a minimum of a one-day gap between measurements, 
to lessen the carry-over effect. On the day of the test, participants were asked to report 
to the clinic in the morning, having fasted for 12 hours. They were served a test food 
or the reference food and were asked to consume it within 15 minutes. All the test and 






Capillary blood samples were obtained by finger-prick as described earlier in 
section 3.3.4. Blood glucose was measured using the HemoCue Glucose 201+ portable 
system (HemoCue® Ltd, UK, Figure 3.8). A fasting blood sample was obtained at 0 
minutes and the reference or a test food was consumed directly afterwards. Additional 
blood samples were obtained at 15, 30, 45, 60, 90 and 120 minutes after the participant 
had begun to eat. During the time of the measurements, participants were asked to stay 
in the testing room and reduce physical activity to the minimum [270]. 
 
3.3.6.1 Glycemic Index Calculation 
Blood glucose response is usually expressed as the area under the curve (AUC). 
The total AUC includes the area underneath the curve down to a blood glucose 
measure of zero, and it is a measure of the average blood glucose concentration during 
the testing period; However, the incremental AUC is a measure of the change of blood 
glucose from the fasting plasma glucose measurement; therefore, the GI calculation is 
based on the incremental area under the blood glucose response curve (IAUC), and 
above the fasting level only. Thus if blood glucose level falls below the baseline, the 
area beneath it was ignored. Accordingly, the IAUC cannot be less than zero [270].The 
IAUC for each test food consumed by each subject was expressed as a percentage of 
the mean IAUC for the reference food consumed by the same subject, as follows: 
𝐺𝐼 =  
𝐼𝐴𝑈𝐶 𝑓𝑜𝑟 𝑡ℎ𝑒 𝑡𝑒𝑠𝑡 𝑓𝑜𝑜𝑑 𝑐𝑜𝑛𝑡𝑎𝑖𝑛𝑖𝑛𝑔 (𝑋)𝑔 𝑜𝑓 𝑎𝑣𝑎𝑖𝑙𝑎𝑏𝑙𝑒 𝐶𝐻𝑂
𝐼𝐴𝑈𝐶 𝑜𝑓 𝑎 𝑟𝑒𝑓𝑒𝑟𝑛𝑐𝑒 𝑓𝑜𝑜𝑑 𝑤𝑖𝑡ℎ 𝑎𝑛 𝑒𝑞𝑢𝑎𝑙 𝐶𝐻𝑂 𝑝𝑜𝑟𝑡𝑖𝑜𝑛
× 100 







3.3.6.2 Glycemic Load Calculation 
The glycemic load is a measure of the overall glycemic impact of the meal. 
Studies have shown that diets with a high glycemic load increase risk of type 2 diabetes 
mellitus [19, 21]. Epidemiologic studies also suggest that a high dietary GL increases 
the risk of coronary heart diseases (CHD) in manner independent of known CHD risk 
factors [108]. Glycemic load was calculated by the following formula [301]: 
𝐺𝐿 =  
𝐺𝐼 𝑜𝑓 𝑡𝑒𝑠𝑡 𝑓𝑜𝑜𝑑 × 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑎𝑣𝑎𝑖𝑙𝑎𝑏𝑙𝑒 𝐶𝐻𝑂 𝑖𝑛 𝑎 𝑠𝑒𝑟𝑣𝑖𝑛𝑔 𝑜𝑓 𝑡𝑒𝑠𝑡 𝑓𝑜𝑜𝑑(𝑔)
100
 
Serving size of test foods was not available from manufacturer, therefore it  
was adopted [195] from the Photographic Atlas of Food Portions for the Emirate of 
Abu Dhabi [302]. The amount that provides the best fit in the exchange system was 
then chosen to be a serving [286]. 
 
3.3.7 Power Analysis 
 The number of participants enrolled in the study will determine the width of 
the confidence interval (CI) and the power of the study to detect differences in 
glycemic index. It has been suggested that inclusion of 10 participants provides a 
reasonable degree of power and precision for most purposes of measuring GI [194]. In 
order to increase the power of the study to detect small differences in GI as well as to 
increase precision, a minimum of 15 participants were enrolled for each test food. 
 A recent study by Al Dhaheri and colleagues [303] reported a GI difference of 
1.4 for glucose response over time, and 1.6 for glucose response between the foods 
tested. A difference of 1.4 was also reported by Wolever in 2003 [301]. A power 






PA). The power of the study was calculated to estimate the number of participants 
needed to detect 1.4 unit differences in GI with an alpha of 0.05 using a paired t-test. 
A sample size of 15 participants for each test food was considered sufficient to detect 
difference in GI with 88% power. 
 
3.3.8 Statistical Analysis 
Data entry and analysis were carried out using Statistical Package for Social 
Sciences (SPSS) for windows, version 21.0 (SPSS Inc., Chicago, Ill., USA). Data was 
analyzed using Kruskal-Wallis to compare medians of measurements of nutrients for 
the various foods, because these measurements did not satisfy the normality 
assumption of ANOVA. The Paired t-test was used for the comparison of the mean 
glucose responses of the reference food with each one of the test foods. The Kruskal-
Wallis test was used to find the significant differences between the IAUC of the 23 
meals and Mann-Whitney test was used to follow these differences. Statistical 
significance was set at P-value of < 0.05. Values of different parameters were 







Chapter 4: Prevalence of Metabolic Syndrome among Young Female 
Emirati Adults at United Arab Emirates University  
 
4.1 Introduction 
Non-communicable diseases (NCDs) are the leading cause of deaths 
worldwide, and diabetes mellitus (DM) is the fourth major cause of NCD deaths [1]. 
DM is a complex, chronic illness that occurs either when pancreatic cells do not 
produce enough insulin or when the body is resistance to the insulin it produces [255]. 
The International Diabetes Federation (IDF) estimated the global prevalence for DM 
to be 8.3% in 2014. However; 46% of people with diabetes remained undiagnosed. 
Moreover, the IDF expects 205 million new cases of DM by the year 2035 [304]. With 
a DM prevalence of 19%, the United Arab Emirates (UAE) was ranked as having the 
fifth highest prevalence in the Middle East and North Africa (MENA) region, coming 
after other Gulf Cooperation Council (GCC) countries, like Saudi Arabia, Kuwait, 
Bahrain and Qatar [304]. In 2010, a survey conducted in the UAE reported the 
prevalence of undiagnosed DM and pre-diabetes (prediabetes refers to individuals with 
impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) [255]) to be 
14.6% and 31% respectively [3].This indicates the great number of people living with 
undiagnosed DM and pre-diabetes in the country.  
The diagnosis of Metabolic Syndrome (MetS) is based on the existence of pre-
diabetes combined with dyslipidemia (elevated levels of total or low-density 
lipoprotein (LDL) cholesterol, or low high-density lipoprotein (HDL) cholesterol 
levels), elevated blood pressure, and obesity [33]. A study conducted on Emirati adults 
(+20 years old) by Malik and others in 2008, reported the prevalence of MetS to be 
32.9% among men, 45.9% among women, and the overall prevalence of MetS was 






to be emerging from the high incidence of MetS among younger age groups 
(adolescents 12-18 years old) as suggested by Mehairi and others in 2013 [6]. The 
latter study reported that 13% of adolescents suffered from MetS, and this prevalence 
showed a positive correlation with higher body mass index (BMI) values, as it reached 
59% in obese boys. This dramatic increase in the incidence of MetS including pre-
diabetes, emphasizes the need to apply the current screening recommendations by the 
American Diabetes Association (ADA) for type 2 diabetes; hence, this endorses the 
case for testing overweight children and adolescents to detect pre-diabetes [16]. 
 The UAE is located in the Arabian Gulf region, and has a population with a 
median age of 30 years. Only 1% of the population is aged over 60 years, and about 
15% of the population is aged under 15 years of old [305]. The country has undergone 
numerous social and economic changes since oil was discovered forty years ago. The 
lifestyle of the Emirati population has changed considerably over the past 40 years due 
to the rapid improvement in socioeconomic status. This transition has led to less 
physical activity and altered eating habits. These changes, in addition to the adoption 
of a western lifestyle and diet, have led to the rise in the prevalence of overweight and 
obesity in the UAE, particularly among females [167].  
The United Arab Emirates University (UAEU) was founded in 1976, and it is 
the first and oldest comprehensive national university in the UAE. It is located in Al 
Ain city in the Abu Dhabi Emirate (capital of the UAE). The University admits UAE 
nationals from all seven Emirates and is currently enrolling around 14,000 students. 
The prevalence of MetS among Emirati females has been reported to be higher 
than that for Emirati males in the adult population (32.9% among men, 45.9% among 






lower than it is for males (21% among boys, and 4% among girls) [5, 6]. Several 
studies from the UAE have reported the sedentary lifestyle of adolescent females [135, 
306]. This highlights the importance of investigating MetS among young female 
adults, in order to facilitate the understanding of its prevalence and risk factors.  
High prevalence of MetS is a significant contributor to the increased 
cardiovascular morbidity and mortality associated with DM [74]. Primary prevention 
of the syndrome should address its risk factors including obesity, prediabetes, and 
prehypertension [121]. Aiming efforts toward reducing obesity and physical inactivity, 
across young populations is a start, especially among those at high risk. Therefore, 
identification of high risk population coupled with risk reduction strategies, could 
reduce the prevalence of MetS and may prevent its development. 
There is a paucity of data available about the prevalence of MetS and its 
relation with overweight and obesity among young female adults in the UAE. 
Furthermore, this research aimed to determine the prevalence of MetS in Emirati 
females aged 17–25 years as this age range has not been studied previously, and its 
relation to overweight and obesity in the UAE. Therefore, the purpose of this study 
was to answer two main questions:  
 What is the prevalence of MetS in Emirati females aged 17–25 years? 







4.2 Results  
 
4.2.1 Characteristics of Study Population 
The demographic and clinical characteristics of the study population by 
metabolic syndrome status are presented as mean ± standard deviation, in Table 4.1. 
The mean age of the study population was 20.4 ± 1.7 years, ranging from 17 to 25 
years. The average age of participants with MetS was not significantly different from 
those without MetS (20.9 vs. 20.4 years, P = 0.057). However, participants with MetS 
had a significantly higher weight; height; hip circumference; neck circumference; body 
mass index; body fat percentage; and high-sensitivity C-reactive protein (P< 0.001). 
MetS was also associated with higher glycated hemoglobin (6.3±1.1 vs. 5.5±0.8 %; 








Table 4.1: Demographic and Clinical characteristics of the study population by metabolic syndrome status 
*P < 0.05.
 
With Metabolic Syndrome (N=38) 
Mean ± SD 
Without Metabolic Syndrome (N= 517) 
Mean ± SD 
Student’s t-test P-value * 
Age (Year) 20.9 ± 1.7 20.4 ± 1.7 0.057 
Weight (kg) 82.1 ± 17.1 58.9 ± 12.2 < 0.001 
Height (cm) 161.3 ± 5.2 158.9 ± 5.8 0.013 
Hip Circumference (cm) 115.42 ± 12.35 98.67 ± 9.71 <0.001 
Neck Circumference (cm) 33.51 ± 5.47 30.88 ± 3.62 <0.001 
Body Mass Index (kg/m2) 31.5 ± 6.3 23.2 ± 4.6 <0.001 
Body Fat (%) 40.3 ± 3.9 32.9 ± 5.3 <0.001 
Serum Low Density Lipoprotein 
(mg/dL) 
102.5 ± 30.9 91.0 ± 24.7 0.006 
Serum Total Cholesterol (mg/dL) 165.7 ± 37.9 155.6 ± 31.9 0.063 
Glycated Hemoglobin (%) 6.3 ± 1.1 5.5 ± 0.8 <0.001 
Hemoglobin (g/dL) 12.00 ± 1.6 11.8 ± 1.5 0.482 
High sensitivity C-reactive protein 
(mg/L)  





4.2.2 Prevalence of Metabolic Syndrome 
The overall prevalence of the MetS using the IDF harmonized joint scientific 
statement criteria was 6.8 % (95% CI: 5% to 9%) (N = 38). Moreover, no MetS 
defining components were found in 242 (43.6%) participants. At least one MetS 
component was found in 213 participants (38.4%); two MetS components were present 
in 62 participants (11.2%); three MetS components were found in 27 participants 
(4.9%); four components of MetS were present in 10 participants (1.8%); and all five 




Figure 4.1: Number of Metabolic Syndrome (MetS) defining components present 









































The prevalence of MetS components among the study population are presented 
in Figure 4.2. The most frequent component of MetS among UAEU young female 
adults was reduced HDL-C levels (48.8%); followed by central obesity (18.2%); 
impaired fasting glucose (9.7%); hypertension (5.45); and hypertriglyceridemia 
(1.4%). 
 
A Chi-square test of association between MetS and BMI categories among 
young female adults showed a statistically significant association (P < 0.001), and was 
particularly high among participants living with obesity (34.5%) compared to 10.1% 
overweight, and 1.7% normal-weight, as shown in Figure 4.3. None of the five MetS 
components were observed in 69% of the normal-weight participants whereas all obese 
participants had at least one MetS component. Obese participants were more likely to 
have three or more MetS components (52.6%) than overweight (34.2%) and normal-
weight (13.2%) participants. Furthermore, none of the underweight participants had 










































Figure 4.2: Prevalence of metabolic syndrome components among UAEU young 






Figure 4.4: Percentage of participants per number of metabolic syndrome 
components and BMI category among young female adults aged 17 to 25 years 

































Body Mass Index Category
Figure 4.3: Prevalence of metabolic syndrome by body mass index (BMI) 


















































4.2.3 Univariable and Multivariable Logistic Regression Analyses 
Logistic regression was used to determine the association between independent 
variables such as age, family history, anthropometric measures and biochemical 
measures, and the presence of metabolic syndrome defined according to the IDF 
harmonized criteria. Table 4.2 and Table 4.3 show the univariable and multivariable 
logistic regression results for the odds of MetS by potential risk factors, respectively. 
In the univariable analyses, older participants (23–25 years) were three times more 
likely to have MetS (odds ratio [OR] = 2.96; 95% CI: 1.03 to 8.52) than younger 
participants (17–19 years) but this effect was not significant in the multivariable 
analyses (adjusted OR [aOR]= 1.14; 95% CI: 0.30 to 4.30). 
Participants who reported having a family history of diabetes or hypertension 
(n = 305) had a 2.8 times elevated risk of MetS (OR = 2.81; 95% CI: 1.31 to 6.06) 
compared with participants without a family history of diabetes or hypertension 
(n=250) in the univariable analyses but not in the adjusted analyses (aOR=1.85; 95% 
CI: 0.73 to 4.65). 
Participants who were overweight or obese were, respectively, 6.4 (95% CI:2.3 
to 17.5) and 29 (95% C1; 29.2 to 79.3) times more likely to have MetS than those of 
normal-weight in the univariable analysis (P<0.001). These findings remained 
significant even after adjusting for other potential confounders (i.e. aOR = 3.8; 95% 
CI: 1.15–12.52 for overweight; and aOR = 11.2; 95% CI: 3.06–40.86 for obese 
participants). Participants with percentage body fat ≥35% (n = 227) showed a 
significantly higher risk for the development of MetS in the univariable analyses (OR 
= 14.27; 95% CI: 4.99 to 40.83; P<0.001), but the difference was not significant after 





A waist-hip ratio (WHR) of more than 0.8 was significantly associated with at 
least three times increased risk of MetS (P<0.001) in the adjusted analyses when 
compared with those with a WHR <0.8 (aOR= 3.04; 95% CI: 1.10–8.44). 
Elevated glycated hemoglobin (HbA1c) (≥6.5%) showed a high significant 
association with the presence of MetS (OR=14.15; 95% CI: 4.78 to 41.86; P<0.001) 
in univariable analyses and remained significant in the adjusted analyses (aOR = 22.49, 
95% CI: 6.37 to 79.42; P<0.001). 
Total cholesterol ≥200 mg/dL and low density lipoprotein (LDL) ≥130 mg/dL 
conferred a greater likelihood for MetS: OR= 3.34 (95% CI: 1.48 to 7.49), and OR:1.86 
(95% CI: 0.96 to 3.63), respectively, in the univariable analyses but not in the adjusted 
analyses aOR:1.04 (95% CI: 0.46 to 2.35), and aOR:1.71 (95% CI: 0.53 to 5.55), 
respectively. However, the odds of MetS were significantly higher in those with high 
sensitivity C-reactive protein >3 mg/L (OR = 339.92; 95% CI: 77.6 to 1489.5), when 
compared to high sensitivity C-reactive protein ≤3 mg/L in univariable analyses and 
remained significant in the adjusted analyses (aOR=217.89; 95% CI: 36.87 to 1287.81; 
P<0.001). 
A subgroup analysis was conducted for the study population excluding all 
females with HbA1c ≥ 6.5 resulting in a total sample size of 507 participants. Results 
of the subgroup analysis remain largely unchanged based on the magnitude of the 
effect sizes, direction of significance and overall conclusions. However, in the 
multivariate analysis, only waist hip-ratio was no longer significant in the subgroup 





Table 4.2: Univariable analyses - Risk factors for MetS among young female adults 










Age, Year (%)  0.103 
17-19 194 8 (4.1) Reference  
 20-22 299 23 (7.7) 1.94 (0.85 - 4.42) 0.116 
23-25 62 7 (11.3) 2.96 (1.03 - 8.52) 0.044 
Family history of diabetes or 
hypertension (%) 
 0.005 
No 250 9 (3.6) Reference  
 
Yes 305 29 (9.5) 2.81 (1.31 - 6.06) 0.008 
Body Mass Index (kg/m2)  <0.001 
Underweight (<18.5) 62 0 (0.0) 0.44 (0.02 - 8.03) 0.58 
 
Normal weight (18.5 - <25) 306 5 (1.6) Reference  
Overweight (25-29.9) 129 13 (10.1) 6.35 (2.30 - 17.51) <0.001 
Obese (≥30.0) 
58 20 (34.5) 
29.19 (10.75 - 
79.28) 
<0.001 
Body Fat (%)*  <0.001 
<35% 328 4 (1.2) Reference   
≥35% 227 34 (14.9) 14.27 (4.99 - 40.83) <0.001  
Waist-Hip Ratio**  0.001 
<0.8 509 28 (5.5) Reference   
≥0.8 46 10 (21.7) 4.77 (2.15 - 10.59) <0.001  
Anemia***  0.246 
No 271 22 (8.1) Reference   
Yes 284 16 (5.6) 0.67 (0.35 - 1.32) 0.249  
Total Cholesterol (mg/dL)  0.007 
< 200 502 29 (5.8) Reference   
≥200 53 9 (16.9) 3.34 (1.48 - 7.49) 0.004  
Low Density Lipoprotein 
(mg/dL) 
 0.072 
<130 380 21 (5.5) Reference   
≥ 130 173 17 (9.8) 1.86 (0.96 - 3.63) 0.067  
High sensitivity C-reactive 
protein (mg/L) 
 <0.001 
≤3 493 2 (0.4) Reference   




Glycated Hemoglobin (%)  <0.001 
< 5.6 374 6 (1.6) Reference   
5.6 - 6.4 133 23 (17.3) 12.82 (5.09 - 32.29) <0.001  
> 6.5 48 9 (18.8) 14.15 (4.78 - 41.86) <0.001  
* Physical status: the use and interpretation of anthropometry 1995 [213] 
** Waist circumference and waist-hip ratio: Report of a WHO expert consultation 2011 [222] 





Table 4.3: Multivariable analyses - Risk factors for MetS among young female adults 
aged 17 to 25 years (n=555), Al Ain, UAE 
Characteristics N n (%) 
With MetS 




Age (Year)  
17-19 194 8 (4.1) Reference  
20-22 299 23 (7.7) 1.89 (0.72 – 4.94) 0.19 
23-25 62 7 (11.3) 1.14 (0.30 – 4.30) 0.85 
Family history of diabetes or 
hypertension (%) 
 
No 250 9 (3.6) Reference  
Yes 305 29 (9.5) 1.85 (0.73 – 4.65) 0.19 
Body Mass Index (kg/m2)   
Underweight (<18.5) 62 0 (0.0) 0.85 (0.04 – 17.26) 0.92 
Normal weight (18.5 - <25) 306 5 (1.6) Reference  
Overweight (25-29.9) 129 13 (10.1) 3.80 (1.15 – 12.52) 0.028 
Obese (≥30.0) 58 20 (34.5) 11.19 (3.06 – 40.86) <0.001 
Body Fat (%)*  
<35% 328 4 (1.2) Reference  
≥35% 227 34 (14.9) 3.12 (0.91 – 10.68) 0.07 
Waist-Hip Ratio**  
<0.8 509 28 (5.5) Reference  
≥0.8 46 10 (21.7) 3.04 (1.10 – 8.44) 0.033 
Anaemia***  
No 271 22 (8.1) Reference  
Yes 284 16 (5.6) 1.04 (0.46 – 2.35) 0.92 
Total Cholesterol (mg/dL)  
< 200 502 29 (5.8) Reference  
≥200 53 9 (16.9) 1.71 (0.53 – 5.55) 0.37 
Low Density Lipoprotein (mg/dL)  
<130 380 21 (5.5) Reference  
≥ 130 173 17 (9.8) 0.92 (0.37 – 2.32) 0.86 
High sensitivity C-reactive protein 
(mg/L) 
 
≤3 493 2 (0.4) Reference   
>3 62 36 (58.1) 217.89 (36.87 – 1287.81) <0.001  
Glycated Haemoglobin (%)  
< 5.6 374 6 (1.6) Reference  
5.6 - 6.4 133 23 (17.3) 8.92 (3.39 - 23.48) <0.001 
≥ 6.5 48 9 (18.8) 22.49 (6.37 – 79.42) <0.001 
* Physical status: the use and interpretation of anthropometry 1995 [213] 
** Waist circumference and waist-hip ratio: Report of a WHO expert consultation 2011 [222] 





Table 4.4: Subgroup multivariable analysis - Risk factors for MetS among young 
female adults aged 17 to 25 years (n=507), Al Ain, UAE – excluding 48 participants 
that had HbA1c ≥ 6.5 
* Physical status: the use and interpretation of anthropometry 1995 [213] 
** Waist circumference and waist-hip ratio: Report of a WHO expert consultation 2011 [222] 
*** Hemoglobin concentrations for the diagnosis of Anemia according to the WHO 2011 [261]  
Characteristics Sample n (%) 
With MetS 








Age (Year)  
17-19 175 6 (3.4) Reference  Reference  
20-22 278 17 (6.1) 1.83 (0.71, 4.75 0.211 1.50 (0.53 – 4.28) 0.448 
23-25 54 6 (11.1) 3.52 (1.09, 11.41) 0.036 1.89 (0.47 – 7.60) 0.365 




No 223 7 (3.1) Reference  Reference  
Yes 284 22 (7.8) 2.59 (1.09, 6.18) 0.032 1.03 (0.73 – 4.65) 0.19 





58 0 (0.0) 0.94 (0.044, 19.88) 0.969 




(18.5 - <25) 
277 2 (0.7) Reference  Reference  
Overweight (25-
29.9) 
120 11 (9.2) 11.57 (2.89, 46.26) 0.001 
5.62 (1.13 – 
27.86) 
0.035 
Obese (≥30.0) 52 16 (30.8) 49.82 (12.61, 196.88) <0.001 
15.35 (2.92 – 
80.75) 
0.001 
Body Fat (%)*  
<35% 296 2 (0.7) Reference  Reference  
≥35% 211 27 (12.8) 21.57 (5.07, 91.78) <0.001 
2.84 (0.57 – 
14.06) 
0.201 
Waist-Hip Ratio**  
<0.8 467 23 (4.9) Reference  Reference  
≥0.8 40 6 (15.0) 3.41 (1.30, 8.93) 0.013 2.12 (0.65 – 6.87) 0.211 
Anaemia***  
No 247 18 (7.3) Reference  Reference  




< 200 459 22 (4.8) Reference  Reference  





<130 348 16 (4.6) Reference  Reference  




< 5.6 374 6 (1.6) Reference  Reference  
5.6 - 6.4 133 23 (17.3) 12.82 (5.09, 32.29) <0.001 







4.2.4 High Sensitivity C-Reactive Protein and Metabolic Syndrome 
Logistic regression analyses showed that the odds of MetS were significantly 
higher in those with high sensitivity C-reactive protein (Hs-CRP) >3 mg/L (OR = 
339.92; 95% CI: 77.6 to 1489.5), when compared to high sensitivity C-reactive protein 
≤3 mg/L in univariable analyses with the odds remained significant in the adjusted 
analyses (aOR:217.89; 95% CI: (36.87 to 1287.81) (P<0.001). Figure 4.5 displays the 
distribution of Hs-CRP levels after females were classified according to their total 
number of components of the MetS. The MetS represents an inflammatory state that 
could be seen by the progressive increase of Hs-CRP levels with the increased number 
of MetS components according to the harmonized IDF criteria. The graph illustrates 
the strong linear increase in Hs-CRP levels as the number of MetS components 
increased. The median Hs-CRP levels for those with 0, 1, 2, ≥3 components of the 
































Figure 4.5: Distribution of High Sensitivity C-reactive protein according to 
number of metabolic syndrome components present among young female adults 
aged 17 to 25 years (n=555), Al Ain, UAE. Box plots demonstrate minimum, 





4.2.5 Prevalence of Overweight/Obesity 
The distribution of the studied population according to their body mass index 
(BMI) categories showed that 11.2% were underweight; 55.1% were normal weight; 
and 33.7% were overweight or obese (23.2% and 10.5%, respectively) as indicated in 
Figure 4.6. 
Table 4.5 demonstrates that 7.6% of the studied population were classified at 
class I obesity (BMI 30.00 – 34.9 kg/m2); 1.6% met the class II obesity classification 
(BMI 35.00 – 39.9 kg/m2); and 1.3% had a BMI ≥ 40.00 kg/m2.  
Central obesity was prevalent among 18.2% of the studied population based on 
the waist circumference (WC) classification. Whereas, only 8.3% of the studied 
population were found living with central obesity when waist-hip ratio ≥0.8 was used 
as a cutoff point. In opposition, measurement of body fat percentage from skinfold 
thickness at four sites (biceps, triceps, subscapular and suprailiac) via Durnin’s 







Underweight Normal weight Overweight Obese
Figure 4.6: Distribution of Emirati young female adults aged 17 to 25 years (n=555) 





Table 4.5: Distribution of the study population according to different measures of 
obesity 
Variable N  % 
Body Mass Index  
Underweight (<18.50 kg/m2) 62 11.2 
Normal weight (18.50 – 24.99 kg/m2) 306 55.1 
Overweight (25.00 – 29.99 kg/m2) 129 23.2 
Obese class I (30.00 – 34.9 kg/m2) 42 7.6 
Obese class II (35.00 – 39.99 kg/m2) 9 1.6 
Obese class III (≥ 40.00 kg/m2) 7 1.3 
Waist Circumference  
<80 cm 454 81.8 
≥80 cm (central obesity) 101 18.2 
Waist-Hip Ratio  
<0.8 509 91.7 
≥0.8 46 8.3 
Body Fat  
<35% 328 59.1 






4.2.6 Prevalence of Diabetes  
 According to the standards of medical care in diabetes set by the American 
Diabetes Association (ADA) in 2016 [255] (previously presented in Table 3.4) 
diabetes mellitus (DM) could be diagnosed based on the level of fasting plasma 
glucose (FPG) or glycated hemoglobin (HbA1c). The classification of the study 
population according to FPG and HbA1c for the diagnosis of diabetes and prediabetes 
are presented in Table 4.6. The prevalence of diabetes mellitus and prediabetes based 
on FPG was 0.5% and 9.2%, respectively. However, 8.6% of the studied population 
were diagnosed with diabetes, and 24% were living with prediabetes according to the 
percentage of HbA1c. Thus, the crude prevalence of diabetes mellitus and pre-diabetes 
(shown in Figure 4.7) among the study population was 8.6% and 24.7%, respectively.  
 
Table 4.6: Classification of the study population according to different standards for 
the diagnosis of diabetes and prediabetes 
Variable N % 
Fasting Plasma Glucose (FPG)  
Normal (≤99 mg/dL) 501 90.3 
Prediabetes (100-125 mg/dL) 51 9.2 
Diabetes (≥126 mg/dL) 3 0.5 
Glycated Hemoglobin (HbA1C)  
Normal (About 5 %) 374 67.4 
Prediabetes (5.7-6.4 %) 133 24.0 
Diabetes (≥6.5 %) 48 8.6 
FPG or HbA1c  
Normal  370 66.7 
Prediabetes 137 24.7 






Logistic regression was used to determine the association between age; family 
history; anthropometric measures; and biochemical measures, and the presence of 
diabetes or prediabetes, as illustrated in Table 4.7. Neither age of the participant, nor 
having a family history of diabetes or hypertension had a significant association with 
the risk of DM (P=0.66, 0.809, respectively). Nevertheless, participants living with 
obesity (n=58) were almost 2.5 times (OR: 2.407; 95% CI: 1.373 to 4.221) more likely 
to have DM than those with BMI<25.0 (n=368) (P=0.002). 
Percentage of body fat did not show an association with the risk of DM 
(P=0.329). However, waist circumference of more than 80 cm was significantly 
associated with increased risk of DM (OR: 2.561; 95% CI: 1.650, 3.975) (P<0.001). 
Hip circumference was also associated with an increased odds of DM (OR: 1.028; 95% 
CI: 1.011, 1.045). Elevated high sensitivity C-reactive protein ≥3 mg/L, conferred a 








Figure 4.7: Prevalence of abnormal glycemic status based on fasting plasma glucose 
(FPG) and glycated hemoglobin (HbA1c) among Emirati young female adults aged 





Table 4.7: Univariate logistic regression analysis model of the association between 
abnormal glycemic status based on fasting plasma glucose (FPG) and glycated 
hemoglobin (HbA1c) and selected variables among young Emirati female adults 
aged 17 to 25 years (n=555), Al Ain, UAE 
Variable N 
With abnormal glycemic status 
n (%) Odds Ratio (95% CI) P-value P-value  
Age Year (%) 0.66 
17-19 194 62 (32.0) Reference   
20-22 299 94 (31.4) 0.976 (0.662 - 1.439) 0.903  
23-25 62 29 (46.8) 1.871 (1.044 - 3.352) 0.035  
Parents Diabetic or Hypertensive (%) 0.809 
No 250 82 (32.8) Reference   
Yes 305 103 (33.8) 1.045 (0.732 - 1.490) 0.809  
Blood Pressure (mm Hg) 0.119 
Normal 453 147 (32.5) Reference   
Prehypertension 93 37 (39.8) 1.375 (0.869 - 2.178) 0.174  
Hypertension 9 1 (11.1) 0.260 (0.32 - 2.100) 0.206  
Body Mass Index (kg/m2) 0.013 
Underweight (<18.5) 62 16 (25.8) Reference   
Normal weight (18.5 - <25) 306 92 (30.1) 1.236 (0.665 - 2.296) 0.502  
Overweight (25-29.9) 129 48 (37.2) 1.704 (0.870 - 3.335) 0.120  
Obese (≥30.0) 58 29 (50.0) 2.875 (1.335 - 6.192) 0.007  
Body Fat (%) 0.329 
<35 328 104 (31.7) Reference   
≥35 227 81 (35.7) 1.195 (0.836 - 1.709) 0.329  
Waist Circumference (cm) <0.001 
<80 454 133 (29.3) Reference   
≥80 101 52 (51.5) 2.561 (1.650 - 3.975) <0.001  
Hip Circumference (cm) 555 185 (33.3) 1.028 (1.011 -1.045) 0.001 0.001 
Neck Circumference (cm) 555 185 (33.3) 1.022 (0.975 - 1.071) 0.365 0.353 
Waist-hip Ratio 0.238 
<0.8 509 166 (32.6) Reference   
≥ 0.8 46 19 (41.3) 1.454 (0.786 - 2.691) 0.233  
Anemia (%)  0.904 
No 271 91 (33.6) Reference   
Yes 284 94 (33.1) 0.979 (0.688 - 1.393) 0.904  
Total Cholesterol (mg/dL) 0.313 
< 200 502 164 (32.7) Reference   





Low Density Lipoprotein (mg/dL) 0.078 
<130 380 118 (31.1) Reference   
≥ 130 173 67 (38.7) 1.403 (0.964 - 2.042) 0.077  
High Density Lipoprotein (mg/dL) <0.001 
>45 284 70 (24.6) Reference   
≤ 45 271 115 (42.4) 2.254 (1.570 - 3.236) <0.001  
High-sensitivity C-reactive Protein (mg/L) <0.001 
Low (<1) 326 72 (22.1) Reference   
Intermediate (1-2.9) 167 65 (38.9) 2.248 (1.497 - 3.376) <0.001  
High (≥ 3) 62 48 (77.4) 12.095 (6.312- 23.176) <0.001  
 
Table 4.8: Adjusted analysis model of the association between abnormal glycemic 
status based on fasting plasma glucose (FPG) and glycated hemoglobin (HbA1c) and 
selected variables among young Emirati female adults aged 17 to 25 years (n=555), 
Al Ain, UAE 




Body Mass Index 
(kg/m2) 
1.164 0.738 1.835 0.514 
Waist circumference 
(cm) 
0.978 0.941 1.016 0.252 
Hip circumference (cm) 1.007 0.969 1.046 0.737 
Hs-CRP* (mg/L) 1.578 1.360 1.832 <0.001 






In the United Arab Emirates (UAE) rapid socioeconomic growth has resulted 
in profound lifestyle changes including sedentary behaviors, westernized diets and 
increased energy intake [167]. The prevalence of MetS among Emirati females has 
been reported to be higher than that for Emirati males in the adult population (32.9% 
among men, 45.9% among women) [5]. This research highlights the importance of 
investigating MetS among young female adults, to facilitate understanding of the 
prevalence and risk factors of MetS. There is paucity of data on the prevalence of MetS 
among Emirati females aged 17–25 years. The current study reveals a MetS prevalence 
of 6.8% among young female Emirati adults aged 17–25 years, and 34.5% among 
young obese female Emirati adults. 
There are few data available about the prevalence of MetS among Emirati 
females aged 17-25. The current study reveals a MetS prevalence of 6.8% among 
young female Emirati adults aged 17-25. This percentage is much higher than the 4% 
prevalence previously reported in a separate study of female Emirati adolescents (12-
18 years old) [6] and much lower than that among Emirati female adults (≥20 years) 
45.9% reported in 2008 [5]. A recent study by Hajat and others in 2012, during the 
Weqaya screening program in the Emirate of Abu Dhabi [307], found that the overall 
prevalence of MetS among Emirati adults was 48.7% and 50.3% using the MetS 
definition of IDF and ATPIII, respectively. These findings suggest about 8% increase 
during the period of 4 years only, when compared with those described in 2008 [5] 
using the same IDF criteria, where the overall prevalence of MetS was 40.5%. The 
same prevalence was described in 2010 [308] among overweight and obese adults (18-





the UAE was stated to be 44% in the same year [309]. In the present study, the 
prevalence of MetS was 34.5% among obese students.  
The results of the current study are in line with findings among college students 
(18–26 years) in Saudi Arabia [310], where the overall MetS prevalence was 7.8%, 
and 26.4% in obese students. In the same study, the prevalence of MetS among Saudi 
female college students was 1.7% compared to 9.9% among males. However, the 
prevalence of MetS among Saudi female adults was stated to be 34.1% and 36.6% 
among male adults in 2010[134].  
In Kuwait, the prevalence of MetS was even higher among female adolescents 
(10–19 years) at 9.1% and 14.8% according to ATP III and IDF criteria, respectively 
[159]. MetS among adult Kuwaitis were similar between men and women at 36.2% 
and 36.1%, respectively [133]. In Oman, the overall prevalence of MetS among adults 
(>20 years old) was 23.6%, it was somewhat higher in women 24.4% compared to 
men 22.8% [131]. These numbers are certainly close to those described in the UAE, 
which is not surprising, considering the relatively similar rapid increase in obesity and 
diabetes rates throughout the Gulf region [311, 312]. These trends are as a result of a 
sedentary and westernised lifestyle [313-316], and could also be partially explained by 
the “thrifty genes” hypothesis [309], which suggests that the genotype of mankind 
existed as hunter-gatherers can efficiently store food in the adipose tissue during 
periods of food abundance, to compensate for periods of food shortage. 
Worldwide, the prevalence of MetS among young female adults in the USA 
(18-21 years) was 4.7% [317], in Brazilian college students it was 1.7% [318], in 
Chinese female adolescents (14-16 years) it was 2.5% [319], in Spanish female 





years) it was 2.4% [321], and 11.7% among Indian female adolescents (10-19 years) 
[322]. Clearly, the prevalence of MetS could differ between countries depending on 
the MetS defining criteria used, study method and target population. We have used the 
IDF and AHA/NHLBI joint statement, as it was an international attempt to harmonize 
the definition of MetS; central obesity is not an obligatory component of this definition 
and it is ethnic specific. 
The most frequent component of MetS in this study was reduced HDL-C 
levels, which was also reported in the female Emirati adolescents [6], and female 
Kuwaiti adolescents [159]. Reduced HDL-C accompanied by elevated triglyceride 
levels indicates dyslipidemia, which is highly prevalent among the UAE population 
[323]. Insufficient physical activity and poor dietary habits are associated with low 
HDL-C levels [324-326]. Elmagd et. al. reported low physical activity (defined as less 
than 150 minutes/week) in 60% of Emirati college students [327]. The consumption 
of high caloric diet was also reported in 33.5% of female Emirati adolescents [167]. 
These findings could explain the high prevalence of low-HDL-C levels observed in 
our study. Regular checks and screening in this age group could be helpful in 
identifying participants at an increased risk of developing MetS. 
The current study found strong correlations between BMI, body fat, hbA1c, 
High sensitivity C-reactive protein and the prevalence of MetS in Emirati female 
students. The relationship between overweight and obesity and MetS has been 
supported by many other studies [134, 158, 328].  
Ridker and his colleagues showed a strong evidence that the MetS represents 
an inflammatory state that could be seen by the progressive increase of Hs-CRP levels 





[67]. Up to date, the only well-standardized marker of inflammation and a predictor of 
the MetS and future cardiovascular events, is the Hs-CRP [68]. However, the 
measurement of Hs-CRP is not yet included in the diagnostic criteria of the MetS, 
although it has been recommended by a large number of investigators [67-71]. 
Inflammation is usually measured through the measurement of serum Hs-CRP, where 
a level above 3 mg/L is considered high according to the recommendations of the CDC 
and the AHA for cardiovascular disease (CVD) risk assessment [63]. However, Hs-
CRP is a sensitive marker for acute phase inflammation and has a high within-subject 
variability [329]. Therefore, a value above 3 mg/L might indicate an increased risk of 
cardiovascular, but could also be a result of an infection or inflammation, which may 
vague any projection of coronary risk that might be attributed to the elevated level 
[330]. 
The association between HbA1c and the prevalence of MetS has not been 
previously reported; nevertheless, insulin resistance is a major underlying mechanism 
accountable for the prevalence of the MetS [331]. Interestingly, the prevalence of 
diabetes (8.6%) was also high in the study population. Future studies need to explore 
this finding more closely. 
The prevalence of diabetes mellitus and prediabetes based on FPG (0.5% and 
9.2%, respectively) was found much lower than that based on the percentage of HbA1c 
(8.6% and 24%, respectively) However, the crude prevalence of diabetes mellitus and 
pre-diabetes among Emirati young female adults was 8.6% and 24.7%, respectively.  
Our present results are in disagreement with those previously reported in a 
hospital-based study were the prevalence of diabetes was higher using the FPG 





retrospective study in Saudi Arabia, the prevalence of impaired glucose tolerance was 
54% when using HbA1c as a diagnostic test, and 60.3% when using FPG as a 
diagnostic test [333]. In contrast, our results are in agreement with a population-based 
study among Palestinian Arab population that showed a lower prevalence of diabetes 
diagnoses using the FPG criterion (4.5%) compared to HbA1c criterion (5.3%)[334]. 
In study among the Korean population, the prevalence of diabetes and prediabetes 
using FPG only (10.5% and 19.3%, respectively) were lower compared to the 
prevalence of diabetes and prediabetes using HbA1c as a diagnostic test (12.4% and 
38.3%, respectively) [335]. In Canada, using HbA1c only for the diagnoses of overall 
prediabetes prevalence resulted in a three-fold increase compared to FPG and a six-
fold increase among females (FPG 2.22%, HbA1c 13.31%)[336]. 
Although more participants were diagnosed with diabetes when HbA1c was 
added as a diagnostic criterion, yet the simultaneous measurement of FPG and HbA1c 
(FPG and/or HbA1C) is recommended by the American Diabetes Association [255] 
and has been shown to be a more sensitive and specific screening tool for identifying 
high-risk individuals with diabetes and IGT at an early stage [337, 338]. Advantages 
of using HbA1C include: convenience, pre-analytical stability, and minimum day-to-
day perturbations during periods of stress and illness. Nevertheless, this test is pricey, 
and might not be available in certain regions of the developing world [255]. 
The strengths of this study include a trained researcher who obtained all 
measurements in the study and each measurement was repeated three times and the 
average used in the analyses. Anthropometric measures and blood withdrawal were 
conducted during one 50-minute morning session after assurance of a 12-hour 





MetS prevalence in college students have been conducted in the UAE. UAEU is the 
main university in the UAE and it enrolls students from all seven emirates. However, 
restricting the study to college students makes it not representative of all the Emirati 
females in this age group.  
Moreover, the cross-sectional design is another limitation of this study, as 
causal inference cannot be drawn. Participants were voluntarily enrolled in the study, 
which could have caused selection bias (overweight and obese individuals might avoid 
anthropometric measurements). Additionally, a study conducted by Malik and Razig 
in 2008 showed that Emirati female adults who had no formal education were 1.27 
(95% CI:1.03 to 1.58) times more likely to have MetS than those who had higher 
education (>12 grade) (P= 0.028) according to the IDF definition of MetS [5]. 
Therefore, limiting participation in the current study to university students only might 
have introduced underestimation of MetS prevalence among young adults, especially 
that Malik reported only 25.4% of Emirati female adults (>20) had university degrees 
[5]. 
In addition, studying female students only does not allow for examination of 
gender differences or generalizability of results to all young adults. Therefore, future 
prospective studies are needed to confirm the prevalence of MetS and its relation to 
overweight and obesity in Emirati young adults. Additionally, it was challenging to 
clearly define the “young adult” age group. Some studies reported the MetS prevalence 
in adolescents and included ages 12–18 years [6] or 10–19 years old [159]. Other 
studies defined young adults as 18–24 years [317], 17–37 years [339] or college 
students aged 17–25 years [340]. Having one international definition for the “young 






In summary, we have shown that the prevalence of MetS is high among UAEU 
female young adults aged 17–25 years (6.8%). One third of the studied population was 
overweight and obese. The prevalence of diabetes mellitus and prediabetes based on 
FPG was found much lower than that based on the percentage of HbA1c (0.5% and 
9.2% Vs. 8.6% and 24% respectively). However, the crude prevalence of diabetes 
mellitus and pre-diabetes among Emirati young female adults was 8.6% and 24.7%, 
respectively.  
MetS prevalence was highest among obese participants, as compared with 
normal-weight and overweight participants. In addition, reduced HDL-C levels 
followed by central obesity were the most frequent components of MetS. Using 
logistic regression model MetS was significantly associated with overweight, obesity, 
waist-hip ratio, glycated hemoglobin (HbA1c) and high sensitivity C-reactive protein 
(P < 0.01). 
The high prevalence of MetS highlights the importance of regular screening 
and intervention programs targeting weight reduction. It is also necessary to design 
public health policy, clinical practice, and prevention programs for the screening and 
treatment of Emirati females at high risk for metabolic syndrome. Such strategies 
should address cultural and community life of Emiratis to ensure relevance and 










Diabetes mellitus (DM) is a chronic disease characterized by abnormalities in 
the metabolism of carbohydrates, fat, and protein along with hyperglycemia. 
Complications of the disease include macrovascular and microvascular damage in the 
eyes (retinopathy) [341], kidneys (nephropathy) [342] and nerves (neuropathy) [343]. 
If left untreated, these complications could progress into blindness, kidney failure, 
amputation, and even death [205]. 
During the past three decades, the prevalence of DM in the world has doubled, 
which presents a great challenge to international public health. According to the recent 
regional fact sheets of the International Diabetes Federation (IDF), there are 382 
million people living with diabetes in the world, with a prevalence of 8.3% [2]. The 
IDF expects an increase of 205 million patients by 2035. The 9.7% prevalence of 
diabetes in the Middle East and North Africa (MENA) regions is even higher than the 
world average [2]. Based on the same fact sheets, United Arab Emirates (UAE) was 
ranked fifth with regards to the highest prevalence of diabetes mellitus in the region 
(19%), ranked after other Gulf Cooperation Council (GCC) countries, Saudi Arabia, 
Kuwait, Bahrain and Qatar which have the prevalence of 23.9%, 23.1%, 21.9% and 
19.8% respectively [304].  
Type 2 Diabetes Mellitus (T2DM) is the most common type of diabetes. It was 
thought to occur among adults, but is increasingly reported in children and adolescents. 
With this type of diabetes, the body is capable of producing insulin but it is either not 
in a sufficient amount or the body is insulin resistant, leading to the accumulation of 





T2DM is an increasing source of concern in the UAE. The prevalence of T2DM 
was 6% among adults, according to a prevalence survey performed between1989 and 
1990 [344]. A later survey conducted between 1999 and 2000 reported a greater 
prevalence of about 20% [23]. A recent survey reported the prevalence of diagnosed 
DM at10.5%, undiagnosed DM at 6.6%, and pre-diabetes at 20.2% [345]. The latter 
also reported the prevalence of retinopathy at 54.2%, neuropathy at 34.7%, 
nephropathy at 40.8%, peripheral vascular disease at 11.1%, and coronary heart 
disease at 10.5% among patients diagnosed with DM. 
The observed increase in incidences of T2DM and pre-diabetes among 
children, adolescents and younger adults increases the need for understanding the 
etiology and treatment for the disease. The causes behind the epidemic of T2DM are 
part of a very complex group of genetic and social systems which, in turn, control 
behavioral and environmental factors [212]. Moreover, there are several risk factors 
believed to be mainly contributing to the occurrence of the disease, these include: 
weight gain and obesity [11]; sedentary lifestyle with low physical activity [12, 13]; 
ethnicity [14]; family history of diabetes [14]; poor dietary habits [346]; other factors 
like cigarette smoking and alcohol consumption [255]. 
The focus on the prevention and treatment of T2DM are lifestyle factors, 
including diet (for glycemic control), physical activity, and weight reduction [346-
348]. The American Diabetes Association (ADA) recommends an effective ongoing 
support program targeting glycemic control (using carbohydrates counting and 
selection of low glycemic index foods), weight loss of seven percent of body weight 
within the first six months of intervention, and increasing physical activity to at least 





 Dietary management and prevention of DM was found to be dependent on the 
quality and quantity of nutrient intake. Studies suggest that total amount of 
carbohydrate or fat in the diet does not seem to be associated with T2DM risk but 
specific forms of carbohydrate or fat were associated with the disease [18, 19]. For 
example: the ability of dietary carbohydrates to increase blood glucose and insulin 
levels after ingestion differs, and that is known as the glycemic index (GI) of 
carbohydrate foods [20]. This concept was developed in 1981 by Jenkins et. al. as a 
tool for predicting blood glucose response to various foods [20]. It is defined as the 
ratio of the blood glucose response for a tested food as compared to the blood glucose 
response of a standard (usually a glucose or white bread) [349]. If glucose is used as 
the reference, then a GI of ≤ 55 is considered low, between 56-69 is intermediate, and 
≥ 70 is high [20]. Since the amount of carbohydrate in a food varies according to the 
serving size, researchers have also introduced the concept of glycemic load (GL), 
which is the amount of available carbohydrates in a serving size of food item 
multiplied by its glycemic index [21]. 
Prospective studies investigating the relations between dietary carbohydrate 
intake and risk of T2DM using GI and GL supported the protective role that low GI 
and low GL diets play against the development of T2DM [19, 192, 350]. Since a high 
GI food would cause a higher increase in the levels of blood glucose after its ingestion, 
it will, in turn, increase the demand of insulin in the body. Regular consumption of 
high GI foods would therefore contribute to beta cell distraction, due to the elevated 
insulin demand and/or continuously raised glucose concentration in the blood [19]. 
In 2010, a study was conducted in the UAE to determine the factors associated 





poor glycemic control among patients with T2DM was mainly because patients were 
not following the dietitian’s recommended eating plan and/or had a negative attitude 
towards diabetes [22]. In a different study, researchers were examining differences in 
the prevalence of DM between different ethnic groups in the UAE [23]. They reported 
a higher DM prevalence among UAE citizens (25%) compared to expatriates (13–
19%, depending on country of origin) [23]. These results advocate the need for better 
counseling programs focusing on Emirati citizens, which, in turn, requires more 
information about dietary practices of the Emiratis, food composition tables of locally 
consumed foods in the UAE, an exchange list of these foods, and glycemic index 
values of Emirati foods to facilitate the role of dietitians in developing better programs 
targeting glycemic control in diabetics and pre-diabetics. 
This study was designed to test the null hypothesis that Emirati traditional 
foods are high in their GI and GL values which might be contributing to the high 
prevalence of DM and CVD. Therefore, it aimed to develop a comprehensive food 
composition table with GI and GL values of locally consumed foods in the UAE. These 
tables would serve as a great tool for nutrition therapy planning and dietary 
management for dietitians in the UAE and other GCC countries.  





5.2 Results and Discussion 
 
5.2.1 Proximate Analysis 
 Proximate analyses including fat, protein, ash, fiber and moisture content were 
measured according to previously described methods in Section 3.3.5.3. The 
proximate analyses data were expressed as mean ± standard derivation on a fresh 
weight basis of each test food (Table 5.1). There were significant differences in the 
nutritional composition of the analyzed foods due to different ingredients and 
preparation methods (see Table 3.8 for main ingredients). 
 Moisture content ranged from 15.63g/100g in Muhalla bread to 86.66g/100g 
in Arseyah. Dishes containing meat (all main dishes) like Harees (beef), Thareed 
(beef), Thareed (chicken), Biryani (chicken), Machbous (fish), Arseyah (chicken), and 
Marqoqa (chicken) were found to have relatively high moisture content, ranging from 
63.26g/100g to 86.66g/100g. Similar results of high moisture values in dishes 
containing meat have been reported by many other studies investigating food 
composition of traditional dishes in the Gulf Region [172, 175, 351, 352]. Musaiger 
et. al. (1998) [172], Habib et. al. (2011) [175], and Musaiger (2011) [351] reported 
similar moisture content for Harees: 80.2, 79.9 and 81, respectively. These values are 
only slightly higher than the 77.7g/100g of moisture in Harees presented in this study. 
Machbous was found to have 68.3g/100g of moisture, which is comparable to the 
68.9g/100g reported by ElObeid et. al. (2015)[352], and to the 65.91g/100g described 
by Habib et. al. (2011) [175]. Breads had relatively low moisture content, ranging from 
15.6g/100g for Muhalla bread to 35.7g/100g for Chebab bread. Regag bread had a 
moisture content of 21.9g/100g, which is lower than what ElObeid et. al. (2015) 





than Bahraini and Emirati Regag bread reported in 2011(6.5 and 8.6g/100g, 
respectively) [175, 351]. The moisture content of Sago was 74.9g/100g. Previous 
studies reported varying moisture content in Sago, ranging from 39.8g/100g in Kuwaiti 
Sago [352], to 70.7g/100g in Bahraini Sago [351]. Moisture content of a dish 
resembles the amount of water available in it. Factors like recipe, cooking time, and 
cooking method could affect the water content of the same dish, thus explaining the 
differences found between studies.  
Sago and Asida had the lowest protein content (0.80 and 0.99g/100g, 
respectively) since their main ingredients are sugar and water. Similarly, ElObeid et. 
al. (2015) [352] and Musaiger (2011) [351] found low protein content in Sago 
(1.9g/100g and 1.0g/100g, respectively) and Asida (1.7 and 3.5g/100g, respectively). 
However, the protein content was the highest in Chami (15.48g/100g). Chami is the 
Emirati cottage cheese; therefore, it is expected to have high protein content. Dishes 
containing meat like Biryani (chicken) and Thareed (beef) were also high in protein 
(11.55 and 7.04g/100g, respectively). Mugaiger (2011) [351] found 6.8g/100 of 
protein in Thareed (beef), and 8.1g/100g of protein in Biryani (beef). All six varieties 
of bread had relatively high protein content, because they either contain milk, egg, or 
both. The protein content of Regag bread in this study was 10.5g/100g. However, 
protein content in Bahraini Regag bread was reported to be 12.5g/100g [351], and 
protein content in Emirati Regag bread was 10.89g/100g [175]. Differences in protein 
content could result from the type of wheat flour used, as processed wheat flour 
contains less protein compared to whole grain wheat flour. 
Fat content was the lowest in Asida (0.04g/100g), and the highest in 





content in Asida (0.08g/100g), although ghee was one of the ingredients of Asida in 
both studies. 
The preparation of Khanfaroosh (Emirati doughnut) requires deep-frying of the 
dough in vegetable oil, which accounts for its high fat content. Lower fat content in 
Bahraini Khanfaroosh (10.1g/100g) was reported by Musaiger (2011)[351]. The 
difference in fat content could result from differences in cooking methods (deep 
frying) and recipe (addition of vegetable oil for the dough).  
 Fiber values varied from 12.20g/100g in Balalet to 0.12g/100g in Chami. 
Sago, a sweet dish consisting of Sago seeds and ghee, had 0.3g/100g of fiber. 
Similarly, Bahraini Sago was reported to have 0.5g/100g of fiber [351]. Other dessert 
dishes like Leqemat, Asida and Khanfaroosh had a fiber content of 1.45, 0.67, and 
1.16/100g, respectively. However, fiber content in Leqemat, Asida and Khanfaroosh 
from Bahrain was 0.5, 2.0, and 0.9/100g, respectively [351]. Differences in fiber 
content could result from the type of wheat flour used (processed wheat flour or whole 
grain wheat flour), since whole-wheat flour is a better source of fiber. 
Carbohydrate content was calculated by the difference of {𝐶𝐻𝑂 = 100 −
(𝑃𝑟𝑜𝑡𝑒𝑖𝑛 + 𝑓𝑎𝑡 + 𝑎𝑠ℎ + 𝑤𝑎𝑡𝑒𝑟)}. Breads were found to have the highest 
carbohydrate values, ranging from 68.20g in Muhalla bread to 47.08g in Chebab bread. 
Arabic bread and Regag bread had a carbohydrate content of 63.61 and 65.25g/100g, 
respectively. However, Musaiger (2011) [351] reported a carbohydrate content of 63.1 
and 79.8g/100g in Bahraini Arabic bread and Regag bread, respectively. 
Dessert dishes had lower carbohydrate content as compared to breads. Leqemat 





values for carbohydrate content of Emirati Leqemat (42.13g/100g) and Balalet (33.76 
g/100g) were reported by Habib et. al. (2011)[175]. 
In this study, the carbohydrate content of Harees (beef) was 13.30g/100g. 
Habib et. al. (2011)[175] found similar carbohydrates content in Emirati Harees (beef) 
(13.71g/100g), whereas Bahraini Harees had somewhat lower carbohydrate content 
(10.5g/100g) [351]. 
Khanfaroush provided the highest amount of energy per 100g (462.91 Kcal) 
due to its high fat content. Whereas, the energy provided by Arseyah was 57.32 
Kcal/100g only because of its high water content. Breads provided similar energy 
values, ranging from 298.26 Kcal/100g in Chebab bread to 382.97Kcal/100g in 
Khameer bread. 
 In this study, Regag and Arabic breads provided 307.04, and 302.56 
Kcal/100g, respectively. Lower amounts of energy were found in Bahraini Regag and 
Arabic breads (297 Kcal/100g) [351]. Whereas, Habib et. al. (2011)[175] reported 
much higher energy value for Emirati Regag bread (361.68 Kcal/100g). 
Leqemat, a sweet dish similar to doughnut cake, had 416.49 Kcal of energy per 
100g. However, a lower energy content was reported in Kuwaiti [173], Emirati [175], 
and Bahraini [351] Legemat (301, 339.06, and 275 Kcal/100g, respectively). The 
amount of energy provided by foods differs according to varying content of 






Table 5.1: Proximate Analysis of United Arab Emirates Traditional Dishes 
Test Food Moisture Protein Fat Ash Fiber CHO Energy (Kcal) 
Arabic bread 25.12 ± 0.34 9.45 ± 0.05 1.15 ± 0.04 0.68 ± 0.04 0.13 ± 0.01 63.61 ± 0.38 303 ± 1.14 
Regag bread 21.93 ± 0.79 10.49 ± 0.07 0.46 ± 0.01 1.88 ± 0.02 1.23 ± 0.14 65.25 ± 0.73 307 ± 3.25 
Chebab bread 35.70 ± 2.15 7.08 ± 0.35 9.07 ± 0.83 1.07 ± 0.07 1.20 ± 0.77 47.08 ± 1.51 298 ± 11.54 
Muhalla Bread 15.63 ± 5.91 10.34 ± 0.82 4.24 ± 1.00 1.59 ± 0.27 0.54 ± 0.03 68.20 ± 4.78 352 ± 26.53 
Khameer Bread 18.43 ± 6.42 10.45 ± 0.75 12.69 ± 2.13 1.69 ± 0.27 1.81 ± 0.31 56.74 ± 3.42 383 ± 35.07 
Gurus 23.89 ± 1.84 8.76 ± 0.16 7.71 ± 0.90 1.07 ± 0.21 4.11 ± 0.73 58.56 ± 2.80 339 ± 5.80 
Fendal 62.48 ± 0.20 1.86 ± 0.02 0.57 ± 0.01 0.55 ± 0.06 2.91 ± 0.05 34.54 ± 0.24 151 ± 0.95 
Chami 77.25 ± 0.23 15.48 ± 0.28 0.66 ± 0.17 1.17 ± 0.18 0.12 ± 0.10 5.44 ± 0.49 90 ± 0.74 
Harees, beef 77.70 ± 1.63 5.55 ± 0.38 2.43 ± 0.84 1.01 ± 0.17 5.56 ± 0.86 13.30 ± 0.92 97 ± 10.83 
Thareed, beef 78.40 ± 0.55 7.04 ± 0.23 2.13 ± 0.08 0.31 ± 0.01 1.26 ± 0.19 12.12 ± 0.34 96 ± 2.56 
Thareed, chicken 78.33 ± 3.38 5.37 ± 0.58 1.54 ± 0.81 1.01 ± 0.23 1.02 ± 0.36 13.75 ± 2.50 90 ± 16.37 
Biryani, chicken 63.26 ± 1.34 11.55 ± 0.86 3.28 ± 0.42 1.26 ± 0.12 0.96 ± 0.45 20.65 ± 1.06 158 ± 3.72 
Machbous, fish 68.26 ± 2.24 6.96 ± 1.56 1.98 ± 0.29 1.20 ± 0.12 3.60 ± 0.56 21.60 ± 0.45 132 ± 10.11 
Arseyah 86.66 ± 0.34 2.24 ± 0.04 0.88 ± 0.10 0.11 ± 0.01 0.26 ± 0.01 10.11 ± 0.46 57 ± 0.95 
Marqoqa 74.18 ± 1.66 5.89 ± 0.89 2.16 ± 1.24 1.20 ± 0.26 0.56 ± 0.13 16.57 ± 0.47 109 ± 12.93 
Khabisa 24.91 ± 4.01 5.38 ± 0.87 10.54 ± 1.60 0.32 ± 0.08 2.72 ± 0.41 58.85 ± 4.56 352 ± 16.12 
Leqemat 23.26 ± 1.72 7.29 ± 0.28 22.80 ± 2.09 1.02 ± 0.10 1.45 ± 0.34 45.63 ± 1.12 417 ± 16.87 
Batheetha 16.40 ± 0.14 5.81 ± 0.04 9.54 ± 0.09 1.14 ± 0.07 6.12 ± 0.44 67.11 ± 0.03 378 ± 0.89 
Khanfaroosh 21.57 ± 2.08 6.72 ± 0.20 30.32 ± 1.91 0.60 ± 0.10 1.16 ± 0.28 40.79 ± 0.77 463 ± 18.05 
Sago 74.91 ± 2.69 0.80 ± 1.09 0.53 ± 0.17 0.04 ± 0.01 0.30 ± 0.11 23.73 ± 3.56 103 ± 11.56 
Asida 77.17 ± 1.30 0.99 ± 0.05 0.04 ± 0.05 0.05 ± 0.01 0.67 ± 0.34 21.75 ± 1.25 91 ± 5.27 
Habba Hamra 80.24 ± 1.60 1.23 ± 0.97 1.84 ± 1.31 0.48 ± 0.05 0.25 ± 0.06 16.21 ± 1.22 86 ± 12.70 
Balalet 55.67 ± 3.50 2.40 ± 0.26 1.72 ± 0.58 0.12 ± 0.04 12.20 ± 1.31 40.09 ± 3.19 185 ± 15.89 
P value* <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 





5.2.2 Minerals Analysis 
Major minerals and trace metals (Ca, K, Na, Mg, P, Cu, Fe, Mn, and Zn) were 
simultaneously determined in locally-consumed Emirati foods by Inductively Coupled 
Plasma Optical Emission Spectrometer (ICP-OES), as previously described in section 
3.3.5.5. The results of major mineral content and trace metal content in the fresh weight 
basis are presented in Table 5.2 and Table 5.3, respectively. 
The calcium content was the highest in Chami (432.971mg/100 g) and the 
lowest in Sago (18.049mg/100g). Chami is a type of cottage cheese, which explains 
the high calcium content. Calcium value in Sago was also reported low by ElObeid et. 
al. (2015) [352] (13.91mg/100g) and Musaiger (2011)[351] (18mg/100g). Breads had 
relatively low calcium values, ranging from 26.345mg/100g in Qurus to 
59.395mg/100g in Chebab bread. Chebab and Khameer breads had higher calcium 
contents when compared to other breads (59.395 and 47.831 mg/100g, respectively), 
due to the presence of milk powder in their ingredients list. Ali et. al.(2013) reported 
that the mean calcium intakes among Emirati children (6-10 years) and adolescents 
(11-18 years) were much lower than the estimated average requirement (EAR) values 
[353]. Consequently, low calcium intake could decrease the level of serum calcium, 
triggering the secretion of the parathyroid hormone, which partially results in bone 
resorption leading to a reduction in bone mass and osteoporosis [354]. Several studies 
showed the association between adequate intakes of calcium and vitamin D, and 
decreased risk of osteoporosis [354, 355]. Thus, dishes high in calcium like Chami are 
favorable especially for children and women. 
The phosphorus content was high in all main dishes, because they all contained 





(374.353mg/100g) among main dishes, followed by Harees (beef) (374.353mg/100g), 
and Thareed chicken (287.484mg/100g). The phosphorus content was the highest in 
Chami (761.187mg/100g) as it is a milk product. Moreover, it was very similar among 
different breads, as it ranged from 120.03mg/100g in Arabic bread to 148.839mg/100g 
in Khameer bread. This study found 120.03mg/100g of phosphorus in Arabic bread, 
and 156.958mg/100g in Regag bread. However, Musaiger (2011) [351] reported 
100mg/100g of phosphorus in Arabic bread, and 231mg/100g in Regag bread. 
Conversely, Habib et. al. (2011)[175] reported 158.65mg/100g of phosphorus in 
Regag bread. 
Healthy individuals have tightly regulated serum phosphorus levels, however, 
several studies proposed that high intakes of phosphorus could be associated with an 
increased risk of cardiovascular disease [356-358]. Moreover, high phosphorus intake 
with low calcium intake could have negative impact on calcium metabolism, poor bone 
density and development of osteoporosis [356, 358].  
The highest sodium content was found in these main dishes: Arseyah 
(1569.877mg/100g), Thareed chicken (1413.947mg/100g), thareed (beef) 
(1320.167mg/100g), and Harees (beef) (1015.980mg/100g). Varied values of sodium 
were observed in the breads, ranging from 12.910mg/100g in Khameer bread to 
355.100mg/100g in Regag bread. ElObeid et. al. [352] reported a sodium content of 
707.40mg/100g in Regag bread, whereas Habib  et. al. [175] found 574.21mg/100g of 
sodium in Regag bread. This variation might be due to different amounts of salt added 
to the bread dough during the preparation process. The lowest content of sodium was 





Most dishes containing meat and Regag bread presented in this study had very 
high sodium levels. Consuming a high-sodium diet was found associated with an 
increased risk of cardiovascular disease (CVD), hypertension, stroke, chronic kidney 
disease (CKD), heart failure, and stomach cancer [359]. The prevalence of CVD in the 
Middle East is increasing and becoming a major health problem [360]. According to 
the 2008 Emirati CVD risk assessment study, 28.4% of Emirati adults had a 
Framingham risk assessment score (a risk assessment tool for estimating a person's 
ten-year risk of developing CVD [361]) of more than 20%, and 20.8% of the studied 
population were found to be hypertensive [362]. Therefore, it is highly important to 
take serious steps nationally towards reducing the sodium intake in diets in order to 
lessen the risk of developing CVD, hypertension, and other associated complications. 
The potassium content was high in main dishes like Thareed (beef) (670.667 
mg/100g), Marqoqa (657.492 mg/100g), and Thareed (chicken) (610.488mg/100g). 
However, it was the highest in Fendal (1123.920mg/100g), which is expected as it is 
boiled sweet potato. Khameer bread had the highest content of potassium 
(215.488mg/100g) among breads, whereas other breads had very similar values, 
ranging from 100.256mg/100g in Arabic bread to 127.629mg/100g in Muhalla bread. 
Regag bread had potassium content of 128.672mg/100g. However, Habib et. al. 
(2011)[175] reported a higher potassium value in Regag bread (171.53mg/100g). The 
lowest potassium content was in Sago (5.816mg/100g); ElObeid et. al. (2015) [352] 
found 18.03mg/100g of potassium in Sago. The use of Sago planted in potassium 
depleted soil and the use of different cooking methods between countries could be the 





Reducing sodium intake accompanied by increasing dietary potassium intake 
(low-sodium/high-potassium diet) could play an essential role in preventing and 
treating kidney disease, hypertension, stroke, and CVD [363, 364]. 
The highest magnesium content was found in Fendal (122.697mg/100g) and 
the lowest was in Sago (13.697mg/100g). Arabic bread, Biryani chicken, Arseyah, 
Legemat, Asida and Balaleet had similar magnesium concentrations (36.361, 32.286, 
37.206, 33.608, 33.475, and 33.733 mg/100g, respectively). The results of this study 
were not in agreement with ElObeid et. al. (2015)[352], who reported the magnesium 
content of Asida, Thareed (beef), and Sago to be 71.67, 57.97 and 2.42mg/100g 
respectively. Additionally, Habib et. al. (2011) reported lower magnesium content in 
Regag bread, Qurus, Legemat, and Balalet 51.420, 34.2, 22.93, and 9.42 mg/100g, 
respectively. Furthermore, Al Nagdy et. al. [273], found 44 mg/100g of magnesium in 
Asida. Musaiger et. al. (1998) [172] found only 5.9 mg/100g of magnesium in the 
Omani Asida. While, Musaiger (2011) [351] reported 32 mg/100g of magnesium in 
the Bahraini Asida. Such differences could occur due to the use of different recipes in 
different gulf countries, as well as the use of fortified wheat flour in some countries. 
Low serum magnesium level (hypomagnesemia) is associated with metabolic 
syndrome (MetS) [365, 366], T2DM [367, 368] and hypertension [369]. Accordingly, 
increasing magnesium intake could prevent high blood pressure [370] and improves 
the glycemic status of adults with prediabetes and hypomagnesaemia [371]. Moreover, 
higher serum magnesium levels were found associated with lower risk of MetS [366, 






The iron content was higher among breads compared to other dishes. It ranged 
from 9.61mg/100g in Regag bread to 3.11mg/100g in Qurus. ElObeid et. al. (2015) 
[352] found 7.36 mg/100g of iron in Kuwaiti Regag bread. However, Musaiger (2011) 
[351] found 1.8mg/100g of iron only in Bahraini Regag bread. This difference could 
be a result of using fortified wheat flour, or due to the use of date paste as an ingredient 
for the production of Rgag bread in some countries.  
Moreover, among main dishes, Margooga and Thareed (beef) had the highest 
iron content (5.673mg/100g and 5.263mg/100g), followed by Thareed chicken 
(4.306mg/100g). Low iron content was found in Sago, Khabisa and Arseyah 
(0.518mg/100g, 0.599 mg/100g, and 0.711 mg/100g, respectively). 
Aiming for high iron food sources (like Regag, Chebab, Muhalla, and Khameer 
bread) as part of the daily diet is recommended to reduce the risk of iron deficiency 
(anemia). Iron deficiency is considered one of the major public health problems in the 
Arab Gulf countries. Musaiger (2002) conducted a study in the Arab gulf countries 
and stated that iron deficiency prevalence among preschoolers ranged from 20% to 
67%, and ranged from 12.6% to 50% among school age children. Moreover, the 
percentage of pregnant women with anemia ranged from 22.7% to 54%. In the UAE, 
the overall prevalence of anemia (Hb <12g/dL) among female college students 
attending the University of Sharjah was 26.7% [373]. Moreover, the prevalence of 
anemia, iron depletion and iron deficiency among Emirati preschoolers were estimated 
to be 36.1%, 26%, and 9.9%, respectively [374]. 
The highest zinc content was found in Thareed (beef) and Thareed (chicken) 
(4.690mg/100g and 4.870mg/100g), while Sago and Khabisa (0.119mg/100g and 





contents, ranging from 1.033mg/100g in Arabic bread to 1.760mg/100g in Regag 
bread. Lower zinc content was reported by Habib et. al. (2011) [175] in Harees, Regag, 
Qurus, Legemat, and balaleet (0.630, 1.00, 0.77, 0.8, and 0.5mg/100g, respectively). 
A zinc rich diet is recommended to avoid zinc deficiency and related developmental 
abnormalities [375].  
Lastly, the copper and manganese concentration was very low in all foods. 
Batheetha had the highest copper content (2.252mg/100g) because its main ingredient 
is date fruit, and Harees (beef) had the highest manganese value (1.697mg/100g) due 






Table 5.2: Micronutrient (Major Elements) Composition of United Arab Emirates Traditional Dishes 
Data are expressed as mg/100 g on a fresh weight basis, (mean ± SD)
Test Food Ca P Na K Mg 
Arabic Bread 23.128 ± 0.258 120.030 ± 0.878 163.866 ± 1.190 100.256 ± 0.831 36.361 ± 0.366 
Regag Bread 31.526 ± 0.296 156.958 ± 0.030 355.100 ± 1.618 128.672 ± 0.563 54.819 ± 0.121 
Chebab Bread 59.395 ± 0.255 143.556 ± 0.609 29.516 ± 0.304 133.194 ± 0.046 48.594 ± 0.483 
Muhalla Bread 31.413 ± 0.294 125.495 ± 0.309 258.910 ± 1.532 127.629 ± 0.552 44.236 ± 0.334 
Khameer Bread 47.831 ± 0.447 148.839 ± 0.571 12.910 ± 0.147 215.488 ± 0.531 61.460 ± 0.749 
Qurus 26.345 ± 0.335 145.118 ± 0.842 343.263 ± 4.430 104.193 ± 0.837 50.187 ± 0.538 
Fendal 92.019 ± 0.153 250.605 ± 0.093 185.567 ± 1.276 1123.920 ± 0.065 122.697 ± 0.265 
Chami 432.971 ± 3.000 761.187 ± 3.291 661.612 ± 8.737 363.357 ± 3.126 44.450 ± 3.263 
Harees, beef 307.293 ± 4.636 322.488 ± 4.038 1015.980 ± 1.365 229.026 ± 4.631 67.878 ± 4.700 
Thareed, beef 164.897 ± 0.714 374.353 ± 0.616 1320.167 ± 3.758 670.667 ± 0.770 91.784 ± 0.462 
Thareed, chicken 73.908 ± 0.246 287.484 ± 0.958 1413.947 ± 5.294 610.488 ± 0.468 76.364 ± 0.219 
Biryani, chicken 87.003 ± 0.758 241.033 ± 0.313 711.897 ± 7.661 241.940 ± 0.047 32.286 ± 0.137 
Machbous, fish 94.765 ± 0.352 251.137 ± 0.330 818.807 ± 1.688 338.951 ± 0.527 45.076 ± 0.666 
Arseyah 123.126 ± 0.422 186.523 ± 0.649 1569.877 ± 10.597 154.863 ± 0.741 37.206 ± 0.355 
Marqoqa 67.646 ± 0.391 218.739 ± 0.924 1513.897 ± 9.729 657.492 ± 0.790 62.527 ± 0.274 
Khabisa 24.154 ± 0.266 56.100 ± 0.993 143.485 ± 2.912 65.303 ± 0.118 17.403 ± 0.196 
Legemat 37.515 ± 0.055 124.039 ± 0.937 26.431 ± 0.204 113.173 ± 0.768 33.608 ± 0.421 
Batheetha 63.539 ± 0.346 116.993 ± 0.826 5.440 ± 0.035 416.591 ± 0.625 65.605 ± 0.190 
Khanfaroosh 24.135 ± 0.482 103.445 ± 0.274 55.498 ± 1.397 61.774 ± 0.971 24.332 ± 0.003 
Sago 18.049 ± 0.102 2.998 ± 0.112 141.127 ± 1.332 5.816 ± 0.097 13.697 ± 0.061 
Asida 37.980 ± 0.155 105.896 ± 0.474 161.374 ± 1.285 99.773 ± 0.459 33.475 ± 0.474 
Habba Hamra 235.230 ± 1.256 159.128 ± 1.071 100.352 ± 0.693 196.556 ± 1.186 66.875 ± 1.610 





Table 5.3: Micronutrient (Trace Elements) Composition of United Arab Emirates 
Traditional Dishes 
Test Food Fe Zn Cu Mn 
Arabic Bread 4.815 ± 0.072 1.033 ± 0.049 0.206 ± 0.009 0.718 ± 0.003 
Regag bread 9.613 ± 0.041 1.760 ± 0.024 0.302 ± 0.001 1.581 ± 0.003 
Chebab Bread 8.479 ± 0.036 1.462 ± 0.041 0.241 ± 0.005 1.526 ± 0.003 
Muhalla Bread 8.238 ± 0.060 1.343 ± 0.063 0.245 ± 0.010 1.221 ± 0.003 
Khameer 8.212 ± 0.074 1.423 ± 0.028 0.306 ± 0.005 1.335 ± 0.003 
Qurus 3.111 ± 0.026 1.401 ± 0.055 0.244 ± 0.002 1.133 ± 0.003 
Fendal 2.399 ± 0.010 0.765 ± 0.037 0.462 ± 0.008 0.632 ± 0.003 
Chammi 0.798 ± 0.008 2.184 ± 0.037 0.093 ± 0.009 0.024 ± 0.003 
Harees, beef 2.142 ± 0.027 1.841 ± 0.019 0.279 ± 0.005 1.697 ± 0.003 
Thareed, beef 5.263 ± 0.021 4.690 ± 0.040 0.311 ± 0.004 1.558 ± 0.003 
Thareed, chicken 4.306 ± 0.023 4.870 ± 0.067 0.320 ± 0.008 1.195 ± 0.003 
Biryani, chicken 1.253 ± 0.011 1.920 ± 0.043 0.215 ± 0.006 0.447 ± 0.003 
Machbous, fish 1.742 ± 0.018 1.338 ± 0.038 0.211 ± 0.002 0.789 ± 0.003 
Arseyah 0.711 ± 0.009 1.777 ± 0.062 0.189 ± 0.009 0.489 ± 0.003 
Marqooqa 5.673 ± 0.021 2.077 ± 0.038 0.246 ± 0.004 0.666 ± 0.003 
Khabisa 0.599 ± 0.006 0.378 ± 0.039 0.127 ± 0.004 0.501 ± 0.003 
Legemat 3.019 ± 0.024 0.965 ± 0.024 0.161 ± 0.006 0.721 ± 0.003 
Batheetha 6.311 ± 0.083 1.090 ± 0.033 2.252 ± 0.029 1.029 ± 0.003 
Khanfaroosh 3.138 ± 0.052 0.996 ± 0.013 0.170 ± 0.005 0.706 ± 0.003 
Sago 0.518 ± 0.002 0.119 ± 0.014 0.021 ± 0.009 0.095 ± 0.003 
Asida 3.544 ± 0.043 1.004 ± 0.011 0.180 ± 0.003 0.940 ± 0.003 
Habba Hamra 4.781 ± 0.027 1.434 ± 0.038 0.079 ± 0.003 0.307 ± 0.003 
Balaleet 2.651 ± 0.011 1.134 ± 0.020 0.297 ± 0.004 0.744 ± 0.003 





5.2.3 Vitamins Analysis 
Seven water-soluble and all fat-soluble vitamins (Vitamin C, Thiamin, 
Riboflavin, Niacin, Vitamin B-6, Folate, Vitamin B-12, Vitamin A, Vitamin E (alpha-
tocopherol), Vitamin D (D2 + D3), and Vitamin K (phylloquinone)) were 
simultaneously found in foods using the High-Performance Liquid Chromatography 
(HPLC) method, as described earlier in section 3.3.5.8. Data on the analysis of water-
soluble and fat-soluble vitamins per 100g of fresh weight is presented in Table 5.4, 
and Table 5.5 respectively. 
Vitamin C (total ascorbic acid) content was the highest in Biryani chicken 
(631.01mg/100g) and Arseyah (624.86mg/100g). However, no vitamin C was found 
in Arabic bread, Regag bread, Gurus and Asida. Musaiger (2011) [351] reported 
similar results for Arabic bread (0 mg/100g), and traces of vitamin C in Asida 
(0.6mg/100g). Breads usually do not contain vitamin C, yet Chebab bread, Khameer 
bread and Muhallah bread were found to have 247.82mg/100g, 245.71mg/100g, and 
362.51mg/100g of vitamin C respectively, due to their milk content. 
The concentration of thiamin in breads ranged from 1.40mg/100g in Regag 
bread to 7.83mg/100g in Gurus. This study reported 3.94 mg/100g of thiamin in Arabic 
bread, whereas lower thiamin content was found in Bahraini Arabic bread 
(0.1mg/100g) [351]. These differences could result from the use of fortified wheat 
flour in some recipes. Moreover, thiamin was found to be the highest in Sago 
(13.98mg/100g), and no thiamin was found in Fendal, Thareed (beef), Thareed 





As expected, dishes containing meat had relatively higher riboflavin content: 
Thareed (beef) (183.14mg/100g), Biryani chicken (76.51mg/100g), Margooga 
(64.20mg/100g), and Harees (beef) (56.89mg/100g). Whereas, Arabic bread, Regag 
bread, Muhallah bread, Khameer bread, Gurus, Chami, Khabisa, Batheetha, 
Khanfaroosh, Sago, Asida, and Balaleet did not contain riboflavin. 
High niacin content was found in Thareed chicken (13.73mg/100g), Fendal 
(11.89 mg/100g) and Thareed (beef) (9.86mg/100g). However, no niacin was present 
in Khameer bread, Gurus, Chami, Biryani chickin, Machbous fish, Khabisa, 
Batheetha, Khanfaroosh, and Sago. The results of this study were not in agreement 
with Musaiger (2011) [351], who reported the niacin content of Asida, Batheetha, 
Harees, Khabisah, Khanfaroosh, Marqoqa, and Sago to be 1.2, 6.5, 1.9, 1.2, 1.0, 0.3 
and 0.3 mg/100g respectively. The use of different ingredients and cooking methods 
could account for these differences between studies. 
The highest concentration of vitamin B-6 was found in Batheetha 
(8.49mg/100g), followed by Thareed (beef) (5.70mg/100g) and Biryani chicken 
(4.06mg/100g). Vitamin B-6 was not present in Regag bread, Khameer bread, 
Khanfaroosh, Habba Hamra and Sago.  
Habba Hamra, a red seed added in milk drink had the highest folic acid content 
(188.07mg/100g), followed by Thareed (beef) (13.59mg/100g) and Thareed Chicken 
(9.70mg/100g). Folate content was low in all breads, ranging from zero in Arabic and 
Regag bread, to 0.97mg/100g in Qurus. The results of this study were not in agreement 
with Musaiger (2011) [351], who reported much higher folic acid content in Thareed 
(26.7mg/100g). This could be due to the national flour fortification program adopted 





(WHO) in 2001 to control and prevent anemia by fortifying flour with iron and folic 
acid [376]. 
All foods included in this study did not contain vitamin B-12 or vitamin A 
except for Habba Hamra, which had 0.64mg/100g of vitamin B-12, due to its milk 
content. Likewise, in Bahrain, B-12 was not present in Sago, Kabisah, Marqoqa, or 
batheetha [351]. Vitamin E concentration was the highest in Fendal (1.79mg/100g). 
However, Arabic bread (0.03mg/100g), Sago (0.05mg/100g) and Chami 
(0.08mg/100g) had the lowest vitamin E content. On the other hand, Bahraini Sago did 
not have vitamin E (0mg/100g), and Bahraini Asida, Marqoqa, and khanfaroosh had 
slightly higher vitamin E content as compared to values reported in this study (0.7, 0.7, 
and 1.6 mg/100g vs. 0.31, 0.51, and 0.27 mg/100g, respectively) [351]. 
Some traditional foods did not contain vitamin D, such as Thareed (beef), 
Thareed (chicken), Gurus, Arseya, Marqoqa, Khabisa, Sago, and Asida. Similarly, 
Musaiger (2011) [351] reported 0 mg/100g of vitamin D in Sago and Marqoqa. 
Vitamin K was also low in all tested foods. It ranged from 0.01mg/100g in Margooga 
and Habba Hamra, to 0.11mg/100g in Thareed (beef) and Biryani (chicken). 
The duration, temperature of cooking, food recipe composition, and storage 
conditions are all factors that substantially influence the stability and status of vitamins 
in foods [377]. The major micronutrient deficiencies reported in the UAE are iron 
deficiency anemia [373, 374] and vitamin D deficiency [378, 379]. Programs aiming 
to prevent and control these deficiencies could include: nutrition education; 
fortification of drinks with vitamin D [380]; flour fortification with iron and folic acid 






Table 5.4:Water-Soluble Vitamin Composition of United Arab Emirates Traditional Dishes 
Data are expressed as mg/100 g on a fresh weight basis, (mean ± SD)
Test Food Vitamin C Thiamin Riboflavin Niacin Vitamin B-6 Folate Vitamin B-12 
Arabic bread 0.00 3.94 ± 0.10 0.00 0.31 ± 0.06 0.73 ± 0.05 0.00 0.00 
Regag bread 0.00 1.40 ± 0.16 0.00 0.11 ± 0.05 0.00 0.00 0.00 
Chebab bread 247.82 ± 0.06 3.46 ± 0.03 28.21 ± 0.68 0.35 ± 0.06 0.46 ± 0.28 0.63 ± 0.10 0.00 
Muhalla Bread 245.71 ± 0.53 2.04 ± 0.24 0.00 0.31 ± 0.01 2.27 ± 0.03 0.49 ± 0.20 0.00 
Khameer Bread 362.51 ± 6.22 1.50 ± 0.02 0.00 0.00 0.00 0.67 ± 6.02 0.00 
Gurus 0.00 7.83 ± 0.10 0.00 0.00 0.98 ± 0.03 0.97 ± 0.06 0.00 
Fendal 351.28 ± 7.95 0.00 121.53 ± 0.34 11.89 ± 1.62 1.55 ± 0.16 5.28 ± 7.05 0.00 
Chami 121.77 ± 1.68 0.33 ± 0.02 0.00 0.00 1.01 ± 0.72 0.25 ± 1.05 0.00 
Harees, beef 591.50 ± 17.54 2.12 ± 0.42 56.89 ± 3.54 0.38 ± 0.04 2.63 ± 0.06 0.25 ± 17.03 0.00 
Thareed, beef 453.91 ± 9.52 0.00 183.14 ± 4.55 9.86 ± 0.53 5.70 ± 0.44 13.59 ± 9.45 0.00 
Thareed, chicken 636.92 ± 1.84 0.00 81.77 ± 6.60 13.73 ± 1.48 2.67 ± 0.47 9.70 ± 1.56 0.00 
Biryani, chicken 631.01 ± 26.81 2.07 ± 0.56 76.51 ± 1.98 0.00 4.06 ± 0.17 2.14 ± 26.29 0.00 
Machbous, fish 583.00 ± 0.18 2.02 ± 0.11 30.83 ± 1.11 0.00 1.92 ± 1.53 0.13 ± 0.01 0.00 
Arseyah 624.86 ± 11.49 2.56 ± 0.31 36.90 ± 1.15 3.12 ± 1.15 2.60 ± 0.00 1.07 ± 11.08 0.00 
Marqoqa 581.81 ± 26.16 0.00 64.20 ± 1.09 4.23 ± 1.89 1.11 ± 0.19 0.81 ± 26.09 0.00 
Khabisa 339.24 ± 1.95 3.99 ± 0.08 0.00 0.00 1.28 ± 0.17 2.08 ± 1.12 0.00 
Leqemat 322.43 ± 2.91 1.80 ± 0.14 15.65 ± 0.40 0.71 ± 0.08 0.74 ± 0.23 0.15 ± 2.02 0.00 
Batheetha 244.09 ± 6.49 4.30 ± 0.26 0.00 0.00 8.49 ± 2.17 0.58 ± 6.00 0.00 
Khanfaroosh 200.69 ± 8.33 1.17 ± 0.22 0.00 0.00 0.00 2.41 ± 8.07 0.00 
Sago 133.34 ± 6.27 13.98 ± 1.21 0.00 0.00 0.00 0.13 ± 6.00 0.00 
Asida 0.00 5.10 ± 0.27 0.00 0.11 ± 0.04 0.54 ± 0.11 1.38 ± 0.00 0.00 
Habba Hamra 252.23 ± 21.24 8.52 ± 0.92 28.69 ± 1.41 0.01 ± 0.01 0.00 188.07 ± 21.84 0.64 ± 0.05 





Table 5.5: Fat-Soluble Vitamin Composition of United Arab Emirates Traditional 
Dishes 
Food Vitamin A Vitamin E Vitamin D Vitamin K 
Arabic bread 0.00 0.03 ± 0.00 0.04 ± 0.00 0.04 ± 0.00 
Regag bread 0.00 0.17 ± 0.00 0.04 ± 0.00 0.02 ± 0.00 
Chebab bread 0.00 0.16 ± 0.00 0.03 ± 0.00 0.03 ± 0.00 
Muhalla Bread 0.00 0.26 ± 0.00 0.03 ± 0.00 0.03 ± 0.00 
Khameer Bread 0.00 0.67 ± 0.00 0.01 ± 0.00 0.08 ± 0.00 
Gurus 0.00 0.41 ± 0.00 0.00 0.08 ± 0.00 
Fendal 0.00 1.79 ± 0.00 0.02 ± 0.00 0.04 ± 0.00 
Chami 0.00 0.08 ± 0.00 0.01 ± 0.00 0.02 ± 0.00 
Harees, beef 0.00 0.09 ± 0.00 0.07 ± 0.01 0.04 ± 0.00 
Thareed, beef 0.00 0.79 ± 0.00 0.00 0.11 ± 0.00 
Thareed, chicken 0.00 0.77 ± 0.00 0.00 0.02 ± 0.00 
Biryani, chicken 0.00 0.54 ± 0.12 0.04 ± 0.00 0.11 ± 0.12 
Machbous, fish 0.00 0.44 ± 0.00 0.02 ± 0.00 0.01 ± 0.00 
Arseyah 0.00 0.06 ± 0.00 0.00 0.02 ± 0.00 
Marqoqa 0.00 0.51 ± 0.00 0.00 0.01 ± 0.00 
Khabisa 0.00 0.20 ± 0.00 0.00 0.04 ± 0.00 
Leqemat 0.00 0.11 ± 0.00 0.06 ± 0.00 0.04 ± 0.00 
Batheetha 0.00 0.50 ± 0.00 0.02 ± 0.00 0.04 ± 0.00 
Khanfaroosh 0.00 0.27 ± 0.00 0.02 ± 0.00 0.05 ± 0.00 
Sago 0.00 0.05 ± 0.00 0.00 0.00 
Asida 0.00 0.31 ± 0.00 0.00 0.06 ± 0.00 
Habba Hamra 0.00 0.13 ± 0.00 0.01 ± 0.00 0.01 ± 0.00 
Balalet 0.00 0.11 ± 0.00 0.10 ± 0.03 0.06 ± 0.00 






5.2.4 Lipids Analysis 
Lipid analysis, including fatty acids and cholesterol, were found in Emirati 
foods using the Gas Chromatograph (GC) and High-Performance Liquid 
Chromatography (HPLC) respectively, as previously described in section 3.3.5.7. Data 
on the analysis of fatty acids (saturated, monounsaturated, polyunsaturated, and trans 
fatty acids) and cholesterol is presented in Table 5.6. 
Khanfaroosh and Legemat had the highest content of saturated fatty acids 
(13.520g/100g and 9.586g/100g, respectively). This could be a result of the deep-
frying preparation method used in these sweet dishes. Among breads, Chebab bread 
had the highest saturated fatty acids content (6.178g/100g) followed by Khameer bread 
(5.633g/100g), and Gurus (4.373g/100g). Excessive dietary fat consumption, 
especially saturated fat, has been linked to an increase in many health risks such as 
obesity, coronary heart disease (CHD), and certain types of cancer [383]. The 2015 
USDA’s dietary guidelines recommends limiting intake of saturated fats to less than 
10% of energy intake, to acquire optimal cardiovascular health [384]. Moreover, the 
WHO dietary guidelines for the Eastern Mediterranean Region (2012) recommends 
reducing saturated fats and trans fats to <10% and < 1% of total energy intake, 
respectively, and replacing both types of fat with unsaturated fats [385]. 
Monounsaturated fatty acid content ranged from 0g/100g in Asida and Regag 
bread to 4.202g/100g in Legemat. Whereas, polyunsaturated fatty acids content ranged 
from 0.018g/100g in Asida to 15.99g/100g in Khanfaroosh. The USDA and the WHO 
emphasize on replacing saturated fatty acids - usually found in red meat, processed 
meats, and fried foods - with healthier monounsaturated and polyunsaturated fatty 





should be combined with healthy sources of carbohydrates (fiber-rich whole-grain 
sources), and adequate consumption of fruits and vegetables [384, 385]. 
Most foods studied did not contain trans fatty acids such as Regag bread, 
Chebab bread, Muhallah bread, Khameer bread, Harees (beef), and Thareed (beef). 
However, Khabisa contained the highest trans fatty acids content (1.731g/100g). 
Observational studies and controlled trials provide evidence that trans fatty acid intake 
from partially hydrogenated oils adversely affects several cardiovascular risk factors 
and contributes significantly to increased risk of CHD events [386]. 
Cholesterol content ranged from 1.10mg/100g in Regag bread and Legemat, to 
27.25mg/100g in Thareed chicken. Among breads, Khameer had the highest 
cholesterol content (9.70mg/100g), followed by Chebab bread (6.25mg/100g) and 
Muhallah bread (4.60mg/100g). These breads contain eggs, and according to Schärer 
and Schulthess [387], egg yolk has the highest content of cholesterol detected in 








Table 5.6: Lipid profile of United Arab Emirates Traditional Dishes 
Test Food 
Fatty acids, total 
saturated (g) 




Trans Fatty acids (g) Cholesterol (mg) 
Arabic bread 0.574 ± 0.130 0.027 ± 0.013 0.536 ± 0.143 0.013 ± 0.000 1.40 ± 0.14 
Regag bread 0.116 ± 0.014 0.000 ± 0.000 0.316 ± 0.021 0.00 1.10 ± 0.00 
Chebab bread 6.178 ± 0.085 0.199 ± 0.029 2.693 ± 0.114 0.00 6.25 ± 0.07 
Muhalla Bread 2.741 ± 0.264 0.147 ± 0.074 1.352 ± 0.189 0.00 4.60 ± 0.00 
Khameer Bread 5.633 ± 0.187 0.401 ± 0.152 6.656 ± 0.035 0.00 9.70 ± 0.00 
Gurus 4.373 ± 0.352 0.095 ± 0.049 3.197 ± 0.238 0.046 ± 0.065 1.70 ± 0.14 
Fendal 0.322 ± 0.013 0.010 ± 0.009 0.222 ± 0.009 0.016 ± 0.004 1.60 ± 0.00 
Chami 0.395 ± 0.013 0.010 ± 0.002 0.225 ± 0.027 0.030 ± 0.042 6.40 ± 0.00 
Harees, beef 0.856 ± 0.011 0.066 ± 0.002 1.415 ± 0.019 0.00 11.60 ± 0.00 
Thareed, beef 0.826 ± 0.022 0.052 ± 0.012 1.169 ± 0.011 0.00 15.75 ± 0.07 
Thareed, chicken 0.656 ± 0.005 0.043 ± 0.001 0.744 ± 0.006 0.008 ± 0.011 27.25 ± 0.07 
Biryani, chicken 1.797 ± 0.326 0.097 ± 0.029 1.365 ± 0.268 0.021 ± 0.029 26.25 ± 0.07 
Machbous, fish 0.861 ± 0.003 0.062 ± 0.003 1.042 ± 0.016 0.015 ± 0.022 14.15 ± 0.07 
Arseyah 0.234 ± 0.007 0.119 ± 0.016 0.365 ± 0.013 0.129 ± 0.008 14.05 ± 0.07 
Marqoqa 0.840 ± 0.008 0.054 ± 0.001 1.170 ± 0.006 0.00 22.30 ± 0.14 
Khabisa 3.226 ± 0.178 1.640 ± 0.049 3.795 ± 0.033 1.731 ± 0.111 1.15 ± 0.07 
Leqemat 9.586 ± 0.439 4.202 ± 0.131 7.989 ± 0.154 0.00 1.10 ± 0.00 
Batheetha 3.758 ± 0.022 0.093 ± 0.005 5.052 ± 0.030 0.157 ± 0.047 6.55 ± 0.49 
Khanfaroosh 13.520 ± 0.021 0.178 ± 0.007 15.990 ± 0.095 0.725 ± 0.021 3.50 ± 0.28 
Sago 0.338 ± 0.036 0.005 ± 0.003 0.147 ± 0.018 0.041 ± 0.057 2.95 ± 0.07 
Asida 0.020 ± 0.000 0.000 ± 0.000 0.018 ± 0.001 0.00 1.30 ± 0.00 
Habba Hamra 0.538 ± 0.029 0.170 ± 0.018 1.127 ± 0.054 0.005 ± 0.007 5.85 ± 0.07 
Balalet 0.739 ± 0.008 0.00 0.913 ± 0.008 0.019 ± 0.001 1.90 ± 0.00 





5.2.5 Sugars Analysis 
Various types of sugars including monosaccharides (glucose, and fructose), 
disaccharides (sucrose, maltose, and lactose), and trisaccharide (raffinose) were found 
in foods using the High-Performance Liquid Chromatography (HPLC) method, as 
previously described in section 3.3.5.6. Data on the analysis of sugar is presented in 
Table 5.7. 
 Khameer and Muhalla bread had the highest content of fructose, glucose and 
total sugars among breads; this might be due to sugar added during preparation or the 
use of date paste. However, fructose and glucose were not present in Chami and 
Marqoqa. Recent human studies suggest that high dietary fructose levels might elevate 
serum triglyceride levels and cause other metabolic diseases, dyslipidemia, non-
alcoholic fatty liver, obesity and weight gain [388-390]. 
The highest content of sucrose was found in Sago (3.046g/100g) and Gurus 
(3.005g/100g), which could be explained by the high amount of sugar in the recipe.  
Most foods did not contain maltose and raffinose sugars, such as Arabic bread, 
Harees (beef), Marqoqa, Leqemat, Sago, and Balalet. However, Gurus contained the 
highest maltose content (0.373g/100g) and Habba Hamra had the highest content of 
raffinose (0.261g/100g).  
Lactose content was the highest in Fendal (1.091g/100g), followed by Chami 
(0.899g/100g). However, Gurus, Thareed (Chicken), Biryani (Chicken), Machbous 





Total sugars ranged from 0.009g/100g in Marqoqa to 5.018g/100g in 
Batheetha. Dessert dishes like Batheetha, Sago, and Habba Hamra had higher amounts 
of total sugars compared to other foods.  
It is important to monitor the total amount of added sugar in the diet. According 
to the 2015 World Health Organization’s (WHO) guidelines on sugar intake [391], 
adults and children are recommended to reduce their daily intake of added sugars to 
less than 10% of their total energy intake. Welsh et al. (2011) [392] suggested that an 








Table 5.7: Sugar Composition of United Arab Emirates Traditional Dishes 
Test Food Fructose Glucose Sucrose Maltose Lactose Raffinose Total, Sugars 
Arabic bread 0.387 ± 0.005 0.258 ± 0.008 0.000 0.000 0.257 ± 0.014 0.000 0.902 ± 0.027 
Regag bread 0.009 ± 0.001 0.017 ± 0.001 0.039 ± 0.007 0.030 ± 0.001 0.162 ± 0.012 0.000 0.257 ± 0.018 
Chebab bread 1.263 ± 0.002 0.769 ± 0.004 0.000 0.021 ± 0.008 0.450 ± 0.019 0.000 2.503 ± 0.005 
Muhalla Bread 1.336 ± 0.001 1.214 ± 0.004 0.009 ± 0.002 0.014 ± 0.005 0.302 ± 0.012 0.022 ± 0.002 2.897 ± 0.007 
Khameer Bread 1.685 ± 0.001 1.333 ± 0.006 0.000 0.010 ± 0.010 0.264 ± 0.010 0.000 3.291 ± 1.006 
Gurus 0.045 ± 0.002 0.040 ± 0.000 3.005 ± 0.003 0.373 ± 0.009 0.000 0.050 ± 0.070 3.512 ± 0.068 
Fendal 0.042 ± 0.001 0.085 ± 0.000 0.139 ± 0.003 0.080 ± 0.008 1.091 ± 0.007 0.126 ± 0.009 1.562 ± 0.009 
Chami 0.000 0.000 0.000 0.010 ± 0.010 0.899 ± 0.059 0.000 0.909 ± 0.069 
Harees, beef 0.012 ± 0.002 0.047 ± 0.001 0.10 ± 0.001 0.000 0.297 ± 0.019 0.000 0.366 ± 0.022 
Thareed, beef 0.017 ± 0.001 0.000 0.012 ± 0.001 0.015 ± 0.001 0.059 ± 0.005 0.022 ± 0.014 0.124 ± 0.019 
Thareed, chicken 0.011 ± 0.002 0.012 ± 0.001 0.024 ± 0.001 0.018 ± 0.003 0.000 0.000 0.064 ± 0.000 
Biryani, chicken 0.015 ± 0.006 0.007 ± 0.001 0.024 ± 0.002 0.004 ± 0.004 0.000 0.000 0.050 ± 0.001 
Machbous, fish 0.017 ± 0.002 0.012 ± 0.001 0.028 ± 0.005 0.005 ± 0.002 0.000 0.000 0.062 ± 0.006 
Arseyah 0.000 0.005 ± 0.002 0.011 ± 0.001 0.006 ± 0.007 0.187 ± 0.018 0.000 0.208 ± 0.029 
Marqoqa 0.000 0.000 0.009 ± 0.000 0.000 0.000 0.000 0.009 ± 0.000 
Khabisa 0.094 ± 0.002 1.285 ± 0.005 0.086 ± 0.000 0.001 ± 0.000 0.053 ± 0.000 0.000 1.518 ± 0.002 
Leqemat 1.240 ± 0.006 1.168 ± 0.004 0.053 ± 0.002 0.000 0.396 ± 0.005 0.000 2.856 ± 0.000 
Batheetha 1.309 ± 0.015 1.181 ± 0.000 2.468 ± 0.002 0.000 0.000 0.060 ± 1.001 5.018 ± 0.016 
Khanfaroosh 0.912 ± 0.007 0.771 ± 0.006 0.000 0.019 ± 0.001 0.299 ± 0.005 0.000 2.001 ± 0.010 
Sago 0.294 ± 0.001 1.576 ± 0.004 3.046 ± 0.015 0.000 0.095 ± 0.006 0.000 5.010 ± 0.015 
Asida 0.227 ± 0.002 0.847 ± 0.004 2.621 ± 0.020 0.040 ± 0.000 0.063 ± 0.011 0.045 ± 0.064 3.842 ± 0.027 
Habba Hamra 0.561 ± 0.001 1.192 ± 0.007 1.808 ± 0.026 0.018 ± 0.001 0.397 ± 0.006 0.261 ± 0.005 4.237 ± 0.046 
Balalet 0.260 ± 0.004 1.688 ± 0.018 0.276 ± 0.001 0.000 0.154 ± 0.006 0.000 2.377 ± 0.017 





5.2.6 Characteristics of Study Population 
 One hundred and twelve normal weight, healthy female students and staff 
participants were recruited from United Arab Emirates University (UAEU) to 
voluntarily participate in this study, as described earlier in section 3.3.1. The physical 
characteristics of the population of this study are presented as mean ± standard 
deviation, in Table 5.8. The mean age of the study population was 22.8 ± 5.01 years 
old, the mean weight was 58.26 ± 8.25 kg, and the mean body mass index (BMI) was 
22.86 ± 3.57 kg/m2. Other physical characteristics such as waist circumference, fat 
mass and fat-free mass are also reported in Table 5.8. 
 
Table 5.8: Physical Characteristics of the Study Population 
Characteristics Mean ± SD, (n=112) 
Age (years) 22.8 ± 5.01 
Height (m) 1.60 ± 0.06 
Weight (kg) 58.26 ± 8.25 
Body Mass Index (kg/m²) 22.86 ± 3.57 
Waist Circumference (cm) 74.12 ± 14.31 
Fat Mass (%) 29.00 ± 5.60 
Fat Mass (kg) 17.57 ± 6.27 
Fat-Free Mass (%) 65.54 ± 13.47 
Fat-Free Mass (kg) 44.27 ± 12.11 







5.2.7 Glycemic Response  
Twenty-three traditional foods commonly consumed in the United Arab 
Emirates (UAE) were chosen to investigate their glycemic index and glycemic load, 
according to the previously described methodology in section 3.3.6. The mean 
incremental area under the glycemic response curves of the standard food and each 
test food are presented in Figures A to W of Appendix 11. 
The mean incremental areas under the glycemic response curves (IAUCs) for 
low glycemic index traditional meals (Chebab bread, Khameer bread, Harees (beef), 
Biryani (chicken), Leqemat, Khanfaroosh, and Habba Hamra) are presented in Figure 
5.1. Biryani (chicken) showed the highest increase in glycemic response compared 
with other low GI foods, whereas, Harees and Khanfashoosh produced a slower and 
lower raise in the glycemic response over 120 minutes. Differences in glucose 
response between the meals were calculated using the Kruskal-Wallis test. The 
incremental increase in blood glucose at 15 min was significantly different between 
Chebab bread, Khanfaroosh, and Habba Hamra (P = 0.009, median = 0.90, 0.20, and 
0.80 respectively). At 30 min the incremental increase in blood glucose was 
significantly different between Chebab bread, Khameer bread, Harees (beef), Biryani 
(chicken), Leqemat, Khanfaroosh, and Habba Hamra (P = 0.008, median = 1.60, 0.90, 
1.10, 2.00, 1.10, 0.50, and 2.10 respectively). At 45 min the significant differences in 
incremental blood glucose were between Chebab bread, Harees (beef), Biryani 
(chicken), Leqemat, Khanfaroosh, and Habba Hamra (P = 0.006, median = 1.10, 1.40, 
2.40, 1.10, 1.20, and 1.50 respectively). At 60 min the significant differences in 
incremental blood glucose were between Harees (beef), Biryani (chicken), Leqemat, 





respectively). At 90 min the significant differences in incremental blood glucose were 
between Chebab bread, Leqemat, and Habba Hamra (P = 0.015, median = 1.10, 1.10, 
and 0.40 respectively). 
Several factors may alter the GI of food (Section 2.5.3), including the presence 
of macronutrients such as fat and protein, the type of starch, processing, and the 
addition of acids, sugars, gelling fibers, or amylase inhibitors [196].  
The high protein content in Biryani (11.55g/100g) along with added vegetables 
(onion, garlic and pepper) could explain its low GI [393]. Likewise, the addition of 
vegetable mixed curry showed considerable reduction of GI and GL of traditional Sri 
Lankan breakfast foods [394]. The high amount of dietary fibers present in Harees 
(5.56g/100g) may cause its low GI, because the presence of dietary fibers in test foods 
may delay its glycemic response, as it contributes to slower nutrient absorption and a 






























Chebab Bread Khameer Bread Harees Meat Biryani Chicken
Leqemat Khanfaroosh Habba Hamra
Figure 5.1: The incremental area under the blood glucose curves (IAUC) for low 






The IAUCs value for low GI test foods is presented in Table 5.9 as mean ± 
standard error. The table illustrates that the IAUC for all seven low GI test foods are 
significantly different from the IAUCs of the reference food (P ≤ 0.002). Among low 
GI test foods, Harees and Khanfarosh had the smallest IAUC (88.08 and 93.39, 
respectively). However, Biryani (chicken) had the highest IAUC (138.13 ± 10.64). 
 
Table 5.9: Incremental Area Under the Curve (IAUC) for low GI test foods 
Test Foods IAUC ± SE P-Value 
Reference Food 267.96 ± 32.86 
0.002 
Chebab Bread 134.83 ± 18.08 
Reference Food 215.56 ± 16.19 
<0.001 
Khameer Bread 93.51 ± 5.65 
Reference Food 215.61 ± 14.55 
<0.001 
Harees 88.08 ± 4.67 
Reference Food 285.57 ± 26.68 
<0.001 
Biryani, chicken 138.13 ± 10.64 
Reference Food 285.67 ± 26.68 
<0.001 
Leqemat 117.38 ± 8.85 
Reference Food 215.56 ± 16.19 
<0.001 
Khanfarosh 93.39 ± 7.34 
Reference Food 215.56 ± 16.19 
<0.001 
Habba Hamra 97.61 ± 5.94 
 
The mean IAUCs of medium glycemic index traditional meals (Arabic bread, 
Chami, Machbous (Fish), Khabisah, Batheetha, and Balalet) are shown in Figure 5.2. 
Differences in glucose response between the meals were calculated using the Kruskal-
Wallis test. The incremental increase in blood glucose at 30 min was significantly 
different between Arabic bread, Chami, Machbous (Fish), Khabisah, Batheetha, and 
Balalet (P = 0.029, median = 1.00, 0.16, 1.50, 1.60, 1.75, and 1.70 respectively). At 45 
min the incremental increase in blood glucose was significantly different between 
Arabic bread, Chami, Machbous (Fish), Khabisah, Batheetha, and Balalet (P = 0.039, 





differences in incremental blood glucose were between Arabic bread, Chami, 
Machbous (Fish), Khabisah, Batheetha, and Balalet (P = 0.034, median = 1.70, 0.13, 
1.00, 1.90, 1.10, and 1.60 respectively). At 90 min the significant differences in 
incremental blood glucose were between Arabic bread, Chami, Machbous (Fish), 
Khabisah, Batheetha, and Balalet (P = 0.016, median = 1.40, 0.19, 0.45, 1.20, 0.70, 
and 0.80 respectively). At 120 min the significant differences in incremental blood 
glucose were between Arabic bread, Chami, Machbous (Fish), Khabisah, Batheetha, 
and Balalet (P = 0.006, median = 1.00, 0.80, 0.20, 0.90, 0.20, and 0.10 respectively). 
Chami created a slow and low rise in the glycemic response over 120 minutes, due to 


































Arabic Bread Chami Machbous (Fish)
Khabisah Batheetha Balalet
Figure 5.2: The incremental area under the blood glucose curves (IAUC) for medium 
glycemic index traditional meals. Standard errors of the mean values are represented 





Table 5.10 shows the IAUC for medium GI foods. The IAUC for all medium 
GI test foods showed a significant difference compared to the IAUC of the reference 
food (P < 0.001), except for Chami (P=0.739). Khabisah had the highest IAUC value 
(IAUC ± SE: 164.23 ± 13.58), while Chami reported the lowest IAUC value (IAUC ± 
SE: 76.23 ± 8.36) among medium GI foods. 
 
Table 5.10: Incremental Area Under the Curve (IAUC) for medium GI test foods 
Test Foods IAUC ± SE P-Value 
Reference Food 224.77 ± 11.61 
<0.001 
Arabic Bread 145.33 ± 11.14 
Reference Food * 77.9313 ± 5.49 
0.739 
Chami 76.23 ± 8.36 
Reference Food 186.37 ± 10.41 
<0.001 
Machbous, fish 103.47 ± 7.99 
Reference Food 250.01 ± 16.87 
<0.001 
Khabisa 164.23 ± 13.58 
Reference Food 186.3650 ± 10.41 
<0.001 
Batheetha 107.93 ± 7.76 
Reference Food 215.61 ± 14.55 
<0.001 
Balalet 132.82 ± 13.34 
*(25g glucose) 
 
The mean IAUCs of high glycemic index traditional meals (Regag bread, 
Muhalla bread, Qurus, Fendal, Thareed (beef), Thareed (chicken), Arseyah, Marqoqa, 
Sago, and Asida) are presented in Figure 5.3. Muhalla bread, Asida and Sago produced 
the highest increase in glycemic response, compared with other high GI foods. 
Whereas, Thareed (beef) showed the highest peak (at 45 minutes) among high GI 
foods. Regag bread showed a slow and low rise in glycemic response during the first 
15 minutes, and then a sharp increase between 15 to 60 minutes. Differences in glucose 
response between the meals were calculated using the Kruskal-Wallis test. The 
incremental increase in blood glucose at 15 min was significantly different between 





0.90, 0.90, and 0.90 respectively). At 30 min the incremental increase in blood glucose 
was significantly different between Regag bread, Qurus, Thareed (beef), Sago, and 
Asida (P = 0.006, median = 1.10, 1.20, 2.30, 2.60, and 2.70 respectively). At 90 min 
the significant differences in incremental blood glucose were between Regag bread, 
Muhalla bread, Fendal, and Thareed (beef) (P = 0.01, median = 1.50, 1.30, 0.20, and 
1.30 respectively).  
At 120 min the significant differences in incremental blood glucose were 
between Regag bread, Muhalla bread, Qurus, Fendal, Thareed (beef), Arseyah, and 
Asida (P = 0.04, median = 1.10, 0.90, 1.00, 0.00, 0.90, 1.10, and 0.10 respectively). 
Sago had the highest incremental blood glucose response at 15 and 30 min compared 
to other high GI foods. The high moisture content (humidity) of Sago (74.91g/100g), 
along with high cooking temperatures and prolonged cooking durations (time) could 
have increased starch gelatinization and digestibility degree, thus, resulting in high 
glycemic responses for this traditional desserts [396, 397].  
 
The IAUC’s values for high GI test foods are presented in Table 5.11 as mean 
± standard error. The table demonstrates that the IAUC for all high GI test foods are 
significantly different from the IAUCs of the reference food (P ≤ 0.001), except for 
Marqoqa, Sago, and Asida (P = 0.074, P =0.654, and P = 0.745, respectively). Among 
high GI test foods, Fendal had the smallest IAUC (IAUC ± SE: 123.95 ± 12.02), and 






Table 5.11: Incremental Area Under the Curve (IAUC) for high GI test foods 
Test Foods IAUC ± SE P-Value 
Reference Food 224.77 ± 11.61 
0.001 
Regag Bread 162.98 ± 14.88 
Reference Food 261.9 ± 20.57 
<0.001 
Muhalla Bread 198.78 ± 12.39 
Reference Food 202.58 ± 8.92 
0.001 
Qurus 143.65 ± 14.5 
Reference Food 186.37 ± 10.41 
0.001 
Fendal 123.95 ± 12.02 
Reference Food 250.01 ± 16.87 
<0.001 
Thareed, beef 186 ± 55.45 
Reference Food 202.8 ± 8.92 
<0.001 
Thareed, chicken 142.41 ± 8.36 
Reference Food 250.01 ± 16.87 
<0.001 
Arseyah 176.5 ± 10.77 
Reference Food 202.58 ± 8.92 
0.074 
Marqoqa 162.65 ± 19.17 
Reference Food 202.58 ± 8.92 
0.654 
Sago 194.17 ± 14.95 
Reference Food 202.58 ± 8.92 
0.745 



































Regag Bread Muhalla Bread Qurus Fendal
Thareed (Meat) Thareed (Chicken) Arseyah Marqoqa
Sago Asida
Figure 5.3: The incremental area under the blood glucose curves (IAUC) for the high 






5.2.8 Glycemic Index and Glycemic Load Classifications 
The GI and GL values for all tested foods are presented in Table 5.12. GI values 
are given as means with their standard errors. GI calculation was performed according 
to the previously described procedure in Section 3.3.6.1. For practicality, GI and GL 
values are usually grouped into categories of low, medium or high. If the GI of test 
food was ≤ 55, then it is labeled as low GI food, between 56 and 69 (inclusive) is 
medium GI food, and ≥ 70 is high GI food [398].  
The four groups of food included in this study (breads, entrée, main, and 
dessert) produced a wide range of GI values, with seven foods producing low GI 
(Chebab bread, Khameer bread, Harees (beef), Biryani (chicken), Leqemat, 
Khanfaroosh, and Habba Hamra), six foods were classified as medium GI (Arabic 
bread, Chami, Machbous (fish),Khabisah, Batheetha, and Balalet), and ten foods had 
high GI (Regag bread, Muhalla bread, Qurus, Fendal, Thareed (beef), Thareed 
(chicken), Arseyah, Marqoqa, Sago, and Asida). Several factors may alter the GI of 
food (Section 2.5.3), including the presence of macronutrients such as fat and protein, 
the type of starch, processing, and the addition of acids, sugars, gelling fibers, or 
amylase inhibitors [196]. Other factors may include the degree of chewing, the 
concentration of amylase in the gut, the presence of other food components in the gut, 
the amount of the insulin response and the rate of gastric emptying [399]. 
Rice is the main staple and energy source for almost half the world’s 
population. Hence, it has significant nutrition and health implications. Many studies 
on rice and rice products led to the conclusion that rice should generally be classified 





rice products, including: rice variety and starch content (Amylose and Amylopectin), 
cooking, processing, cooling, soaking, fiber content, and particle size [402].  
Additionally, rice is barely ever consumed on its own, it is often accompanied 
with other foods such as pulses, legumes, vegetables, seafood, nuts, and meats, which 
could alter the high GI of rice. In this study, Biryani, Machbous, and Arseyah - mixed 
rice dishes (rice with chicken or fish) - were found to have low (52), medium (60) and 
high (72) GI values, respectively. The high protein content in Biryani (11.55g/100g) 
along with added vegetables (onion, garlic and pepper) could explain its low GI. In Sri 
Lanka, parboiled Mottai Karupan red rice showed a mean GI value of 47 when it was 
consumed with Amaranthus leaf curry, and 56 for parboiled rice with soya meat gravy 
[393]. Moreover, the addition of vegetable mixed curry showed considerable reduction 
of GI and GL of traditional Sri Lankan breakfast foods [394]. Many studies have also 
showed a reduction in the GI of rice when consumed with legumes and pulses such as 
lentils [403-405]. Furthermore, the addition of acidic condiments (vinegar or pickles), 
emulsifiers, dairy products (milk, cheese, and yogurt), vegetables, pulses, and viscous 
fibers seems to decrease the GI of rice [402]. 
Harees is a traditional dish with a porridge-like consistency; it is prepared from 
crushed wheat with meat (beef or chicken) [175]. The GI value of Harees was the 
lowest among the traditional dishes studied (42). The presence of dietary fibers in test 
foods may delay its glycemic response, as it contributes to slower nutrient absorption 
and a delayed transit time in the small intestines [193, 395]. Hence, the high amount 
of dietary fibers presents in Harees (5.56g/100g) may cause its low GI. 
The GI values of potatoes reported in the literature ranged from low (23) to 





(high) [186]. In the current study, Fendal (boiled sweet potato) had a GI of 74 (high). 
Jenkins et. al. (1981) found that sweet potato from Canada had a GI of 48 [20] while 
sweet potato (Ipomoea Batatas) in Australia had a GI of 44 only [406]. However, in 
New Zealand, Perry et. al. (2000) reported a GI of 77 for Kumara (sweet potato) [407]. 
Whereas, the GI for sweet potato that has been peeled, cubed, boiled (in salted water 
for 15 minutes) was 59 [408]. Furthermore, three varieties of boiled Australian 
potatoes (Sebago, Desiree, and Pontiac) showed varying high GI values (87, 101, and 
88, respectively) [409].  
According to the International Tables of Glycemic Index and Glycemic Load 
Values (2008), boiled potato has a mean GI value of 78, whereas, the mean GI for 
boiled sweet potato is 63 [187]. Thus, the consumption of sweet potatoes seems to be 
a better choice for individuals wishing to reduce their dietary GI. However, studies 
have shown that the GI value of potatoes could differ depending on the variety, 
maturity, cooking method (baking, steaming, roasting, frying, or boiling), cutting 
method (cubing, peeling, mashing, or slicing), cooling process, and storage conditions 
(period and temperature) [398, 409-411].  
To reduce the GI value of potatoes, researchers advise to precook potatoes and 
consume them cold (potato salad, for example) or reheated [410, 412]. Moreover, 
consuming potatoes with other ingredients such as acetic acid (vinegar) [413], 
vinaigrette dressing (vinegar and olive oil added to potato salad) [414], or topping 
baked potatoes with cheddar cheese [415] may lower the GI of potatoes but could limit 
the form in which they can be consumed. Additionally, aiming to develop low GI 





Bread is a staple food that is prepared usually by baking a dough of flour 
(wheat, rye, rice, oat, or barley) and water. In this study, six kinds of wheat bread and 
three main dishes containing wheat bread were tested. Two of the breads were 
classified as high GI - Regag bread (mean GI = 76) and Muhalla bread (mean GI = 77) 
- and all three main dishes containing bread were also high in GI - beef Thareed (mean 
GI =74), chicken thareed (mean GI = 72), and Marqoqa (mean GI = 85). Likewise, the 
International Tables of Glycemic Index and Glycemic Load Values (2008) reported a 
mean GI value of 75 (high) for White wheat bread and 70 (high) for unleavened wheat 
bread [187].  
Chebab bread and Khameer bread showed low GI values, which might be due 
to their high protein (7.08g/100 and 10.45g/100g, respectively) and fat content 
(9.07g/100g, and 12.69g/100g, respectively). Studies suggest that adding fat and 
protein to foods containing carbohydrates could possibly reduce their glycemic 
response and decrease their overall GI [416, 417]. It has been proposed that protein 
stimulates greater gastric inhibitory peptide (GIP) and higher insulin responses, which, 
in turn, lowers the postprandial peak of glucose and reduces the glycemic response of 
high GI foods [418]. High fat content was shown to delay the rate of gastric emptying, 
thus, reducing the rate of glucose digestion and absorption [415]. High fat content in 
Legemat and Khanfaroosh (22.8g/100g, and 30.32g/100g, respectively) might be the 
reason behind their low GI values (44 and 45, respectively). However, food choice 
should not solely depend on the GI value of the food, since high fat content - especially 
saturated fats as in the case of Khanfaroosh and Legemat (13.520g/100g and 





White Arabic wheat bread, also referred to as “Lebanese bread” or “Pita 
bread”, was also tested in the current study and showed a mean GI value of 67 
(Medium). Similarly, Ali et. al. (2012) evaluated the GI of eight different types of 
traditional Omani wheat breads and reported a GI value of 63 (Medium) for white 
Lebanese wheat bread [419]. Moreover, Wolever et. al. (1994) found that white Pita 
bread has a GI of 57 (medium) when tested on subjects with type one or type 2 diabetes 
[408].  
Khameer, Chebab and Arabic bread are considered leavened breads (fermented 
by yeast), which could explain their lower GI values compared to other breads. The 
effect of sourdough fermentation of leavened baked breads on the glycemic index has 
been reported by many researchers [420-423]. Several hypotheses were proposed to 
explain the reduced effect that sourdough fermentation has on the GI of bread 
including the synthesis of lactic acid which in turn lowers the rate of starch digestion 
[420], the synthesis of acetic and propionic acids, causing a reduction in the gastric 
emptying rate [421], or the synthesis/release of amino acids and peptides, resulting in 
better regulation of glucose metabolism [422]. 
Batheetha is a date paste made out of date fruit, wheat flour, ghee, sugar, 
cardamom and cinnamon. Various studies have reported the low GI value of date fruit 
[424, 425]. In 2002, Miller et. al. determined the GI of three different varieties of dates 
- Khalas = 35.5, Barhi = 49.7, and Bo ma'an= 30.5. In another study, Alkaabi et. al. 
(2011) reported the mean GIs of Fara'd, Lulu, Bo ma'an, Dabbas and Khalas dates 
tested in thirteen healthy individuals to be 54.0, 53.5, 46.3, 49.1, and 55.1, respectively 
[425]. However, in the current study, Batheetha is classified as a medium GI food (59), 





analysis showed a content of 5.02g total sugar in every 100g. The sugar analysis also 
revealed that 2.468g of sugar are in the form of sucrose and 1.181g were found to be 
glucose. Additionally, based on the International Tables of Glycemic Index and 
Glycemic Load Values (2008), the mean GIs for sucrose and glucose are 65 (medium) 
and 103 (high) respectively [187]. 
The low GI (47) of Habba Hamra (milk with red seed) was expected, since the 
literature indicated low GI for full-fat milk, ranging from 11 to 40 [186] and the mean 
GI for full-fat milk reported in the International Tables of Glycemic Index and 
Glycemic Load Values (2008) was 39 [187]. Conversely, other dessert dishes tested in 
the current study, like Sago and Asida, showed high GI values (mean GI = 99 for both 
dishes). The high moisture content (humidity) of Sago (74.91g/100g) and Asida 
(77.17g/100g), along with high cooking temperatures and prolonged cooking durations 
(time) could have increased starch gelatinization and digestibility degree, thus, 
resulting in high glycemic responses for these two traditional desserts [396, 397]. 
The GL of a standard serving size of each test food was calculated using the 
equation described in Section 3.3.6.2. A GL ≤ 10 is considered low, between 11 and 
19 is medium, and ≥ 20 is high. The results of the study demonstrated that the majority 
of test foods were classified as high GL, which is expected as most of the test foods 





























Arabic bread 63.47 ± 0.32 78.8 67 5 90 57.1 38.3 25 Medium High 
Regag bread 44.37 ± 0.49 112.7 76 7 21 9.3 7.1 25 High Low 
Chebab bread 45.88 ± 1.17 109.0 54 8 77 35.3 19.2 15 Low Medium 
Muhalla bread 67.66 ± 4.79 73.9 77 2 47 31.8 24.5 15 High High 
Khameer bread 54.93 ± 3.47 91.0 47 3 76 41.7 19.5 15 Low Medium 
Gurus 54.45 ± 2.60 91.8 72 8 91 49.5 35.5 15 High High 
Fendal 31.64 ± 0.24 158.0 74 7 150 47.5 35.3 20 High High 
Chami 5.31 ± 0.58 470.8 60 9 170 9.0 5.4 16 Medium Low 
Harees 7.74 ± 1.15 323.0 42 2 212 16.4 6.9 15 Low Low 
Thareed (beef) 10.87 ± 0.24 460.0 74 3 245 26.6 19.7 15 High Medium 
Thareed (chicken) 12.73 ± 2.65 392.8 72 4 393 50.0 36.0 15 High High 
Biryani (chicken) 19.69 ± 2.05 253.9 52 4 261 51.4 27.0 15 Low High 
Machbous (fish) 18.00 ± 0.82 277.8 60 3 250 45.0 26.8 20 Medium High 
Arseyah 9.85 ± 0.37 507.6 72 4 261 25.7 18.5 15 High Medium 
Marqoqa 16.00 ± 0.52 312.5 85 9 313 50.1 42.4 15 High High 
Khabisa 56.13 ± 4.65 89.1 67 4 86 48.3 32.1 15 Medium High 
Leqemat 44.19 ± 1.35 113.1 44 4 90 39.8 17.6 15 Low Medium 
Batheetha 38.24 ± 0.97 130.8 59 4 100 38.2 22.7 20 Medium High 
Kanfaroosh 39.62 ± 0.92 126.2 45 3 100 39.6 18.0 15 Low Medium 
Saqo 23.43 ± 3.54 213.4 99 8 214 50.1 49.8 15 High High 
Asida 21.09 ± 1.14 237.1 99 5 237 50.0 49.6 15 High High 
Habba Hamra 15.96 ± 1.20 313.3 47 3 98 15.6 7.4 15 Low Low 
Balalet 27.89 ± 2.19 179.3 63 5 144 40.2 25.4 15 Medium High 





5.2.9 Exchange List 
The food exchange list helps in monitoring food portion sizes and energy 
intake, because it translates scientific nutrition knowledge into a practical tool. Foods 
from the same category can be used interchangeably without changing estimated 
amounts of carbohydrates, fat, protein, and total energy obtainable in a meal [286]. 
The rounding-off method described by Wheeler et. al.[285] was used to fit food items 
into exchanges as previously described in Section 3.3.5.4. 
The exchange list for traditional dishes commonly consumed in the UAE was 
established based on the proximate analysis data presented in Table 5.1. The exchanges 
per serving of test foods are shown in Table 5.13. Serving sizes of test foods are 
presented in standard measures (weight in grams) and equivalent cooking methods. 
All test foods contained one exchange of starch, except Chami and Habba 
Hamra. Habba Hamra, a red seed added to milk drink contained one exchange of low 
fat milk. Whereas, Chami, a type of cottage cheese, was considered an exchange of 
very lean meat, as it belongs to the low-fat meat substitute food group. 
Khanfarosh, a fried dessert dish, contained the highest number of fat exchanges 
(2 exchanges). All main dishes contained 1 exchange of starch and 1 exchange of lean 
meat, which is expected as they are all composed of grain products (wheat or rice) with 







Table 5.13: Meal Planning Exchange List of Twenty-Three United Arab Emirates Traditional Dishes 









CHO Protein Fat 
Arabic bread Baked bread Bread 1 oz. 30 19.1 2.8 0.3 90.7 1 Starch 
Regag bread Thin crispy crepe Bread 1 oz. 30 13.7 3.1 0.1 68.5 1 Starch 
Chebab bread Emirati pancake Bread 1 oz. 30 14.1 2.1 2.7 89.5 1 Starch 
Muhalla Bread Emirati crepe Bread 1 oz. 30 20.5 3.1 1.3 105.7 1 Starch 
Khameer Bread Baked bread Bread 1 oz. 30 17.0 3.1 3.8 114.9 1 Starch, 1/2 Fat 
Gurus Fried bread Bread 1 oz. 30 17.6 2.6 2.3 101.6 1 Starch 
Fendal Boiled sweet potato Starchy vegetable 1 small potato 60 20.7 1.1 0.3 90.4 1 Starch 
Chami Cottage cheese 
Low-fat meat 
substitute’s 
1 oz. 30 1.6 4.6 0.2 26.9 1 Very Lean Meat 
Harees (beef) 





75 10.0 4.2 1.8 73.0 
1 Starch, 1 Lean 
Meat 
Thareed (beef) 





75 9.1 5.3 1.6 71.9 
1 Starch, 1 Lean 
Meat 
Thareed (chicken) 





75 10.3 4.0 1.2 67.8 
1 Starch, 1 Lean 
Meat 
Biryani (chicken) Rice with chicken Starch/Meat 
1/2 cup 
composite dish 
75 15.5 8.7 2.5 118.8 
1 Starch, 1 Lean 
Meat 
Machbous (fish) Rice with fish Starch/Meat 
1/2 cup 
composite dish 
75 16.2 5.2 1.5 99.0 
1 Starch, 1 Lean 
Meat 
Arseyah Rice with chicken Starch/Meat 
1/2 cup 
composite dish 
180 18.2 4.0 1.6 103.2 













75 12.4 4.4 1.6 82.0 






Prepared with fat 
1/2 cup Pudding 25 14.7 1.3 2.6 87.9 1 Starch 
Leqemat Doughnut cake 
Starchy food 
Prepared with fat 
1 oz. 30 13.7 2.2 6.8 125.1 1 Starch, 1 Fat 
Batheetha Date paste 
Starchy food 
Prepared with fat 
1 oz. 30 13.3 1.7 2.9 86.0 1 Starch, 1/2 Fat 
Khanfaroosh Doughnut cake 
Starchy food 
Prepared with fat 
1 oz. 30 12.2 2.0 9.1 138.9 1 Starch, 2 Fat 
Sago 
Sago seed with 
sugar 
Starch 2 oz. 60 14.2 0.5 0.3 61.7 1 Starch 
Asida Flour with Sugar Starch 2 oz. 60 13.1 0.6 0.0 54.8 1 Starch 
Habba Hamra 
Red seed Milk 
drink 
Evaporated Milk 1/2 cup 126 20.4 1.6 2.3 108.8 1 ½ Low Fat Milk 








In conclusion, this study provides a comprehensive food composition table 
including proximate data, minerals, vitamins, lipids, and sugars contents, along with 
GI and GL values of twenty-three locally consumed foods in the UAE including 
breads, entrées, mains and desserts. Determining the nutritional composition and the 
glycemic response of Emirati traditional foods is needed to assess the dietary intake of 
the population and identifying their effects on health promotion and disease 
prevention. Additionally, these tables will serve as a great tool of nutrition therapy 
planning and dietary management for dietitians in the UAE and other GCC countries. 
Furthermore, the availability of this data should be useful for assembling national and 
international food composition tables. Moreover, the knowledge of the GI and GL 
values of traditional Emirati foods helps in developing better dietary guidelines for 
individuals living with diabetes and/or obesity, and could be utilized by further 
research studies interested in the application of GL and GI. 
Most dishes containing meat presented in this study had very high sodium 
levels. Therefore, it is highly important to take serious national steps towards reducing 
the sodium intake in diets in order to lessen the risk of developing CVD, hypertension, 
and other associated complications. Aiming for high iron food sources (like Regag, 
Chebab, Muhalla, and Khameer bread) as part of the daily diet is recommended to 
reduce the risk of iron deficiency (anemia).  
The findings of this study advocate attention to the nutritive value and health 
aspects of traditional desserts when establishing dietary guidelines for UAE. 





saturated fat (Khanfaroosh and Legemat), cholesterol (batheetha), and sugar (Sago, 
Asida, and Batheetha), in addition to their medium to high glycemic response.  
Using whole-grain wheat flour instead of refined wheat flour for the 
preparation of breads is recommended in order to reduce their high GI values. The 
presence of dietary fibers in foods could also delay its glycemic response, as it 
contributes to slower nutrient absorption and delayed transit time in the small intestines 
[193, 395]. Furthermore, the addition of acidic condiments (vinegar or pickles), 
emulsifiers, dairy products (milk, cheese, and yogurt), vegetables, pulses, or viscous 
fiber to rice is recommended, since they appear to decrease its high GI value [402]. It 
is also recommended that foods containing carbohydrate should be consumed with 
protein-rich foods (rice and yogurt, bread and cheese, and rice with pulses) to reduce 
their glycemic response [416, 417]. Controlling the portion size of foods consumed 
can contribute to lowering their GL values, thus, reducing the risk of non-
communicable diseases [107, 108, 209]. 
It is also advised to precook potatoes and consume them cold (potato salad, for 
example) or reheated [410, 412]. Moreover, consuming potatoes with other ingredients 
such as acetic acid (vinegar) [413], vinaigrette dressing (vinegar and olive oil added to 
potato salad) [414], or topping baked potatoes with cheddar cheese [415] are all good 
ways to lower the GI of potatoes. 
Dietitians are advised to consider the macronutrient content of foods, such as 
fiber, total fat, saturated fat and trans fats along with the GI value when making dietary 





The calculated exchange lists serve as a user-friendly guide, which enable 
consumers to exchange foods from the same group without changing energy or 
macronutrient contents. In addition, exchange lists assist dietitians in establishing 






Chapter 6: Summary and Recommendations 
 
6.1 Overall Summary 
Non-communicable diseases (NCDs) are the leading cause of deaths 
worldwide, and diabetes mellitus (DM) is the fourth major cause of NCD deaths [1]. 
United Arab Emirates (UAE) was ranked as having the fifth highest prevalence of DM 
in the Middle East and North Africa (MENA) region [304]. 
The transition in socioeconomic status accompanied with the adoption of a 
western lifestyle and diet for Emirati citizens, have led to a rise in the prevalence of 
overweight and obesity, particularly among females [167]. The existence of pre-
diabetes, dyslipidemia, elevated blood pressure, and obesity is known as metabolic 
syndrome (MetS) [33]. There is paucity of data available about the prevalence of MetS 
and its relation with overweight and obesity among young female adults (17-25 years) 
in the UAE; therefore, determination of the prevalence of MetS in Emirati females 
aged 17–25 years and its relation to overweight and obesity in Al Ain, UAE has been 
part of our study. 
The American Diabetes Association (ADA) recommends the use of low GI 
diets for DM management and prevention [255]. Additionally, the Food and 
Agriculture Organization (FAO) of the United Nations and the World Health 
Organization (WHO) have also validated the use of GI for the classification of 
carbohydrate-containing foods [188]. Likewise, they recommended the use of the GI 
classification system along with food composition tables to guide better food choices. 
Designing public health policy, clinical practice, and prevention programs for the 





important. Unfortunately, very little information is available about the food 
composition and glycemic index of Emirati traditional foods.  
The current study provides a comprehensive food composition table with GI 
and GL values of locally consumed foods in the UAE, which could serve as a tool for 
nutrition therapy planning. In addition, the produced data will facilitate the role of 
dietitians in the dietary management of disease in the UAE and other GCC countries. 
Moreover, the current dataset will add on the existing international table of GI and GL 
values. 
The following is summary of some main findings of both studies performed in 
this dissertation: 
1. One third of the studied population were overweight and obese. 
2. The prevalence of diabetes mellitus and prediabetes based on FPG was 
found much lower than that based on the percentage of HbA1c (0.5% 
and 9.2% Vs. 8.6% and 24% respectively). However, the crude 
prevalence of diabetes mellitus and pre-diabetes among Emirati young 
female adults was 8.6% and 24.7%, respectively. 
3. Screening for pre-diabetes using IFG was independent than screening 
using HbA1c. 
4. The overall prevalence of MetS was 6.8% (95% CI: 5% to 9%). 
5. The most frequent component of MetS was reduced HDL-C levels, 
followed by central obesity and impaired fasting glucose. 
6. MetS prevalence was highest among obese participants, as compared 





7. Using logistic regression model MetS was significantly associated with 
overweight, obesity, waist-hip ratio, glycated hemoglobin (HbA1c) and 
high sensitivity C-reactive protein (P < 0.01). 
8. Most dishes containing meat and Regag bread presented in this study 
had very high sodium levels. 
9. Traditional desserts had high content of saturated fat (Khanfaroosh and 
Legemat), cholesterol (batheetha), and sugar (Sago, Asida, and 
Batheetha), in addition to their medium to high glycemic response. 
10. The exchange list developed in this study could be used by food and 






6.2 Recommendations  
1. Future research needs to include both male and female genders to investigate 
gender differences and generalize the results to all young adults 
2. Additional prospective studies with bigger sample size and including all 
segments of the society are needed to confirm the prevalence of MetS and its 
most predictive risk factors among Emirati young adults. 
3. Developing screening programs for early detection of metabolic syndrome 
among young Emirati adults, so that lifestyle interventions and treatment may 
prevent the development of diabetes and/or cardiovascular disease. 
4. Developing population-based strategies that address cultural and community 
life of Emiratis to ensure relevance and commitment by the community. 
5. Developing food-based dietary guidelines specific for the Emirati population, 
to be used for improving health policies and nutrition education programs. 
6. Advising the Emirati population to consume traditional desserts in moderation 
due to their high content of saturated fat, cholesterol and sugar, in addition to 
their medium to high glycemic response. 
7. Conducting a national flour fortification program to control and prevent anemia 
by fortifying flour with iron and folic acid. 
8. Future intervention studies investigating the beneficial effects of low GI diets 
on the prevalence of the metabolic syndrome in the UAE.  
9. Running awareness campaigns about the effect of the GI on certain non-
communicable diseases common in the UAE including diabetes and obesity. 
10. Encouraging dietitians to use the exchange list of Emirati foods when 
establishing culturally appropriate meal plans particularly for individuals 
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Appendix 1: Information Sheet 
Anthropometric measures and their association with metabolic syndrome risk factors in 
Emirati young female adults 
You are being invited to take part in a research study. Before you decide, it is important for 
you to understand why the research is being done and what it will involve.  Please take time 
to read the following information carefully. 
 
What is the purpose of the study?  
The objective of this research is to identify the anthropometric measures of obesity that best 
identify metabolic syndrome in UAE early adulthood female students of the United Arab 
Emirates University. The results obtained might show that simple measurements are useful 
for predicting metabolic syndrome risk. 
 
Why have I been chosen to take part?  
The subjects chosen to take part in the study are females, aged 17-25 years.We will evaluate 
the screening performance of eight anthropometric measurements, Body mass index (BMI), 
waist circumference (WC), hip circumference (HC), waist-to-hip ratio (WHR), waist to 
height ratio (WHtR), neck circumference (NC), Mid-upper-arm circumference (MUAC) and 
skin-fold thickness at four sites, in identifying metabolic syndrome risk factors. 
 
Do I have to take part?  
It is up to you to decide whether or not to take part. If you do decide to take part you will be 
given this information sheet to keep and be asked to sign a consent form. If you decide to 
take part you are still free to withdraw at any time, without giving a reason, and to withdraw 
any unprocessed data previously supplied. If you are involved in a dependent relationship 
(i.e. teacher/student) with the Project Principle Investigator (PI), your involvement in the 
study will not affect your grades. 
What will happen to me if I do take part? 
The time you will spend participating in this study will be no longer than 40 min. You will 
be asked to visit the Nutrition and Health clinic, UAE University only once. Prior to you test 
session you will be asked to fast overnight (12-14hr), do not come during your menstrual 
cycle, and we would like you to come wearing appropriate clothing to facilitate skin-fold 
measurements. When you come for your appointment the researchers will take your 
anthropometric (e.g. height, weight, waist and hip circumference) and body composition 
measurements, fasting venous blood (by well-trained burse) and blood pressure. You will 








Are there any risks involved? 
 
All measurements taken in the study are simple, easy and painless. Trained personnel will 
collect the blood samples in a designated clean and privet area. The Nutrition and Health 
clinic allows privacy were only females will be involved in taking the measurements and 
counselling the participants. 
 
What are the possible benefits of taking part? 
You will receive your own “health check” profile, including anthropometric and body 
composition measurements. You will also be provided with a participating certificate and 
complementary gift to show appreciation for your valued participation. 
 
What will happen to the results of the study? 
Confidentiality of information provided can only be protected within the limitations of the 
law.  All information collected will be kept strictly confidential.  All samples and records 
will be coded and will only be available to the researchers involved in the study; your name 
will never appear in any published work.  The Project PI and Project Co-PI will carry out 
data analysis and dissemination of results.  All data from the study will be owned by the 
Department of Nutrition and Health and will be stored at the department for a minimum of 5 
years.  
 
Who can I contact if I have any questions?  
 
If you have any questions regarding this study, you can contact the Project PI: 
Ms. Maysm Nezar Mohamad   
Department of Nutrition and Health, College of Food and Agriculture. 
United Arab Emirates University, Maqam Campus, P. O. Box 17555 
Mob: 00971 55 236 8727 



























































Appendix 7: Information Sheet 
Glycaemic Index (GI) value of commonly consumed foods in UAE 
 
You are being invited to take part in a research study.  Before you decide, it is important for 
you to understand why the research is being done and what it will involve.  Please take time 
to read the following information carefully. 
 
What is the purpose of the study?  
The glycaemic index (GI) of foods has potential implications for the prevention and treatment 
of major chronic diseases.  The GI concept was developed to predict post-prandial increases 
in blood glucose concentration after the consumption of food. Type 2 diabetes has been seen 
in various populations whose lifestyle has changed from traditional patterns to a modern 
‘westernized’ model. Accordingly, dietary control could have a positive impact on the number 
of people affected by diabetes. The consumption of some traditional foods in the UAE (e.g. 
Camel milk, Cow milk, "Reqaq bread" and "Arabic bread"….etc) raises the question, should 
the UAE population and especially the diabetic patients eat these foods? 
 
Why have I been chosen to take part?  
The subjects chosen to take part in the study are aged 18-50 years.  At the beginning of the 
study, your fasting plasma glucose level will be tested (this will involve taking a finger-prick 
blood sample after you have fasted overnight).  If you are identified as being at risk of 
developing impaired glucose tolerance or diabetes you will be excluded from taking part in 
this study. 
 
Do I have to take part?  
It is up to you to decide whether or not to take part.  If you do decide to take part you will be 
given this information sheet to keep and be asked to sign a consent form.  If you decide to take 
part you are still free to withdraw at any time, without giving a reason, and to withdraw any 
unprocessed data previously supplied.  If you are involved in a dependent relationship (i.e. 
teacher/student) with the Project Principle Investigator (PI), your involvement in the study will 
not affect your grades. 
 
What will happen to me if I do take part? 
It is anticipated that your time spent taking part in the study will be approximately 2 hours per 
test session (total study duration = 6 sessions).  Each test session will be conducted in the 
morning at the Nutrition and Health laboratory, UAE University.  Prior to each test session, 
you will be asked to fast overnight before anthropometric (e.g. height, weight, waist and hip 
circumference) and body composition measurements are taken.  During each test session, you 
will be asked to eat a portion of food (milk or bread).  Finger-prick blood samples will be taken 
at 0 minutes (fasting) and at 15, 30, 45, 60, 90 and 120 minutes after the start of the meal, and 
your blood glucose measured.  For each test session, the blood glucose measurements will 
require a maximum of seven finger-pricks, however you will not experience any negative 
consequences.  You will be asked to rate your feelings of hunger/satiety at various intervals 
during the test session.  All measurements will be taken by trained personnel.  Tests will be 
undertaken with at least 1 day between sessions. 
 
Are there any risks involved? 
During each test session, the blood glucose measurements will require a maximum of seven 
finger-pricks, however you will not experience any negative consequences.  Trained personnel 





if you are identified as being at risk of developing diabetes, you will be provided with 
immediate information and given details to take to your physician.  It must be stressed that the 
diagnosis of diabetes is never made on the basis of a single abnormal blood glucose value. 
 
What are the possible benefits of taking part? 
You will receive your own “health check” profile, including anthropometric and body 
composition measurements  
 
What will happen to the results of the study? 
Confidentiality of information provided can only be protected within the limitations of the law. 
All information collected will be kept strictly confidential.  All samples and records will be 
coded and will only be available to the researchers involved in the study; your name will never 
appear in any published work.  The Project PI and Project Co-PI will carry out data analysis 
and dissemination of results.  All data from the study will be owned by the Department of 
Nutrition and Health and will be stored at the department for a minimum of 5 years.  
 
Who can I contact if I have any questions?  
If you have any questions regarding this study, you can contact either the Project PI or Project 
Co-PI: 
Dr. Ayesha Al Dhaheri (Project PI)  Ms. Maysm Mohamad (Project Co-PI) 
Department of Nutrition and Health Department of Nutrition and Health 
College of Food and Agriculture College of Food and Agriculture 
UAE University UAE University 
Maqam Campus Maqam Campus 
P. O. Box 17555 P. O. Box 17555 
Tel: 03 7134539 Tel: 055 236 8727 




























Appendix 11: Graphs of the IAUC for all Test Foods 
The mean incremental area under the glycemic response curves of the standard food 




































































Standard Food Regag Bread
Figure A: Incremental area under the blood glucose curves (IAUC) for the 
standard food and Arabic bread. Standard errors of the mean are represented 
by vertical bars. 
Figure B: Incremental area under the blood glucose curves (IAUC) for the 








































Standard Food Chebab Bread
Figure D Incremental area under the blood glucose curves (IAUC) for the 
standard food and Chebab bread. Standard errors of the mean are represented 



































Standard Food Muhalla Bread
Figure C: Incremental area under the blood glucose curves (IAUC) for the 
standard food and Muhalla bread. Standard errors of the mean are represented 










































Standard Food Khameer Bread
Figure F: Incremental area under the blood glucose curves (IAUC) for the 
standard food and Khameer bread. Standard errors of the mean are 


































Figure E: Incremental area under the blood glucose curves (IAUC) for the 










































Figure G: Incremental area under the blood glucose curves (IAUC) for the 



































Standard Food Harees Meat
Figure H: Incremental area under the blood glucose curves (IAUC) for the 









































Figure I: Incremental area under the blood glucose curves (IAUC) for the 



































Standard Food Thareed Meat
Figure J: Incremental area under the blood glucose curves (IAUC) for the 
standard food and Thareed beef. Standard errors of the mean are represented 








































Standard Food Thareed Chicken
Figure K: Incremental area under the blood glucose curves (IAUC) for the 
standard food and Thareed chicken. Standard errors of the mean are 



































Standard Food Biryani Chicken
Figure L: Incremental area under the blood glucose curves (IAUC) for the 
standard food and Biryani chicken. Standard errors of the mean are 







































Standard Food Machbous Fish
Figure N: Incremental area under the blood glucose curves (IAUC) for the 
standard food and Machbous fish. Standard errors of the mean are 


































Figure M: Incremental area under the blood glucose curves (IAUC) for the 









































Figure P: Incremental area under the blood glucose curves (IAUC) for the 



































Figure O: Incremental area under the blood glucose curves (IAUC) for the 












































Figure Q: Incremental area under the blood glucose curves (IAUC) for the 


































Figure R: Incremental area under the blood glucose curves (IAUC) for the 












































Figure S: Incremental area under the blood glucose curves (IAUC) for the 
standard food and Khanfaroosh. Standard errors of the mean are represented 



















































Figure T: Incremental area under the blood glucose curves (IAUC) for the 











































Figure U: Incremental area under the blood glucose curves (IAUC) for the 


































Standard Food Habba Hamra
Figure V: Incremental area under the blood glucose curves (IAUC) for the 
standard food and Habba Hamra. Standard errors of the mean are represented 









































Figure W: Incremental area under the blood glucose curves (IAUC) for the 
























































Appendix 15: Research Paper 2 
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